Molecule ChEMBL ID,Molecule Name,Molecule Max Phase,Molecular Weight,#RO5 Violations,AlogP,Compound Key,Smiles,Standard Type,Standard Relation,Standard Value,Standard Units,pChEMBL Value,Data Validity Comment,Comment,Uo Units,Ligand Efficiency BEI,Ligand Efficiency LE,Ligand Efficiency LLE,Ligand Efficiency SEI,Potential Duplicate,Assay ChEMBL ID,Assay Description,Assay Type,BAO Format ID,BAO Label,Assay Organism,Assay Tissue ChEMBL ID,Assay Tissue Name,Assay Cell Type,Assay Subcellular Fraction,Assay Parameters,Assay Variant Accession,Assay Variant Mutation,Target ChEMBL ID,Target Name,Target Organism,Target Type,Document ChEMBL ID,Source ID,Source Description,Document Journal,Document Year,Cell ChEMBL ID,Properties,Action Type,Standard Text Value,Value,serotype
CHEMBL5605274,,,390.39,0.0,4.36,ASAP-0031221,O=C(Nc1ccc2c(c1)CNC2)c1cc(F)cc2[nH]c(-c3ccccc3F)nc12,IC50,'=',3856.0,nM,5.41,,,UO_0000065,,,,,0,CHEMBL5604072,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 1,,,,,Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK,,,CHEMBL5705862,NS3 protease,dengue virus type 1,SINGLE PROTEIN,CHEMBL5604064,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 2.542 None | IC50 CI (lower) = 3.197 uM | IC50 CI (upper) = 4.651 uM | Maximum measured = 93.83 None | Maximum response = 100.0 % | Minimum measured = -3.458 None | R squared = 0.968 None,,,3.856,1
CHEMBL5605366,,,425.92,0.0,3.27,ASAP-0029888,O=C(NC1CCOCC1)[C@H](Nc1ccc2c(c1)CNC2)c1cc(Cl)cc2[nH]ncc12,IC50,'>',99500.0,nM,,,Falls Outside The Dose Series,UO_0000065,,,,,0,CHEMBL5604072,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 1,,,,,Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK,,,CHEMBL5705862,NS3 protease,dengue virus type 1,SINGLE PROTEIN,CHEMBL5604064,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 1.002 None | Maximum measured = 43.14 None | Maximum response = 100.0 % | Minimum measured = -3.642 None | R squared = 0.957 None,,,99.5,1
CHEMBL5605468,,,295.32,0.0,3.16,ASAP-0029832,O=C(Nc1ccc2c(c1)CNC2)c1cc(F)c2[nH]ccc2c1,IC50,'>',99500.0,nM,,,Falls Outside The Dose Series,UO_0000065,,,,,0,CHEMBL5604072,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 1,,,,,Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK,,,CHEMBL5705862,NS3 protease,dengue virus type 1,SINGLE PROTEIN,CHEMBL5604064,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 11.46 None | Maximum measured = 17.97 None | Maximum response = 100.0 % | Minimum measured = -4.932 None | R squared = 0.717 None,,,99.5,1
CHEMBL5604849,,,409.96,0.0,4.89,ASAP-0030790,O=C(NCCC1CC1)[C@H](Nc1ccc2c(c1)CNC2)c1cc(Cl)cc(C2CC2)c1,IC50,'>',99500.0,nM,,,Falls Outside The Dose Series,UO_0000065,,,,,0,CHEMBL5604072,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 1,,,,,Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK,,,CHEMBL5705862,NS3 protease,dengue virus type 1,SINGLE PROTEIN,CHEMBL5604064,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Maximum measured = 0.543 None | Minimum measured = -36.85 None,,,99.5,1
CHEMBL5604326,,,333.39,0.0,3.15,ASAP-0030062,C=CC[C@H]1NCc2cc(NC(=O)c3cccc4c3CC(=O)N4)ccc21,IC50,'>',99500.0,nM,,,Falls Outside The Dose Series,UO_0000065,,,,,0,CHEMBL5604072,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 1,,,,,Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK,,,CHEMBL5705862,NS3 protease,dengue virus type 1,SINGLE PROTEIN,CHEMBL5604064,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 2.95 None | Maximum measured = 4.988 None | Maximum response = 100.0 % | Minimum measured = -2.535 None | R squared = 0.302 None,,,99.5,1
CHEMBL5605255,,,423.95,0.0,4.61,ASAP-0030850,C=CC[C@H]1NCc2cc(N[C@H](C(=O)NC(C)C)c3cc(Cl)cc4[nH]ncc34)ccc21,IC50,'=',81831.0,nM,4.09,,,UO_0000065,,,,,0,CHEMBL5604072,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 1,,,,,Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK,,,CHEMBL5705862,NS3 protease,dengue virus type 1,SINGLE PROTEIN,CHEMBL5604064,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 0.858 None | IC50 CI (lower) = 74.99 uM | IC50 CI (upper) = 89.3 uM | Maximum measured = 51.98 None | Maximum response = 100.0 % | Minimum measured = -0.731 None | R squared = 0.991 None,,,81.831,1
CHEMBL5606236,,,375.2,0.0,3.32,ASAP-0030085,O=C(Nc1cc2c(cc1Br)CNC2)c1cc(F)cc2[nH]ncc12,IC50,'>',99500.0,nM,,,Falls Outside The Dose Series,UO_0000065,,,,,0,CHEMBL5604072,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 1,,,,,Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK,,,CHEMBL5705862,NS3 protease,dengue virus type 1,SINGLE PROTEIN,CHEMBL5604064,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 0.955 None | Maximum measured = 25.93 None | Maximum response = 100.0 % | Minimum measured = -5.756 None | R squared = 0.885 None,,,99.5,1
CHEMBL5605069,,,311.77,0.0,3.68,ASAP-0030001,O=C(Nc1ccc2c(c1)CNC2)c1cc(Cl)cc2cc[nH]c12,IC50,'>',99500.0,nM,,,Falls Outside The Dose Series,UO_0000065,,,,,0,CHEMBL5604072,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 1,,,,,Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK,,,CHEMBL5705862,NS3 protease,dengue virus type 1,SINGLE PROTEIN,CHEMBL5604064,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Maximum measured = -0.596 None | Minimum measured = -43.7 None,,,99.5,1
CHEMBL5606033,,,293.33,0.0,2.04,ASAP-0029950,O=C1Cc2cc(C(=O)Nc3ccc4c(c3)CNC4)ccc2N1,IC50,'=',4473.0,nM,5.35,,,UO_0000065,,,,,0,CHEMBL5604072,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 1,,,,,Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK,,,CHEMBL5705862,NS3 protease,dengue virus type 1,SINGLE PROTEIN,CHEMBL5604064,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 2.028 None | IC50 CI (lower) = 4.002 uM | IC50 CI (upper) = 4.999 uM | Maximum measured = 100.25 None | Maximum response = 100.0 % | Minimum measured = -1.387 None | R squared = 0.99 None,,,4.473,1
CHEMBL5606429,,,378.41,0.0,3.36,ASAP-0031147,O=C(Nc1cc2c(c(C3=CCOCC3)c1)CNC2)c1cc(F)cc2[nH]ncc12,IC50,'=',39867.0,nM,4.4,,,UO_0000065,,,,,0,CHEMBL5604072,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 1,,,,,Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK,,,CHEMBL5705862,NS3 protease,dengue virus type 1,SINGLE PROTEIN,CHEMBL5604064,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 2.145 None | IC50 CI (lower) = 36.06 uM | IC50 CI (upper) = 44.07 uM | Maximum measured = 92.61 None | Maximum response = 100.0 % | Minimum measured = -5.77 None | R squared = 0.975 None,,,39.867,1
CHEMBL5604988,,,399.52,0.0,4.88,ASAP-0031461,NCc1cccc(-c2csc3cc(C(=O)Nc4ccc5c(c4)CNC5)ccc23)c1,IC50,'=',29855.0,nM,4.53,,,UO_0000065,,,,,0,CHEMBL5604072,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 1,,,,,Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK,,,CHEMBL5705862,NS3 protease,dengue virus type 1,SINGLE PROTEIN,CHEMBL5604064,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 1.726 None | IC50 CI (lower) = 27.62 uM | IC50 CI (upper) = 32.28 uM | Maximum measured = 94.59 None | Maximum response = 100.0 % | Minimum measured = -2.095 None | R squared = 0.988 None,,,29.855,1
CHEMBL5598749,,,421.88,0.0,4.94,ASAP-0020915,O=C(Nc1cc(Cl)cc(C(=O)Nc2ccc3c(c2)CNC3)c1)OCc1ccccc1,IC50,'>',99500.0,nM,,,Falls Outside The Dose Series,UO_0000065,,,,,0,CHEMBL5604072,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 1,,,,,Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK,,,CHEMBL5705862,NS3 protease,dengue virus type 1,SINGLE PROTEIN,CHEMBL5604064,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 3.255 None | Maximum measured = 26.84 None | Maximum response = 100.0 % | Minimum measured = -11.71 None | R squared = 0.606 None,,,99.5,1
CHEMBL5605691,,,312.42,0.0,2.75,ASAP-0027597,Cc1c(C(=O)Nc2cc(CCCN)ccn2)cc(C2CC2)n1C,IC50,'=',25482.0,nM,4.59,,,UO_0000065,,,,,0,CHEMBL5604072,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 1,,,,,Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK,,,CHEMBL5705862,NS3 protease,dengue virus type 1,SINGLE PROTEIN,CHEMBL5604064,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 2.774 None | IC50 CI (lower) = 23.97 uM | IC50 CI (upper) = 27.09 uM | Maximum measured = 97.02 None | Maximum response = 100.0 % | Minimum measured = -2.838 None | R squared = 0.991 None,,,25.482,1
CHEMBL5605142,,,474.95,1.0,6.0,ASAP-0028884,C=CC[C@H](Nc1cc(Cl)cc(NC(=O)OCc2ccccc2)c1)c1cccc(-c2nn[nH]n2)c1,IC50,'=',6406.0,nM,5.19,,,UO_0000065,,,,,0,CHEMBL5604072,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 1,,,,,Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK,,,CHEMBL5705862,NS3 protease,dengue virus type 1,SINGLE PROTEIN,CHEMBL5604064,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 3.23 None | IC50 CI (lower) = 5.656 uM | IC50 CI (upper) = 7.256 uM | Maximum measured = 100.48 None | Maximum response = 100.0 % | Minimum measured = -5.461 None | R squared = 0.986 None,,,6.406,1
CHEMBL5605540,,,452.94,0.0,4.45,ASAP-0027609,CNC(=O)[C@H](Nc1cccc(CN)c1)c1cc(Cl)cc(NC(=O)OCc2ccccc2)c1,IC50,,,,,,,,,,,,0,CHEMBL5604072,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 1,,,,,Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK,,,CHEMBL5705862,NS3 protease,dengue virus type 1,SINGLE PROTEIN,CHEMBL5604064,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Maximum measured = 18.22 None | Minimum measured = -12.27 None,,IC50 could not be calculated,,1
CHEMBL5604249,,,406.91,1.0,5.82,ASAP-0022797,NCc1cccc([C@H]2C[C@@H]2c2cc(Cl)cc(NC(=O)OCc3ccccc3)c2)c1,IC50,'=',25334.0,nM,4.6,,,UO_0000065,,,,,0,CHEMBL5604072,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 1,,,,,Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK,,,CHEMBL5705862,NS3 protease,dengue virus type 1,SINGLE PROTEIN,CHEMBL5604064,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 1.833 None | IC50 CI (lower) = 19.56 uM | IC50 CI (upper) = 32.81 uM | Maximum measured = 85.65 None | Maximum response = 100.0 % | Minimum measured = -19.56 None | R squared = 0.903 None,,,25.334,1
CHEMBL5606319,,,426.47,0.0,2.76,ASAP-0031155,O=C(Nc1cc2c(c(C3=CCS(=O)(=O)CC3)c1)CNC2)c1cc(F)cc2[nH]ncc12,IC50,'>',99500.0,nM,,,Falls Outside The Dose Series,UO_0000065,,,,,0,CHEMBL5604072,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 1,,,,,Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK,,,CHEMBL5705862,NS3 protease,dengue virus type 1,SINGLE PROTEIN,CHEMBL5604064,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 1.197 None | Maximum measured = 46.87 None | Maximum response = 100.0 % | Minimum measured = -5.698 None | R squared = 0.923 None,,,99.5,1
CHEMBL5605985,,,416.48,0.0,2.84,ASAP-0031120,CC(C)(c1nc2c(C(=O)Nc3ccc4c(c3)CNC4)cc(F)cc2[nH]1)S(C)(=O)=O,IC50,'=',16069.0,nM,4.79,,,UO_0000065,,,,,0,CHEMBL5604072,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 1,,,,,Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK,,,CHEMBL5705862,NS3 protease,dengue virus type 1,SINGLE PROTEIN,CHEMBL5604064,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 2.922 None | IC50 CI (lower) = 14.49 uM | IC50 CI (upper) = 17.82 uM | Maximum measured = 93.58 None | Maximum response = 100.0 % | Minimum measured = -6.653 None | R squared = 0.979 None,,,16.069,1
CHEMBL5606112,,,337.45,0.0,3.26,ASAP-0031277,NCCc1csc2cc(C(=O)Nc3ccc4c(c3)CNC4)ccc12,IC50,'>',99500.0,nM,,,Falls Outside The Dose Series,UO_0000065,,,,,0,CHEMBL5604072,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 1,,,,,Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK,,,CHEMBL5705862,NS3 protease,dengue virus type 1,SINGLE PROTEIN,CHEMBL5604064,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 1.785 None | Maximum measured = 27.18 None | Maximum response = 100.0 % | Minimum measured = -4.449 None | R squared = 0.755 None,,,99.5,1
CHEMBL5604539,,,388.39,0.0,3.44,ASAP-0030867,O=C(NCC(F)F)[C@H](Nc1ccc2c(c1)CNC2)c1cc(F)cc2[nH]ccc12,IC50,'>',99500.0,nM,,,Falls Outside The Dose Series,UO_0000065,,,,,0,CHEMBL5604072,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 1,,,,,Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK,,,CHEMBL5705862,NS3 protease,dengue virus type 1,SINGLE PROTEIN,CHEMBL5604064,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Maximum measured = -2.086 None | Minimum measured = -17.29 None,,,99.5,1
CHEMBL5606201,,,389.85,0.0,3.93,ASAP-0030082,O=C(Nc1ccc2c(c1)CNC2)c1cc(Cl)cc2nn(-c3ccccc3)nc12,IC50,'=',2690.0,nM,5.57,,,UO_0000065,,,,,0,CHEMBL5604072,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 1,,,,,Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK,,,CHEMBL5705862,NS3 protease,dengue virus type 1,SINGLE PROTEIN,CHEMBL5604064,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 20.62 None | IC50 CI (lower) = 0.0 uM | IC50 CI (upper) = 4763903498158866000 uM | Maximum measured = 97.29 None | Maximum response = 100.0 % | Minimum measured = -12.26 None | R squared = 0.965 None,,,2.69,1
CHEMBL5605533,,,418.88,0.0,4.75,ASAP-0029841,Cc1cccc(-c2nc3c(C(=O)Nc4ccc5c(c4)CNC5)cc(Cl)cc3[nH]2)c1O,IC50,'=',4255.0,nM,5.37,,,UO_0000065,,,,,0,CHEMBL5604072,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 1,,,,,Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK,,,CHEMBL5705862,NS3 protease,dengue virus type 1,SINGLE PROTEIN,CHEMBL5604064,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 4.058 None | IC50 CI (lower) = 3.316 uM | IC50 CI (upper) = 5.459 uM | Maximum measured = 97.45 None | Maximum response = 100.0 % | Minimum measured = -17.93 None | R squared = 0.972 None,,,4.255,1
CHEMBL5599838,,,459.98,1.0,5.16,ASAP-0030826,CC(C)NC(=O)[C@H](Nc1ccc2c(c1)CNC2)c1cc(Cl)cc2[nH]c(-c3ccccc3)nc12,IC50,'=',7461.0,nM,5.13,,,UO_0000065,,,,,0,CHEMBL5604072,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 1,,,,,Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK,,,CHEMBL5705862,NS3 protease,dengue virus type 1,SINGLE PROTEIN,CHEMBL5604064,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 0.982 None | IC50 CI (lower) = 6.899 uM | IC50 CI (upper) = 8.069 uM | Maximum measured = 94.12 None | Maximum response = 100.0 % | Minimum measured = -2.791 None | R squared = 0.995 None,,,7.461,1
CHEMBL5598576,,,405.88,0.0,4.36,ASAP-0029491,O=C(NCC(F)F)[C@H](Nc1ccc2c(c1)CNC2)c1cc(Cl)cc(C2CC2)c1,IC50,'>',99500.0,nM,,,Falls Outside The Dose Series,UO_0000065,,,,,0,CHEMBL5604072,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 1,,,,,Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK,,,CHEMBL5705862,NS3 protease,dengue virus type 1,SINGLE PROTEIN,CHEMBL5604064,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 1.645 None | Maximum measured = 43.75 None | Maximum response = 100.0 % | Minimum measured = -3.988 None | R squared = 0.964 None,,,99.5,1
CHEMBL5604344,,,373.21,0.0,2.47,ASAP-0029916,O=C(Nc1ccc2c(c1)CNC2)c1cc(Br)cc2[nH]c(=O)[nH]c12,IC50,'=',32728.0,nM,4.49,,,UO_0000065,,,,,0,CHEMBL5604072,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 1,,,,,Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK,,,CHEMBL5705862,NS3 protease,dengue virus type 1,SINGLE PROTEIN,CHEMBL5604064,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 2.06 None | IC50 CI (lower) = 29.68 uM | IC50 CI (upper) = 36.09 uM | Maximum measured = 82.27 None | Maximum response = 100.0 % | Minimum measured = -3.972 None | R squared = 0.977 None,,,32.728,1
CHEMBL5604418,,,351.88,0.0,4.95,ASAP-0029785,Clc1cc([C@@H]2C[C@H]2c2cccc(C3CCNCC3)c2)c2cn[nH]c2c1,IC50,'=',5945.0,nM,5.23,,,UO_0000065,,,,,0,CHEMBL5604072,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 1,,,,,Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK,,,CHEMBL5705862,NS3 protease,dengue virus type 1,SINGLE PROTEIN,CHEMBL5604064,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 13.62 None | IC50 CI (lower) = 0.0 uM | IC50 CI (upper) = 494447660689838100 uM | Maximum measured = 100.38 None | Maximum response = 100.0 % | Minimum measured = -12.78 None | R squared = 0.989 None,,,5.945,1
CHEMBL5598927,,,372.22,0.0,2.8,ASAP-0029728,O=C1Cc2c(cc(Br)cc2C(=O)Nc2ccc3c(c2)CNC3)N1,IC50,'=',84550.0,nM,4.07,,,UO_0000065,,,,,0,CHEMBL5604072,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 1,,,,,Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK,,,CHEMBL5705862,NS3 protease,dengue virus type 1,SINGLE PROTEIN,CHEMBL5604064,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 1.888 None | IC50 CI (lower) = 78.56 uM | IC50 CI (upper) = 91.0 uM | Maximum measured = 58.65 None | Maximum response = 100.0 % | Minimum measured = -3.028 None | R squared = 0.976 None,,,84.55,1
CHEMBL5598845,,,356.22,0.0,3.79,ASAP-0029002,O=C(Nc1ccc2c(c1)CNC2)c1cc(Br)cc2[nH]ccc12,IC50,'=',34724.0,nM,4.46,,,UO_0000065,,,,,0,CHEMBL5604072,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 1,,,,,Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK,,,CHEMBL5705862,NS3 protease,dengue virus type 1,SINGLE PROTEIN,CHEMBL5604064,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 2.877 None | IC50 CI (lower) = 32.99 uM | IC50 CI (upper) = 36.55 uM | Maximum measured = 88.92 None | Maximum response = 100.0 % | Minimum measured = -0.67 None | R squared = 0.992 None,,,34.724,1
CHEMBL5605162,,,387.87,0.0,3.27,ASAP-0028981,CNC(=O)[C@H](Nc1cc(CN)cc(C(=O)O)c1)c1cc(Cl)cc(C2CC2)c1,IC50,'>',99500.0,nM,,,Falls Outside The Dose Series,UO_0000065,,,,,0,CHEMBL5604072,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 1,,,,,Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK,,,CHEMBL5705862,NS3 protease,dengue virus type 1,SINGLE PROTEIN,CHEMBL5604064,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 1.599 None | Maximum measured = 5.598 None | Maximum response = 100.0 % | Minimum measured = -2.665 None | R squared = 0.449 None,,,99.5,1
CHEMBL5598591,,,373.29,0.0,4.6,ASAP-0029041,CC(C)(C)c1cc(Br)cc(C(=O)Nc2ccc3c(c2)CNC3)c1,IC50,'>',99500.0,nM,,,Falls Outside The Dose Series,UO_0000065,,,,,0,CHEMBL5604072,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 1,,,,,Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK,,,CHEMBL5705862,NS3 protease,dengue virus type 1,SINGLE PROTEIN,CHEMBL5604064,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Maximum measured = -0.891 None | Minimum measured = -23.32 None,,,99.5,1
CHEMBL5598577,,,326.79,0.0,3.11,ASAP-0029079,O=C(Nc1ccc2c(c1)CNCC2)c1cc(Cl)cc2[nH]ncc12,IC50,'>',99500.0,nM,,,Falls Outside The Dose Series,UO_0000065,,,,,0,CHEMBL5604072,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 1,,,,,Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK,,,CHEMBL5705862,NS3 protease,dengue virus type 1,SINGLE PROTEIN,CHEMBL5604064,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 1.276 None | Maximum measured = 33.58 None | Maximum response = 100.0 % | Minimum measured = -2.39 None | R squared = 0.972 None,,,99.5,1
CHEMBL5598593,,,309.76,0.0,3.59,ASAP-0027972,Clc1ccc2[nH]cc(Cc3ccc(-c4nn[nH]n4)cc3)c2c1,IC50,'=',62907.0,nM,4.2,,,UO_0000065,,,,,0,CHEMBL5604072,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 1,,,,,Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK,,,CHEMBL5705862,NS3 protease,dengue virus type 1,SINGLE PROTEIN,CHEMBL5604064,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 3.384 None | IC50 CI (lower) = 60.52 uM | IC50 CI (upper) = 65.38 uM | Maximum measured = 83.79 None | Maximum response = 100.0 % | Minimum measured = -1.661 None | R squared = 0.992 None,,,62.907,1
CHEMBL5605497,,,463.97,1.0,5.94,ASAP-0023377,N[C@H]1CC[C@H](c2ccc(NC(=O)c3cc(Cl)cc(NC(=O)OCc4ccccc4)c3)cc2)C1,IC50,'=',8493.0,nM,5.07,,,UO_0000065,,,,,0,CHEMBL5604072,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 1,,,,,Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK,,,CHEMBL5705862,NS3 protease,dengue virus type 1,SINGLE PROTEIN,CHEMBL5604064,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 3.316 None | IC50 CI (lower) = 7.484 uM | IC50 CI (upper) = 9.637 uM | Maximum measured = 100.01 None | Maximum response = 100.0 % | Minimum measured = -11.23 None | R squared = 0.97 None,,,8.493,1
CHEMBL3740727,,,719.79,2.0,2.06,ASAP-0000570,N=C(N)NCCC[C@H](NC(=O)c1nccs1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(N)=O)c1ccc(OCc2ccc(C(F)(F)F)cc2)cc1,IC50,'=',1033.0,nM,5.99,,,UO_0000065,,,,,0,CHEMBL5604072,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 1,,,,,Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK,,,CHEMBL5705862,NS3 protease,dengue virus type 1,SINGLE PROTEIN,CHEMBL5604064,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 1.062 None | IC50 CI (lower) = 0.989 uM | IC50 CI (upper) = 1.079 uM | Maximum measured = 99.36 None | Maximum response = 100.0 % | Minimum measured = 4.771 None | R squared = 0.998 None,,,1.033,1
CHEMBL3919119,,,454.34,,,ASAP-0015081,N=C(N)NCCC[C@H](NC(=O)[C@H](Cc1ccc(CN)cc1)NC(=O)c1ccccc1)B(O)O,IC50,'=',315.0,nM,6.5,,,UO_0000065,,,,,0,CHEMBL5604072,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 1,,,,,Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK,,,CHEMBL5705862,NS3 protease,dengue virus type 1,SINGLE PROTEIN,CHEMBL5604064,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 1.113 None | IC50 CI (lower) = 0.297 uM | IC50 CI (upper) = 0.334 uM | Maximum measured = 99.79 None | Maximum response = 100.0 % | Minimum measured = 12.94 None | R squared = 0.996 None,,,0.315,1
CHEMBL5605856,,,406.91,1.0,5.82,ASAP-0027760,NCc1ccc([C@H]2C[C@@H]2c2cc(Cl)cc(NC(=O)OCc3ccccc3)c2)cc1,IC50,'=',8889.0,nM,5.05,,,UO_0000065,,,,,0,CHEMBL5604072,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 1,,,,,Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK,,,CHEMBL5705862,NS3 protease,dengue virus type 1,SINGLE PROTEIN,CHEMBL5604064,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 5.4 None | IC50 CI (lower) = 8.34 uM | IC50 CI (upper) = 9.474 uM | Maximum measured = 97.61 None | Maximum response = 100.0 % | Minimum measured = -10.59 None | R squared = 0.987 None,,,8.889,1
CHEMBL5605947,,,435.91,0.0,4.99,ASAP-0027652,O=C(Nc1cc(Cl)cc(C(=O)Nc2ccc3c(c2)CCNC3)c1)OCc1ccccc1,IC50,'=',47725.0,nM,4.32,,,UO_0000065,,,,,0,CHEMBL5604072,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 1,,,,,Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK,,,CHEMBL5705862,NS3 protease,dengue virus type 1,SINGLE PROTEIN,CHEMBL5604064,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 3.674 None | IC50 CI (lower) = 42.79 uM | IC50 CI (upper) = 53.23 uM | Maximum measured = 87.09 None | Maximum response = 100.0 % | Minimum measured = -12.68 None | R squared = 0.945 None,,,47.725,1
CHEMBL5598679,,,293.33,0.0,2.04,ASAP-0029208,O=C1Cc2c(cccc2C(=O)Nc2ccc3c(c2)CNC3)N1,IC50,'=',11306.0,nM,4.95,,,UO_0000065,,,,,0,CHEMBL5604072,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 1,,,,,Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK,,,CHEMBL5705862,NS3 protease,dengue virus type 1,SINGLE PROTEIN,CHEMBL5604064,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 2.732 None | IC50 CI (lower) = 10.58 uM | IC50 CI (upper) = 12.08 uM | Maximum measured = 99.43 None | Maximum response = 100.0 % | Minimum measured = -2.578 None | R squared = 0.991 None,,,11.306,1
CHEMBL5598615,,,367.25,0.0,4.46,ASAP-0029045,O=C(Nc1ccc2c(c1)CNC2)c1cc(Br)cc2ccccc12,IC50,'=',83668.0,nM,4.08,,,UO_0000065,,,,,0,CHEMBL5604072,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 1,,,,,Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK,,,CHEMBL5705862,NS3 protease,dengue virus type 1,SINGLE PROTEIN,CHEMBL5604064,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 3.388 None | IC50 CI (lower) = 76.73 uM | IC50 CI (upper) = 91.23 uM | Maximum measured = 63.44 None | Maximum response = 100.0 % | Minimum measured = -9.201 None | R squared = 0.932 None,,,83.668,1
CHEMBL5605520,,,352.82,0.0,2.97,ASAP-0028990,OCC#C[C@H](Nc1ccc2c(c1)CNC2)c1cc(Cl)cc2[nH]ncc12,IC50,'=',19396.0,nM,4.71,,,UO_0000065,,,,,0,CHEMBL5604072,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 1,,,,,Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK,,,CHEMBL5705862,NS3 protease,dengue virus type 1,SINGLE PROTEIN,CHEMBL5604064,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 3.531 None | IC50 CI (lower) = 17.8 uM | IC50 CI (upper) = 21.14 uM | Maximum measured = 96.3 None | Maximum response = 100.0 % | Minimum measured = -11.79 None | R squared = 0.984 None,,,19.396,1
CHEMBL5604375,,,323.79,0.0,3.5,ASAP-0028904,N#C[C@H](Nc1ccc2c(c1)CNC2)c1cc(Cl)cc2[nH]ncc12,IC50,'>',99500.0,nM,,,Falls Outside The Dose Series,UO_0000065,,,,,0,CHEMBL5604072,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 1,,,,,Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK,,,CHEMBL5705862,NS3 protease,dengue virus type 1,SINGLE PROTEIN,CHEMBL5604064,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Maximum measured = 3.796 None | Minimum measured = -7.933 None,,,99.5,1
CHEMBL3919119,,,454.34,,,ASAP-0015081,N=C(N)NCCC[C@H](NC(=O)[C@H](Cc1ccc(CN)cc1)NC(=O)c1ccccc1)B(O)O,IC50,'=',310.0,nM,6.51,,,UO_0000065,,,,,0,CHEMBL5604072,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 1,,,,,Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK,,,CHEMBL5705862,NS3 protease,dengue virus type 1,SINGLE PROTEIN,CHEMBL5604064,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 1.212 None | IC50 CI (lower) = 0.299 uM | IC50 CI (upper) = 0.322 uM | Maximum measured = 99.81 None | Maximum response = 100.0 % | Minimum measured = 12.63 None | R squared = 0.998 None,,,0.31,1
CHEMBL5605561,,,333.4,0.0,2.11,ASAP-0031692,O=C(Nc1ccc2c(c1)CNC2)c1cccc2c(C3CNC3)n[nH]c12,IC50,'=',92913.0,nM,4.03,,,UO_0000065,,,,,0,CHEMBL5604072,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 1,,,,,Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK,,,CHEMBL5705862,NS3 protease,dengue virus type 1,SINGLE PROTEIN,CHEMBL5604064,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 1.221 None | IC50 CI (lower) = 79.45 uM | IC50 CI (upper) = 108.65 uM | Maximum measured = 50.77 None | Maximum response = 100.0 % | Minimum measured = -4.58 None | R squared = 0.954 None,,,92.913,1
CHEMBL5605664,,,390.39,0.0,4.36,ASAP-0031237,O=C(Nc1ccc2c(c1)CNC2)c1cc(F)cc2[nH]c(-c3ccc(F)cc3)nc12,IC50,'=',2796.0,nM,5.55,,,UO_0000065,,,,,0,CHEMBL5604072,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 1,,,,,Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK,,,CHEMBL5705862,NS3 protease,dengue virus type 1,SINGLE PROTEIN,CHEMBL5604064,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 2.2 None | IC50 CI (lower) = 2.27 uM | IC50 CI (upper) = 3.445 uM | Maximum measured = 94.29 None | Maximum response = 100.0 % | Minimum measured = -2.07 None | R squared = 0.95 None,,,2.796,1
CHEMBL5605372,,,323.42,0.0,3.22,ASAP-0031633,NCc1csc2cc(C(=O)Nc3ccc4c(c3)CNC4)ccc12,IC50,'=',9985.0,nM,5.0,,,UO_0000065,,,,,0,CHEMBL5604072,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 1,,,,,Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK,,,CHEMBL5705862,NS3 protease,dengue virus type 1,SINGLE PROTEIN,CHEMBL5604064,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 2.804 None | IC50 CI (lower) = 9.104 uM | IC50 CI (upper) = 10.95 uM | Maximum measured = 99.12 None | Maximum response = 100.0 % | Minimum measured = -7.829 None | R squared = 0.985 None,,,9.985,1
CHEMBL5605310,,,399.52,0.0,4.88,ASAP-0031492,NCc1ccc(-c2csc3cc(C(=O)Nc4ccc5c(c4)CNC5)ccc23)cc1,IC50,'=',31660.0,nM,4.5,,,UO_0000065,,,,,0,CHEMBL5604072,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 1,,,,,Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK,,,CHEMBL5705862,NS3 protease,dengue virus type 1,SINGLE PROTEIN,CHEMBL5604064,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 1.567 None | IC50 CI (lower) = 28.38 uM | IC50 CI (upper) = 35.32 uM | Maximum measured = 65.86 None | Maximum response = 100.0 % | Minimum measured = -6.825 None | R squared = 0.97 None,,,31.66,1
CHEMBL5604216,,,397.41,0.0,4.1,ASAP-0031247,N#Cc1cccc(-c2nc3c(C(=O)Nc4ccc5c(c4)CNC5)cc(F)cc3[nH]2)c1,IC50,'=',2412.0,nM,5.62,,,UO_0000065,,,,,0,CHEMBL5604072,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 1,,,,,Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK,,,CHEMBL5705862,NS3 protease,dengue virus type 1,SINGLE PROTEIN,CHEMBL5604064,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 1.874 None | IC50 CI (lower) = 2.032 uM | IC50 CI (upper) = 2.863 uM | Maximum measured = 92.71 None | Maximum response = 100.0 % | Minimum measured = -3.853 None | R squared = 0.967 None,,,2.412,1
CHEMBL5605238,,,375.5,0.0,4.13,ASAP-0031464,O=C(Nc1ccc2c(c1)CNC2)c1ccc2c(C3=CCNCC3)csc2c1,IC50,'=',56250.0,nM,4.25,,,UO_0000065,,,,,0,CHEMBL5604072,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 1,,,,,Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK,,,CHEMBL5705862,NS3 protease,dengue virus type 1,SINGLE PROTEIN,CHEMBL5604064,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 2.04 None | IC50 CI (lower) = 52.7 uM | IC50 CI (upper) = 60.04 uM | Maximum measured = 77.81 None | Maximum response = 100.0 % | Minimum measured = -3.359 None | R squared = 0.985 None,,,56.25,1
CHEMBL3740727,,,719.79,2.0,2.06,ASAP-0000570,N=C(N)NCCC[C@H](NC(=O)c1nccs1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(N)=O)c1ccc(OCc2ccc(C(F)(F)F)cc2)cc1,IC50,'=',926.0,nM,6.03,,,UO_0000065,,,,,0,CHEMBL5604072,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 1,,,,,Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK,,,CHEMBL5705862,NS3 protease,dengue virus type 1,SINGLE PROTEIN,CHEMBL5604064,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 1.114 None | IC50 CI (lower) = 0.896 uM | IC50 CI (upper) = 0.957 uM | Maximum measured = 99.76 None | Maximum response = 100.0 % | Minimum measured = 2.677 None | R squared = 0.999 None,,,0.926,1
CHEMBL5598732,,,359.27,0.0,4.43,ASAP-0029050,CC(C)c1cc(Br)cc(C(=O)Nc2ccc3c(c2)CNC3)c1,IC50,'>',99500.0,nM,,,Falls Outside The Dose Series,UO_0000065,,,,,0,CHEMBL5604072,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 1,,,,,Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK,,,CHEMBL5705862,NS3 protease,dengue virus type 1,SINGLE PROTEIN,CHEMBL5604064,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Maximum measured = -0.663 None | Minimum measured = -23.93 None,,,99.5,1
CHEMBL5598631,,,312.8,0.0,3.68,ASAP-0029051,O=C(Nc1ccc2c(c1)CNC2)c1cc(Cl)cc2c1CCC2,IC50,'>',99500.0,nM,,,Falls Outside The Dose Series,UO_0000065,,,,,0,CHEMBL5604072,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 1,,,,,Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK,,,CHEMBL5705862,NS3 protease,dengue virus type 1,SINGLE PROTEIN,CHEMBL5604064,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Maximum measured = -0.342 None | Minimum measured = -6.448 None,,,99.5,1
CHEMBL3740727,,,719.79,2.0,2.06,ASAP-0000570,N=C(N)NCCC[C@H](NC(=O)c1nccs1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(N)=O)c1ccc(OCc2ccc(C(F)(F)F)cc2)cc1,IC50,'=',1028.0,nM,5.99,,,UO_0000065,,,,,0,CHEMBL5604072,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 1,,,,,Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK,,,CHEMBL5705862,NS3 protease,dengue virus type 1,SINGLE PROTEIN,CHEMBL5604064,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 1.108 None | IC50 CI (lower) = 0.988 uM | IC50 CI (upper) = 1.069 uM | Maximum measured = 99.67 None | Maximum response = 100.0 % | Minimum measured = 0.737 None | R squared = 0.999 None,,,1.028,1
CHEMBL5604471,,,332.41,0.0,3.92,ASAP-0029790,Cc1c(C(=O)Nc2cc(-c3cccnc3)ccn2)cc(C2CC2)n1C,IC50,'=',4832.0,nM,5.32,,,UO_0000065,,,,,0,CHEMBL5604072,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 1,,,,,Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK,,,CHEMBL5705862,NS3 protease,dengue virus type 1,SINGLE PROTEIN,CHEMBL5604064,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 2.861 None | IC50 CI (lower) = 4.483 uM | IC50 CI (upper) = 5.209 uM | Maximum measured = 98.96 None | Maximum response = 100.0 % | Minimum measured = -3.028 None | R squared = 0.996 None,,,4.832,1
CHEMBL5605549,,,294.31,0.0,1.71,ASAP-0029783,O=C(Nc1ccc2c(c1)CNC2)c1cccc2[nH]c(=O)[nH]c12,IC50,'=',65525.0,nM,4.18,,,UO_0000065,,,,,0,CHEMBL5604072,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 1,,,,,Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK,,,CHEMBL5705862,NS3 protease,dengue virus type 1,SINGLE PROTEIN,CHEMBL5604064,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 1.683 None | IC50 CI (lower) = 62.43 uM | IC50 CI (upper) = 68.77 uM | Maximum measured = 68.28 None | Maximum response = 100.0 % | Minimum measured = -0.988 None | R squared = 0.992 None,,,65.525,1
CHEMBL5605462,,,491.94,0.0,4.17,ASAP-0027759,CNC(=O)[C@H](Nc1cc(Cl)cc(NC(=O)OCc2ccccc2)c1)c1cccc(-c2nn[nH]n2)c1,IC50,'=',46518.0,nM,4.33,,,UO_0000065,,,,,0,CHEMBL5604072,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 1,,,,,Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK,,,CHEMBL5705862,NS3 protease,dengue virus type 1,SINGLE PROTEIN,CHEMBL5604064,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 3.493 None | IC50 CI (lower) = 41.74 uM | IC50 CI (upper) = 51.85 uM | Maximum measured = 93.57 None | Maximum response = 100.0 % | Minimum measured = -7.783 None | R squared = 0.953 None,,,46.518,1
CHEMBL3740727,,,719.79,2.0,2.06,ASAP-0000570,N=C(N)NCCC[C@H](NC(=O)c1nccs1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(N)=O)c1ccc(OCc2ccc(C(F)(F)F)cc2)cc1,IC50,'=',1000.0,nM,6.0,,,UO_0000065,,,,,0,CHEMBL5604072,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 1,,,,,Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK,,,CHEMBL5705862,NS3 protease,dengue virus type 1,SINGLE PROTEIN,CHEMBL5604064,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 1.182 None | IC50 CI (lower) = 0.945 uM | IC50 CI (upper) = 1.059 uM | Maximum measured = 99.41 None | Maximum response = 100.0 % | Minimum measured = 1.783 None | R squared = 0.997 None,,,1.0,1
CHEMBL3740727,,,719.79,2.0,2.06,ASAP-0000570,N=C(N)NCCC[C@H](NC(=O)c1nccs1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(N)=O)c1ccc(OCc2ccc(C(F)(F)F)cc2)cc1,IC50,'=',1695.0,nM,5.77,,,UO_0000065,,,,,0,CHEMBL5604072,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 1,,,,,Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK,,,CHEMBL5705862,NS3 protease,dengue virus type 1,SINGLE PROTEIN,CHEMBL5604064,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 1.153 None | IC50 CI (lower) = 1.613 uM | IC50 CI (upper) = 1.781 uM | Maximum measured = 100.95 None | Maximum response = 100.0 % | Minimum measured = -1.231 None | R squared = 0.998 None,,,1.695,1
CHEMBL5606160,,,372.4,0.0,4.22,ASAP-0030089,O=C(Nc1ccc2c(c1)CNC2)c1cc(F)cc2[nH]c(-c3ccccc3)nc12,IC50,'=',3672.0,nM,5.43,,,UO_0000065,,,,,0,CHEMBL5604072,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 1,,,,,Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK,,,CHEMBL5705862,NS3 protease,dengue virus type 1,SINGLE PROTEIN,CHEMBL5604064,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 2.523 None | IC50 CI (lower) = 2.452 uM | IC50 CI (upper) = 5.499 uM | Maximum measured = 89.22 None | Maximum response = 100.0 % | Minimum measured = -6.225 None | R squared = 0.828 None,,,3.672,1
CHEMBL5604703,,,326.79,0.0,3.38,ASAP-0029875,Cc1nc2c(C(=O)Nc3ccc4c(c3)CNC4)cc(Cl)cc2[nH]1,IC50,'>',99500.0,nM,,,Falls Outside The Dose Series,UO_0000065,,,,,0,CHEMBL5604072,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 1,,,,,Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK,,,CHEMBL5705862,NS3 protease,dengue virus type 1,SINGLE PROTEIN,CHEMBL5604064,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 0.544 None | Maximum measured = 30.39 None | Maximum response = 100.0 % | Minimum measured = -3.72 None | R squared = 0.159 None,,,99.5,1
CHEMBL5598658,,,355.87,0.0,3.72,ASAP-0029621,CNC(=O)[C@H](Nc1ccc2c(c1)CNC2)c1cc(Cl)cc(C2CC2)c1,IC50,'>',99500.0,nM,,,Falls Outside The Dose Series,UO_0000065,,,,,0,CHEMBL5604072,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 1,,,,,Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK,,,CHEMBL5705862,NS3 protease,dengue virus type 1,SINGLE PROTEIN,CHEMBL5604064,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Maximum measured = 0.894 None | Minimum measured = -23.45 None,,,99.5,1
CHEMBL5598743,,,425.96,0.0,4.27,ASAP-0029555,O=C(NC1CCOCC1)[C@H](Nc1ccc2c(c1)CNC2)c1cc(Cl)cc(C2CC2)c1,IC50,'>',99500.0,nM,,,Falls Outside The Dose Series,UO_0000065,,,,,0,CHEMBL5604072,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 1,,,,,Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK,,,CHEMBL5705862,NS3 protease,dengue virus type 1,SINGLE PROTEIN,CHEMBL5604064,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 3.11 None | Maximum measured = 12.16 None | Maximum response = 100.0 % | Minimum measured = -4.915 None | R squared = 0.597 None,,,99.5,1
CHEMBL5598576,,,405.88,0.0,4.36,ASAP-0029491,O=C(NCC(F)F)[C@H](Nc1ccc2c(c1)CNC2)c1cc(Cl)cc(C2CC2)c1,IC50,'>',99500.0,nM,,,Falls Outside The Dose Series,UO_0000065,,,,,0,CHEMBL5604072,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 1,,,,,Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK,,,CHEMBL5705862,NS3 protease,dengue virus type 1,SINGLE PROTEIN,CHEMBL5604064,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 1.79 None | Maximum measured = 32.43 None | Maximum response = 100.0 % | Minimum measured = -4.103 None | R squared = 0.912 None,,,99.5,1
CHEMBL5598746,,,435.96,0.0,4.02,ASAP-0029471,Cn1cc(CNC(=O)[C@H](Nc2ccc3c(c2)CNC3)c2cc(Cl)cc(C3CC3)c2)cn1,IC50,'>',99500.0,nM,,,Falls Outside The Dose Series,UO_0000065,,,,,0,CHEMBL5604072,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 1,,,,,Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK,,,CHEMBL5705862,NS3 protease,dengue virus type 1,SINGLE PROTEIN,CHEMBL5604064,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 11.41 None | Maximum measured = 7.18 None | Maximum response = 100.0 % | Minimum measured = -5.5 None | R squared = 0.319 None,,,99.5,1
CHEMBL5598718,,,298.78,0.0,3.43,ASAP-0029525,Clc1cc(CNc2ccc3c(c2)CNC3)c2cn[nH]c2c1,IC50,'=',30908.0,nM,4.51,,,UO_0000065,,,,,0,CHEMBL5604072,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 1,,,,,Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK,,,CHEMBL5705862,NS3 protease,dengue virus type 1,SINGLE PROTEIN,CHEMBL5604064,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 2.356 None | IC50 CI (lower) = 28.4 uM | IC50 CI (upper) = 33.64 uM | Maximum measured = 85.14 None | Maximum response = 100.0 % | Minimum measured = -4.042 None | R squared = 0.983 None,,,30.908,1
CHEMBL5598786,,,296.3,0.0,2.56,ASAP-0029497,O=C(Nc1ccc2c(c1)CNC2)c1cc(F)cc2[nH]ncc12,IC50,'=',68230.0,nM,4.17,,,UO_0000065,,,,,0,CHEMBL5604072,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 1,,,,,Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK,,,CHEMBL5705862,NS3 protease,dengue virus type 1,SINGLE PROTEIN,CHEMBL5604064,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 0.968 None | IC50 CI (lower) = 60.58 uM | IC50 CI (upper) = 76.85 uM | Maximum measured = 55.66 None | Maximum response = 100.0 % | Minimum measured = -2.271 None | R squared = 0.98 None,,,68.23,1
CHEMBL5598605,,,305.34,0.0,3.2,ASAP-0029713,O=C(Nc1ccc2c(c1)CNC2)c1cccc(-c2cnco2)c1,IC50,'=',20321.0,nM,4.69,,,UO_0000065,,,,,0,CHEMBL5604072,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 1,,,,,Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK,,,CHEMBL5705862,NS3 protease,dengue virus type 1,SINGLE PROTEIN,CHEMBL5604064,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 2.055 None | IC50 CI (lower) = 18.95 uM | IC50 CI (upper) = 21.79 uM | Maximum measured = 95.09 None | Maximum response = 100.0 % | Minimum measured = -3.904 None | R squared = 0.992 None,,,20.321,1
CHEMBL5598765,,,420.9,0.0,3.59,ASAP-0029650,Cn1cc(CCc2nc3c(C(=O)Nc4ccc5c(c4)CNC5)cc(Cl)cc3[nH]2)cn1,IC50,'=',21587.0,nM,4.67,,,UO_0000065,,,,,0,CHEMBL5604072,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 1,,,,,Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK,,,CHEMBL5705862,NS3 protease,dengue virus type 1,SINGLE PROTEIN,CHEMBL5604064,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 1.253 None | IC50 CI (lower) = 18.35 uM | IC50 CI (upper) = 25.4 uM | Maximum measured = 81.39 None | Maximum response = 100.0 % | Minimum measured = -4.32 None | R squared = 0.964 None,,,21.587,1
CHEMBL5604470,,,397.41,0.0,4.1,ASAP-0031299,N#Cc1ccc(-c2nc3c(C(=O)Nc4ccc5c(c4)CNC5)cc(F)cc3[nH]2)cc1,IC50,'=',1680.0,nM,5.78,,,UO_0000065,,,,,0,CHEMBL5604072,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 1,,,,,Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK,,,CHEMBL5705862,NS3 protease,dengue virus type 1,SINGLE PROTEIN,CHEMBL5604064,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 2.462 None | IC50 CI (lower) = 1.525 uM | IC50 CI (upper) = 1.85 uM | Maximum measured = 95.92 None | Maximum response = 100.0 % | Minimum measured = -4.1 None | R squared = 0.985 None,,,1.68,1
CHEMBL5604338,,,360.46,0.0,3.49,ASAP-0031404,O=C(Nc1ccc2c(c1)CNC2)c1ccc2[nH]cc(C3CCNCC3)c2c1,IC50,'=',31174.0,nM,4.51,,,UO_0000065,,,,,0,CHEMBL5604072,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 1,,,,,Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK,,,CHEMBL5705862,NS3 protease,dengue virus type 1,SINGLE PROTEIN,CHEMBL5604064,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 3.859 None | IC50 CI (lower) = 29.64 uM | IC50 CI (upper) = 32.78 uM | Maximum measured = 95.9 None | Maximum response = 100.0 % | Minimum measured = -3.84 None | R squared = 0.992 None,,,31.174,1
CHEMBL5604332,,,312.76,0.0,3.07,ASAP-0027808,O=C(Nc1ccc2c(c1)CNC2)c1cc(Cl)cc2[nH]ncc12,IC50,'=',69217.0,nM,4.16,,,UO_0000065,,,,,0,CHEMBL5604072,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 1,,,,,Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK,,,CHEMBL5705862,NS3 protease,dengue virus type 1,SINGLE PROTEIN,CHEMBL5604064,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 1.291 None | IC50 CI (lower) = 65.83 uM | IC50 CI (upper) = 72.78 uM | Maximum measured = 63.58 None | Maximum response = 100.0 % | Minimum measured = -0.857 None | R squared = 0.994 None,,,69.217,1
CHEMBL5598717,,,565.08,2.0,6.65,ASAP-0027928,O=C(Nc1cc(Cl)cc([C@H]2CN(Cc3ccccc3)C[C@@H]2c2cccc(-c3nn[nH]n3)c2)c1)OCc1ccccc1,IC50,'=',6635.0,nM,5.18,,,UO_0000065,,,,,0,CHEMBL5604072,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 1,,,,,Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK,,,CHEMBL5705862,NS3 protease,dengue virus type 1,SINGLE PROTEIN,CHEMBL5604064,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 3.202 None | IC50 CI (lower) = 6.226 uM | IC50 CI (upper) = 7.071 uM | Maximum measured = 98.36 None | Maximum response = 100.0 % | Minimum measured = -2.827 None | R squared = 0.996 None,,,6.635,1
CHEMBL5605186,,,461.01,1.0,6.83,ASAP-0027756,O=C(Nc1cc(Cl)cc([C@H]2C[C@@H]2c2cccc(C3CCNCC3)c2)c1)OCc1ccccc1,IC50,'=',6279.0,nM,5.2,,,UO_0000065,,,,,0,CHEMBL5604072,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 1,,,,,Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK,,,CHEMBL5705862,NS3 protease,dengue virus type 1,SINGLE PROTEIN,CHEMBL5604064,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 4.195 None | IC50 CI (lower) = 5.297 uM | IC50 CI (upper) = 7.443 uM | Maximum measured = 99.64 None | Maximum response = 100.0 % | Minimum measured = -13.14 None | R squared = 0.981 None,,,6.279,1
CHEMBL5605526,,,409.87,0.0,4.8,ASAP-0016806,NCc1cccc(NC(=O)c2cc(Cl)cc(NC(=O)OCc3ccccc3)c2)c1,IC50,'=',51118.0,nM,4.29,,,UO_0000065,,,,,0,CHEMBL5604072,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 1,,,,,Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK,,,CHEMBL5705862,NS3 protease,dengue virus type 1,SINGLE PROTEIN,CHEMBL5604064,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 3.313 None | IC50 CI (lower) = 47.19 uM | IC50 CI (upper) = 55.37 uM | Maximum measured = 85.83 None | Maximum response = 100.0 % | Minimum measured = -8.718 None | R squared = 0.97 None,,,51.118,1
CHEMBL5605090,,,336.37,0.0,3.67,ASAP-0030071,C=CC[C@H]1NCc2cc(NC(=O)c3cc(F)cc4[nH]ncc34)ccc21,IC50,'>',99500.0,nM,,,Falls Outside The Dose Series,UO_0000065,,,,,0,CHEMBL5604072,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 1,,,,,Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK,,,CHEMBL5705862,NS3 protease,dengue virus type 1,SINGLE PROTEIN,CHEMBL5604064,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 6.384 None | Maximum measured = 5.993 None | Maximum response = 100.0 % | Minimum measured = -1.936 None | R squared = 0.507 None,,,99.5,1
CHEMBL5605716,,,305.34,0.0,2.8,ASAP-0029967,O=C(Nc1ccc2c(c1)CNC2)c1cccc2nc(O)ccc12,IC50,'>',99500.0,nM,,,Falls Outside The Dose Series,UO_0000065,,,,,0,CHEMBL5604072,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 1,,,,,Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK,,,CHEMBL5705862,NS3 protease,dengue virus type 1,SINGLE PROTEIN,CHEMBL5604064,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 4.962 None | Maximum measured = 8.963 None | Maximum response = 100.0 % | Minimum measured = -4.15 None | R squared = 0.598 None,,,99.5,1
CHEMBL5604164,,,345.32,0.0,4.04,ASAP-0030028,O=C(Nc1ccc2c(c1)CNC2)c1cccc2[nH]c(C(F)(F)F)cc12,IC50,'>',99500.0,nM,,,Falls Outside The Dose Series,UO_0000065,,,,,0,CHEMBL5604072,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 1,,,,,Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK,,,CHEMBL5705862,NS3 protease,dengue virus type 1,SINGLE PROTEIN,CHEMBL5604064,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Maximum measured = 1.145 None | Minimum measured = -6.449 None,,,99.5,1
CHEMBL5604667,,,422.49,0.0,4.2,ASAP-0031355,CC(C)c1nnc(-c2nc3c(C(=O)Nc4ccc5c(c4)CNC5)cc(F)cc3[nH]2)s1,IC50,'=',21779.0,nM,4.66,,,UO_0000065,,,,,0,CHEMBL5604072,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 1,,,,,Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK,,,CHEMBL5705862,NS3 protease,dengue virus type 1,SINGLE PROTEIN,CHEMBL5604064,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 1.043 None | IC50 CI (lower) = 15.77 uM | IC50 CI (upper) = 30.08 uM | Maximum measured = 68.13 None | Maximum response = 100.0 % | Minimum measured = -4.215 None | R squared = 0.882 None,,,21.779,1
CHEMBL5605103,,,386.43,0.0,4.53,ASAP-0031310,Cc1ccccc1-c1nc2c(C(=O)Nc3ccc4c(c3)CNC4)cc(F)cc2[nH]1,IC50,'=',2189.0,nM,5.66,,,UO_0000065,,,,,0,CHEMBL5604072,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 1,,,,,Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK,,,CHEMBL5705862,NS3 protease,dengue virus type 1,SINGLE PROTEIN,CHEMBL5604064,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 2.425 None | IC50 CI (lower) = 1.859 uM | IC50 CI (upper) = 2.576 uM | Maximum measured = 96.27 None | Maximum response = 100.0 % | Minimum measured = -2.105 None | R squared = 0.96 None,,,2.189,1
CHEMBL5604531,,,402.43,0.0,4.23,ASAP-0031290,COc1cccc(-c2nc3c(C(=O)Nc4ccc5c(c4)CNC5)cc(F)cc3[nH]2)c1,IC50,'=',5415.0,nM,5.27,,,UO_0000065,,,,,0,CHEMBL5604072,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 1,,,,,Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK,,,CHEMBL5705862,NS3 protease,dengue virus type 1,SINGLE PROTEIN,CHEMBL5604064,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 1.493 None | IC50 CI (lower) = 4.071 uM | IC50 CI (upper) = 7.204 uM | Maximum measured = 87.21 None | Maximum response = 100.0 % | Minimum measured = -3.508 None | R squared = 0.922 None,,,5.415,1
CHEMBL5604114,,,488.94,0.0,4.42,ASAP-0027813,O=C(Nc1cc(Cl)cc([C@H](C#CCO)Nc2cccc(-c3nn[nH]n3)c2)c1)OCc1ccccc1,IC50,'=',12720.0,nM,4.9,,,UO_0000065,,,,,0,CHEMBL5604072,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 1,,,,,Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK,,,CHEMBL5705862,NS3 protease,dengue virus type 1,SINGLE PROTEIN,CHEMBL5604064,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 3.053 None | IC50 CI (lower) = 11.51 uM | IC50 CI (upper) = 14.06 uM | Maximum measured = 98.22 None | Maximum response = 100.0 % | Minimum measured = -4.838 None | R squared = 0.98 None,,,12.72,1
CHEMBL5606153,,,423.9,1.0,5.11,ASAP-0021119,Cc1ccc(NC(=O)c2cc(Cl)cc(NC(=O)OCc3ccccc3)c2)cc1CN,IC50,'>',99500.0,nM,,,Falls Outside The Dose Series,UO_0000065,,,,,0,CHEMBL5604072,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 1,,,,,Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK,,,CHEMBL5705862,NS3 protease,dengue virus type 1,SINGLE PROTEIN,CHEMBL5604064,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 3.519 None | Maximum measured = 43.98 None | Maximum response = 100.0 % | Minimum measured = -17.96 None | R squared = 0.519 None,,,99.5,1
CHEMBL5604414,,,464.91,1.0,5.53,ASAP-0023480,O=C(Nc1cc(Cl)cc(C(=O)Nc2cccc([C@H]3C[C@H]3C(=O)O)c2)c1)OCc1ccccc1,IC50,'=',25164.0,nM,4.6,,,UO_0000065,,,,,0,CHEMBL5604072,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 1,,,,,Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK,,,CHEMBL5705862,NS3 protease,dengue virus type 1,SINGLE PROTEIN,CHEMBL5604064,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 3.325 None | IC50 CI (lower) = 22.49 uM | IC50 CI (upper) = 28.15 uM | Maximum measured = 97.92 None | Maximum response = 100.0 % | Minimum measured = -7.23 None | R squared = 0.969 None,,,25.164,1
CHEMBL5604328,,,459.9,0.0,4.95,ASAP-0028861,N#C[C@H](Nc1cccc(-c2nn[nH]n2)c1)c1cc(Cl)cc(NC(=O)OCc2ccccc2)c1,IC50,'=',10024.0,nM,5.0,,,UO_0000065,,,,,0,CHEMBL5604072,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 1,,,,,Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK,,,CHEMBL5705862,NS3 protease,dengue virus type 1,SINGLE PROTEIN,CHEMBL5604064,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 3.404 None | IC50 CI (lower) = 9.127 uM | IC50 CI (upper) = 11.01 uM | Maximum measured = 100.46 None | Maximum response = 100.0 % | Minimum measured = -5.169 None | R squared = 0.981 None,,,10.024,1
CHEMBL5605251,,,493.41,1.0,5.97,ASAP-0015849,CC(C)CNC(=O)c1cc(Cl)ccc1NS(=O)(=O)c1ccc(Oc2ccccc2Cl)cc1,IC50,'=',14372.0,nM,4.84,,,UO_0000065,,,,,0,CHEMBL5604072,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 1,,,,,Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK,,,CHEMBL5705862,NS3 protease,dengue virus type 1,SINGLE PROTEIN,CHEMBL5604064,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 2.145 None | IC50 CI (lower) = 11.39 uM | IC50 CI (upper) = 18.13 uM | Maximum measured = 83.39 None | Maximum response = 100.0 % | Minimum measured = -11.24 None | R squared = 0.915 None,,,14.372,1
CHEMBL5606457,,,464.87,0.0,3.61,ASAP-0023274,O=C(Nc1cc(Cl)cc(C(=O)Nc2cccc(-n3nn[nH]c3=O)c2)c1)OCc1ccccc1,IC50,'=',11555.0,nM,4.94,,,UO_0000065,,,,,0,CHEMBL5604072,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 1,,,,,Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK,,,CHEMBL5705862,NS3 protease,dengue virus type 1,SINGLE PROTEIN,CHEMBL5604064,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 3.673 None | IC50 CI (lower) = 10.43 uM | IC50 CI (upper) = 12.8 uM | Maximum measured = 98.52 None | Maximum response = 100.0 % | Minimum measured = -9.322 None | R squared = 0.976 None,,,11.555,1
CHEMBL5604806,,,420.85,1.0,5.94,ASAP-0027839,O=C(Nc1cc(Cl)cc(-c2ccc3[nH]c(C(=O)O)cc3c2)c1)OCc1ccccc1,IC50,'=',5819.0,nM,5.24,,,UO_0000065,,,,,0,CHEMBL5604072,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 1,,,,,Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK,,,CHEMBL5705862,NS3 protease,dengue virus type 1,SINGLE PROTEIN,CHEMBL5604064,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 3.144 None | IC50 CI (lower) = 5.486 uM | IC50 CI (upper) = 6.173 uM | Maximum measured = 100.15 None | Maximum response = 100.0 % | Minimum measured = -2.475 None | R squared = 0.997 None,,,5.819,1
CHEMBL5598860,,,325.41,0.0,3.36,ASAP-0029521,Cc1c(C(=O)Nc2cc([C@H]3CCOC3)ccn2)cc(C2CC2)n1C,IC50,'>',99500.0,nM,,,Falls Outside The Dose Series,UO_0000065,,,,,0,CHEMBL5604072,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 1,,,,,Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK,,,CHEMBL5705862,NS3 protease,dengue virus type 1,SINGLE PROTEIN,CHEMBL5604064,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Maximum measured = -0.768 None | Minimum measured = -4.775 None,,,99.5,1
CHEMBL5598575,,,399.92,0.0,3.74,ASAP-0029415,COCCNC(=O)[C@H](Nc1ccc2c(c1)CNC2)c1cc(Cl)cc(C2CC2)c1,IC50,'>',99500.0,nM,,,Falls Outside The Dose Series,UO_0000065,,,,,0,CHEMBL5604072,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 1,,,,,Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK,,,CHEMBL5705862,NS3 protease,dengue virus type 1,SINGLE PROTEIN,CHEMBL5604064,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 11.43 None | Maximum measured = 8.614 None | Maximum response = 100.0 % | Minimum measured = -9.137 None | R squared = 0.23 None,,,99.5,1
CHEMBL5606232,,,278.31,0.0,2.42,ASAP-0030093,O=C(Nc1ccc2c(c1)CNC2)c1cccc2cn[nH]c12,IC50,'=',49934.0,nM,4.3,,,UO_0000065,,,,,0,CHEMBL5604072,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 1,,,,,Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK,,,CHEMBL5705862,NS3 protease,dengue virus type 1,SINGLE PROTEIN,CHEMBL5604064,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 1.865 None | IC50 CI (lower) = 45.44 uM | IC50 CI (upper) = 54.87 uM | Maximum measured = 77.69 None | Maximum response = 100.0 % | Minimum measured = -1.829 None | R squared = 0.973 None,,,49.934,1
CHEMBL5599838,,,459.98,1.0,5.16,ASAP-0031456,CC(C)NC(=O)[C@H](Nc1ccc2c(c1)CNC2)c1cc(Cl)cc2[nH]c(-c3ccccc3)nc12,IC50,'=',2056.0,nM,5.69,,,UO_0000065,,,,,0,CHEMBL5604072,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 1,,,,,Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK,,,CHEMBL5705862,NS3 protease,dengue virus type 1,SINGLE PROTEIN,CHEMBL5604064,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 0.962 None | IC50 CI (lower) = 1.871 uM | IC50 CI (upper) = 2.26 uM | Maximum measured = 95.82 None | Maximum response = 100.0 % | Minimum measured = 2.067 None | R squared = 0.993 None,,,2.056,1
CHEMBL5605097,,,386.43,0.0,4.53,ASAP-0031293,Cc1cccc(-c2nc3c(C(=O)Nc4ccc5c(c4)CNC5)cc(F)cc3[nH]2)c1,IC50,'=',5919.0,nM,5.23,,,UO_0000065,,,,,0,CHEMBL5604072,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 1,,,,,Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK,,,CHEMBL5705862,NS3 protease,dengue virus type 1,SINGLE PROTEIN,CHEMBL5604064,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 1.984 None | IC50 CI (lower) = 4.471 uM | IC50 CI (upper) = 7.834 uM | Maximum measured = 79.56 None | Maximum response = 100.0 % | Minimum measured = -6.56 None | R squared = 0.9 None,,,5.919,1
CHEMBL5605639,,,341.72,0.0,3.61,ASAP-0029970,O=C(Nc1ccc2c(c1)CNC2)c1cc(Cl)cc(C(F)(F)F)n1,IC50,'=',7254.0,nM,5.14,,,UO_0000065,,,,,0,CHEMBL5604072,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 1,,,,,Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK,,,CHEMBL5705862,NS3 protease,dengue virus type 1,SINGLE PROTEIN,CHEMBL5604064,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 1.941 None | IC50 CI (lower) = 6.578 uM | IC50 CI (upper) = 8.0 uM | Maximum measured = 101.69 None | Maximum response = 100.0 % | Minimum measured = -1.395 None | R squared = 0.99 None,,,7.254,1
CHEMBL5604695,,,352.83,0.0,4.19,ASAP-0029944,C=CC[C@H]1NCc2cc(NC(=O)c3cc(Cl)cc4[nH]ncc34)ccc21,IC50,'>',99500.0,nM,,,Falls Outside The Dose Series,UO_0000065,,,,,0,CHEMBL5604072,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 1,,,,,Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK,,,CHEMBL5705862,NS3 protease,dengue virus type 1,SINGLE PROTEIN,CHEMBL5604064,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Maximum measured = -0.655 None | Minimum measured = -9.834 None,,,99.5,1
CHEMBL5605910,,,413.91,0.0,3.13,ASAP-0029914,CCOCCNC(=O)[C@H](Nc1ccc2c(c1)CNC2)c1cc(Cl)cc2[nH]ncc12,IC50,'>',99500.0,nM,,,Falls Outside The Dose Series,UO_0000065,,,,,0,CHEMBL5604072,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 1,,,,,Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK,,,CHEMBL5705862,NS3 protease,dengue virus type 1,SINGLE PROTEIN,CHEMBL5604064,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 10.66 None | Maximum measured = 8.006 None | Maximum response = 100.0 % | Minimum measured = -4.75 None | R squared = 0.327 None,,,99.5,1
CHEMBL5604180,,,312.76,0.0,3.07,ASAP-0029911,O=C(Nc1ccc2c(c1)CNC2)c1cc(Cl)cc2cn[nH]c12,IC50,'>',99500.0,nM,,,Falls Outside The Dose Series,UO_0000065,,,,,0,CHEMBL5604072,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 1,,,,,Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK,,,CHEMBL5705862,NS3 protease,dengue virus type 1,SINGLE PROTEIN,CHEMBL5604064,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 4.008 None | Maximum measured = 47.56 None | Maximum response = 100.0 % | Minimum measured = -4.349 None | R squared = 0.955 None,,,99.5,1
CHEMBL5598685,,,323.83,0.0,4.5,ASAP-0029597,N#C[C@H](Nc1ccc2c(c1)CNC2)c1cc(Cl)cc(C2CC2)c1,IC50,'>',99500.0,nM,,,Falls Outside The Dose Series,UO_0000065,,,,,0,CHEMBL5604072,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 1,,,,,Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK,,,CHEMBL5705862,NS3 protease,dengue virus type 1,SINGLE PROTEIN,CHEMBL5604064,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Maximum measured = 0.166 None | Minimum measured = -62.3 None,,,99.5,1
CHEMBL3740727,,,719.79,2.0,2.06,ASAP-0000570,N=C(N)NCCC[C@H](NC(=O)c1nccs1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(N)=O)c1ccc(OCc2ccc(C(F)(F)F)cc2)cc1,IC50,'=',865.0,nM,6.06,,,UO_0000065,,,,,0,CHEMBL5604072,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 1,,,,,Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK,,,CHEMBL5705862,NS3 protease,dengue virus type 1,SINGLE PROTEIN,CHEMBL5604064,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 1.101 None | IC50 CI (lower) = 0.844 uM | IC50 CI (upper) = 0.887 uM | Maximum measured = 100.24 None | Maximum response = 100.0 % | Minimum measured = 3.126 None | R squared = 0.999 None,,,0.865,1
CHEMBL5605184,,,311.32,0.0,2.18,ASAP-0030065,O=C1Cc2c(cc(F)cc2C(=O)Nc2ccc3c(c2)CNC3)N1,IC50,'=',36199.0,nM,4.44,,,UO_0000065,,,,,0,CHEMBL5604072,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 1,,,,,Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK,,,CHEMBL5705862,NS3 protease,dengue virus type 1,SINGLE PROTEIN,CHEMBL5604064,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 1.855 None | IC50 CI (lower) = 32.78 uM | IC50 CI (upper) = 39.98 uM | Maximum measured = 95.85 None | Maximum response = 100.0 % | Minimum measured = -1.825 None | R squared = 0.979 None,,,36.199,1
CHEMBL5604989,,,390.39,0.0,4.36,ASAP-0031443,O=C(Nc1ccc2c(c1)CNC2)c1cc(F)cc2[nH]c(-c3cccc(F)c3)nc12,IC50,'=',2687.0,nM,5.57,,,UO_0000065,,,,,0,CHEMBL5604072,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 1,,,,,Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK,,,CHEMBL5705862,NS3 protease,dengue virus type 1,SINGLE PROTEIN,CHEMBL5604064,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 2.977 None | IC50 CI (lower) = 2.304 uM | IC50 CI (upper) = 3.134 uM | Maximum measured = 96.09 None | Maximum response = 100.0 % | Minimum measured = -3.624 None | R squared = 0.971 None,,,2.687,1
CHEMBL5598597,,,326.79,0.0,3.41,ASAP-0029027,CN1Cc2ccc(NC(=O)c3cc(Cl)cc4[nH]ncc34)cc2C1,IC50,'>',99500.0,nM,,,Falls Outside The Dose Series,UO_0000065,,,,,0,CHEMBL5604072,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 1,,,,,Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK,,,CHEMBL5705862,NS3 protease,dengue virus type 1,SINGLE PROTEIN,CHEMBL5604064,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 0.97 None | Maximum measured = 38.76 None | Maximum response = 100.0 % | Minimum measured = -2.416 None | R squared = 0.975 None,,,99.5,1
CHEMBL5605115,,,375.2,0.0,3.32,ASAP-0030792,O=C(Nc1cc(Br)c2c(c1)CNC2)c1cc(F)cc2[nH]ncc12,IC50,'=',75519.0,nM,4.12,,,UO_0000065,,,,,0,CHEMBL5604072,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 1,,,,,Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK,,,CHEMBL5705862,NS3 protease,dengue virus type 1,SINGLE PROTEIN,CHEMBL5604064,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 1.812 None | IC50 CI (lower) = 69.96 uM | IC50 CI (upper) = 81.52 uM | Maximum measured = 64.44 None | Maximum response = 100.0 % | Minimum measured = -0.799 None | R squared = 0.975 None,,,75.519,1
CHEMBL5605521,,,296.35,0.0,3.17,ASAP-0030106,O=C(Nc1ccc2c(c1)CNC2)c1cc(F)cc2c1CCC2,IC50,'>',99500.0,nM,,,Falls Outside The Dose Series,UO_0000065,,,,,0,CHEMBL5604072,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 1,,,,,Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK,,,CHEMBL5705862,NS3 protease,dengue virus type 1,SINGLE PROTEIN,CHEMBL5604064,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Maximum measured = 1.851 None | Minimum measured = -31.23 None,,,99.5,1
CHEMBL5598610,,,383.88,0.0,3.5,ASAP-0029974,CC(C)NC(=O)[C@H](Nc1ccc2c(c1)CNC2)c1cc(Cl)cc2[nH]ncc12,IC50,'=',34366.0,nM,4.46,,,UO_0000065,,,,,0,CHEMBL5604072,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 1,,,,,Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK,,,CHEMBL5705862,NS3 protease,dengue virus type 1,SINGLE PROTEIN,CHEMBL5604064,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 1.172 None | IC50 CI (lower) = 30.97 uM | IC50 CI (upper) = 38.14 uM | Maximum measured = 81.12 None | Maximum response = 100.0 % | Minimum measured = -4.919 None | R squared = 0.984 None,,,34.366,1
CHEMBL5606384,,,411.9,0.0,2.76,ASAP-0028903,CNC(=O)[C@H](Nc1cc(CN)cc(-c2nn[nH]n2)c1)c1cc(Cl)cc(C2CC2)c1,IC50,'>',99500.0,nM,,,Falls Outside The Dose Series,UO_0000065,,,,,0,CHEMBL5604072,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 1,,,,,Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK,,,CHEMBL5705862,NS3 protease,dengue virus type 1,SINGLE PROTEIN,CHEMBL5604064,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 2.052 None | Maximum measured = 7.423 None | Maximum response = 100.0 % | Minimum measured = -3.012 None | R squared = 0.431 None,,,99.5,1
CHEMBL5598898,,,323.78,0.0,3.74,ASAP-0029711,O=C(Nc1ccc2c(c1)CNC2)c1cc(Cl)cc2ccncc12,IC50,'>',99500.0,nM,,,Falls Outside The Dose Series,UO_0000065,,,,,0,CHEMBL5604072,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 1,,,,,Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK,,,CHEMBL5705862,NS3 protease,dengue virus type 1,SINGLE PROTEIN,CHEMBL5604064,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 1.956 None | Maximum measured = 36.63 None | Maximum response = 100.0 % | Minimum measured = -4.697 None | R squared = 0.931 None,,,99.5,1
CHEMBL5598611,,,326.79,0.0,3.08,ASAP-0029588,Cn1cc2cc(Cl)cc(C(=O)Nc3ccc4c(c3)CNC4)c2n1,IC50,'>',99500.0,nM,,,Falls Outside The Dose Series,UO_0000065,,,,,0,CHEMBL5604072,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 1,,,,,Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK,,,CHEMBL5705862,NS3 protease,dengue virus type 1,SINGLE PROTEIN,CHEMBL5604064,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Maximum measured = -1.893 None | Minimum measured = -35.85 None,,,99.5,1
CHEMBL5606266,,,277.33,0.0,3.02,ASAP-0029756,O=C(Nc1ccc2c(c1)CNC2)c1ccc2[nH]ccc2c1,IC50,'>',99500.0,nM,,,Falls Outside The Dose Series,UO_0000065,,,,,0,CHEMBL5604072,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 1,,,,,Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK,,,CHEMBL5705862,NS3 protease,dengue virus type 1,SINGLE PROTEIN,CHEMBL5604064,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 1.101 None | Maximum measured = 13.18 None | Maximum response = 100.0 % | Minimum measured = -4.706 None | R squared = 0.489 None,,,99.5,1
CHEMBL5605022,,,321.32,0.0,2.43,ASAP-0031265,N#Cc1cc2c(cc1NC(=O)c1cc(F)cc3[nH]ncc13)CNC2,IC50,'=',59669.0,nM,4.22,,,UO_0000065,,,,,0,CHEMBL5604072,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 1,,,,,Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK,,,CHEMBL5705862,NS3 protease,dengue virus type 1,SINGLE PROTEIN,CHEMBL5604064,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 0.991 None | IC50 CI (lower) = 50.9 uM | IC50 CI (upper) = 69.95 uM | Maximum measured = 62.07 None | Maximum response = 100.0 % | Minimum measured = -4.29 None | R squared = 0.964 None,,,59.669,1
CHEMBL5605673,,,425.9,0.0,4.15,ASAP-0027729,CCc1cc(C(=O)Nc2cccc(-n3nn[nH]c3=O)c2)sc1-c1ccc(Cl)cc1,IC50,'=',11401.0,nM,4.94,,,UO_0000065,,,,,0,CHEMBL5604072,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 1,,,,,Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK,,,CHEMBL5705862,NS3 protease,dengue virus type 1,SINGLE PROTEIN,CHEMBL5604064,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 2.819 None | IC50 CI (lower) = 10.17 uM | IC50 CI (upper) = 12.78 uM | Maximum measured = 95.1 None | Maximum response = 100.0 % | Minimum measured = -6.589 None | R squared = 0.975 None,,,11.401,1
CHEMBL5605183,,,389.38,0.0,2.84,ASAP-0030767,O=C(NCC(F)F)[C@H](Nc1ccc2c(c1)CNC2)c1cc(F)cc2[nH]ncc12,IC50,'>',99500.0,nM,,,Falls Outside The Dose Series,UO_0000065,,,,,0,CHEMBL5604072,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 1,,,,,Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK,,,CHEMBL5705862,NS3 protease,dengue virus type 1,SINGLE PROTEIN,CHEMBL5604064,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 0.805 None | Maximum measured = 21.46 None | Maximum response = 100.0 % | Minimum measured = -2.539 None | R squared = 0.899 None,,,99.5,1
CHEMBL5598576,,,405.88,0.0,4.36,ASAP-0030775,O=C(NCC(F)F)[C@H](Nc1ccc2c(c1)CNC2)c1cc(Cl)cc(C2CC2)c1,IC50,'>',99500.0,nM,,,Falls Outside The Dose Series,UO_0000065,,,,,0,CHEMBL5604072,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 1,,,,,Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK,,,CHEMBL5705862,NS3 protease,dengue virus type 1,SINGLE PROTEIN,CHEMBL5604064,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Maximum measured = -0.12 None | Minimum measured = -17.46 None,,,99.5,1
CHEMBL5605532,,,341.46,1.0,5.1,ASAP-0016252,c1cc(C2CCN(Cc3c[nH]c4ccccc34)CC2)c2ccncc2c1,IC50,'>',99500.0,nM,,,Falls Outside The Dose Series,UO_0000065,,,,,0,CHEMBL5604072,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 1,,,,,Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK,,,CHEMBL5705862,NS3 protease,dengue virus type 1,SINGLE PROTEIN,CHEMBL5604064,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Maximum measured = -7.196 None | Minimum measured = -11.83 None,,,99.5,1
CHEMBL3740727,,,719.79,2.0,2.06,ASAP-0000570,N=C(N)NCCC[C@H](NC(=O)c1nccs1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(N)=O)c1ccc(OCc2ccc(C(F)(F)F)cc2)cc1,IC50,'=',920.0,nM,6.04,,,UO_0000065,,,,,0,CHEMBL5604072,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 1,,,,,Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK,,,CHEMBL5705862,NS3 protease,dengue virus type 1,SINGLE PROTEIN,CHEMBL5604064,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 1.074 None | IC50 CI (lower) = 0.9 uM | IC50 CI (upper) = 0.941 uM | Maximum measured = 99.41 None | Maximum response = 100.0 % | Minimum measured = 3.834 None | R squared = 0.999 None,,,0.92,1
CHEMBL5606202,,,344.46,0.0,4.73,ASAP-0021052,Cc1[nH]c2ccccc2c1CN1CCC(c2c[nH]c3ncccc23)CC1,IC50,'>',99500.0,nM,,,Falls Outside The Dose Series,UO_0000065,,,,,0,CHEMBL5604072,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 1,,,,,Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK,,,CHEMBL5705862,NS3 protease,dengue virus type 1,SINGLE PROTEIN,CHEMBL5604064,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Maximum measured = -5.485 None | Minimum measured = -12.35 None,,,99.5,1
CHEMBL5606033,,,293.33,0.0,2.04,ASAP-0029950,O=C1Cc2cc(C(=O)Nc3ccc4c(c3)CNC4)ccc2N1,IC50,'=',5256.0,nM,5.28,,,UO_0000065,,,,,0,CHEMBL5604072,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 1,,,,,Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK,,,CHEMBL5705862,NS3 protease,dengue virus type 1,SINGLE PROTEIN,CHEMBL5604064,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 2.546 None | IC50 CI (lower) = 4.751 uM | IC50 CI (upper) = 5.814 uM | Maximum measured = 99.75 None | Maximum response = 100.0 % | Minimum measured = -3.951 None | R squared = 0.992 None,,,5.256,1
CHEMBL5605499,,,387.24,0.0,2.48,ASAP-0029933,Cn1c(=O)[nH]c2c(C(=O)Nc3ccc4c(c3)CNC4)cc(Br)cc21,IC50,'>',99500.0,nM,,,Falls Outside The Dose Series,UO_0000065,,,,,0,CHEMBL5604072,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 1,,,,,Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK,,,CHEMBL5705862,NS3 protease,dengue virus type 1,SINGLE PROTEIN,CHEMBL5604064,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Maximum measured = 1.285 None | Minimum measured = -182.12 None,,,99.5,1
CHEMBL5598684,,,433.31,0.0,4.85,ASAP-0029352,O=C(Nc1ccc2c(c1)CNC2)c1cc(Br)cc2[nH]c(-c3ccccc3)nc12,IC50,'=',1242.0,nM,5.91,,,UO_0000065,,,,,0,CHEMBL5604072,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 1,,,,,Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK,,,CHEMBL5705862,NS3 protease,dengue virus type 1,SINGLE PROTEIN,CHEMBL5604064,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 3.442 None | IC50 CI (lower) = 1.076 uM | IC50 CI (upper) = 1.434 uM | Maximum measured = 97.84 None | Maximum response = 100.0 % | Minimum measured = -6.263 None | R squared = 0.961 None,,,1.242,1
CHEMBL5604118,,,367.47,0.0,3.55,ASAP-0031158,NCCc1csc2cc(C(=O)Nc3cc([C@H]4CCOC4)ccn3)ccc12,IC50,'>',99500.0,nM,,,Falls Outside The Dose Series,UO_0000065,,,,,0,CHEMBL5604072,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 1,,,,,Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK,,,CHEMBL5705862,NS3 protease,dengue virus type 1,SINGLE PROTEIN,CHEMBL5604064,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Maximum measured = 1.002 None | Minimum measured = -7.285 None,,,99.5,1
CHEMBL5605908,,,403.42,0.0,3.63,ASAP-0031141,COc1cc(-c2cc(NC(=O)c3cc(F)cc4[nH]ncc34)cc3c2CNC3)ccn1,IC50,'=',82838.0,nM,4.08,,,UO_0000065,,,,,0,CHEMBL5604072,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 1,,,,,Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK,,,CHEMBL5705862,NS3 protease,dengue virus type 1,SINGLE PROTEIN,CHEMBL5604064,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 1.519 None | IC50 CI (lower) = 69.87 uM | IC50 CI (upper) = 98.22 uM | Maximum measured = 56.19 None | Maximum response = 100.0 % | Minimum measured = -7.635 None | R squared = 0.924 None,,,82.838,1
CHEMBL5606429,,,378.41,0.0,3.36,ASAP-0031147,O=C(Nc1cc2c(c(C3=CCOCC3)c1)CNC2)c1cc(F)cc2[nH]ncc12,IC50,'=',8469.0,nM,5.07,,,UO_0000065,,,,,0,CHEMBL5604073,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 3,,,,,Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK,,,CHEMBL5705863,NS3 protease,dengue virus type 3,SINGLE PROTEIN,CHEMBL5604065,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 1.188 None | IC50 CI (lower) = 7.725 uM | IC50 CI (upper) = 9.285 uM | Maximum measured = 97.56 None | Maximum response = 100.0 % | Minimum measured = -5.257 None | R squared = 0.993 None,,,8.469,3
CHEMBL5605908,,,403.42,0.0,3.63,ASAP-0031141,COc1cc(-c2cc(NC(=O)c3cc(F)cc4[nH]ncc34)cc3c2CNC3)ccn1,IC50,'=',12911.0,nM,4.89,,,UO_0000065,,,,,0,CHEMBL5604073,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 3,,,,,Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK,,,CHEMBL5705863,NS3 protease,dengue virus type 3,SINGLE PROTEIN,CHEMBL5604065,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 1.218 None | IC50 CI (lower) = 11.48 uM | IC50 CI (upper) = 14.52 uM | Maximum measured = 90.98 None | Maximum response = 100.0 % | Minimum measured = -6.173 None | R squared = 0.986 None,,,12.911,3
CHEMBL5598743,,,425.96,0.0,4.27,ASAP-0029555,O=C(NC1CCOCC1)[C@H](Nc1ccc2c(c1)CNC2)c1cc(Cl)cc(C2CC2)c1,IC50,'=',53424.0,nM,4.27,,,UO_0000065,,,,,0,CHEMBL5604073,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 3,,,,,Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK,,,CHEMBL5705863,NS3 protease,dengue virus type 3,SINGLE PROTEIN,CHEMBL5604065,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 0.986 None | IC50 CI (lower) = 48.47 uM | IC50 CI (upper) = 58.88 uM | Maximum measured = 64.76 None | Maximum response = 100.0 % | Minimum measured = -3.987 None | R squared = 0.986 None,,,53.424,3
CHEMBL5604849,,,409.96,0.0,4.89,ASAP-0030790,O=C(NCCC1CC1)[C@H](Nc1ccc2c(c1)CNC2)c1cc(Cl)cc(C2CC2)c1,IC50,'>',99500.0,nM,,,Falls Outside The Dose Series,UO_0000065,,,,,0,CHEMBL5604073,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 3,,,,,Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK,,,CHEMBL5705863,NS3 protease,dengue virus type 3,SINGLE PROTEIN,CHEMBL5604065,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 3.123 None | Maximum measured = 36.26 None | Maximum response = 100.0 % | Minimum measured = -9.496 None | R squared = 0.831 None,,,99.5,3
CHEMBL5605115,,,375.2,0.0,3.32,ASAP-0030792,O=C(Nc1cc(Br)c2c(c1)CNC2)c1cc(F)cc2[nH]ncc12,IC50,'=',14995.0,nM,4.82,,,UO_0000065,,,,,0,CHEMBL5604073,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 3,,,,,Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK,,,CHEMBL5705863,NS3 protease,dengue virus type 3,SINGLE PROTEIN,CHEMBL5604065,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 0.697 None | IC50 CI (lower) = 11.37 uM | IC50 CI (upper) = 19.78 uM | Maximum measured = 73.06 None | Maximum response = 100.0 % | Minimum measured = -3.109 None | R squared = 0.938 None,,,14.995,3
CHEMBL5605716,,,305.34,0.0,2.8,ASAP-0029967,O=C(Nc1ccc2c(c1)CNC2)c1cccc2nc(O)ccc12,IC50,'>',99500.0,nM,,,Falls Outside The Dose Series,UO_0000065,,,,,0,CHEMBL5604073,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 3,,,,,Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK,,,CHEMBL5705863,NS3 protease,dengue virus type 3,SINGLE PROTEIN,CHEMBL5604065,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 1.159 None | Maximum measured = 41.64 None | Maximum response = 100.0 % | Minimum measured = 0.86 None | R squared = 0.977 None,,,99.5,3
CHEMBL3919119,,,454.34,,,ASAP-0015081,N=C(N)NCCC[C@H](NC(=O)[C@H](Cc1ccc(CN)cc1)NC(=O)c1ccccc1)B(O)O,IC50,'=',784.0,nM,6.11,,,UO_0000065,,,,,0,CHEMBL5604073,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 3,,,,,Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK,,,CHEMBL5705863,NS3 protease,dengue virus type 3,SINGLE PROTEIN,CHEMBL5604065,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 1.088 None | IC50 CI (lower) = 0.743 uM | IC50 CI (upper) = 0.828 uM | Maximum measured = 99.42 None | Maximum response = 100.0 % | Minimum measured = 4.646 None | R squared = 0.997 None,,,0.784,3
CHEMBL5606153,,,423.9,1.0,5.11,ASAP-0021119,Cc1ccc(NC(=O)c2cc(Cl)cc(NC(=O)OCc3ccccc3)c2)cc1CN,IC50,'=',57739.0,nM,4.24,,,UO_0000065,,,,,0,CHEMBL5604073,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 3,,,,,Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK,,,CHEMBL5705863,NS3 protease,dengue virus type 3,SINGLE PROTEIN,CHEMBL5604065,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 2.639 None | IC50 CI (lower) = 54.78 uM | IC50 CI (upper) = 60.86 uM | Maximum measured = 78.63 None | Maximum response = 100.0 % | Minimum measured = -3.275 None | R squared = 0.987 None,,,57.739,3
CHEMBL5605664,,,390.39,0.0,4.36,ASAP-0031237,O=C(Nc1ccc2c(c1)CNC2)c1cc(F)cc2[nH]c(-c3ccc(F)cc3)nc12,IC50,'=',2955.0,nM,5.53,,,UO_0000065,,,,,0,CHEMBL5604073,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 3,,,,,Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK,,,CHEMBL5705863,NS3 protease,dengue virus type 3,SINGLE PROTEIN,CHEMBL5604065,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 2.454 None | IC50 CI (lower) = 2.475 uM | IC50 CI (upper) = 3.527 uM | Maximum measured = 95.63 None | Maximum response = 100.0 % | Minimum measured = -4.923 None | R squared = 0.967 None,,,2.955,3
CHEMBL5605985,,,416.48,0.0,2.84,ASAP-0031120,CC(C)(c1nc2c(C(=O)Nc3ccc4c(c3)CNC4)cc(F)cc2[nH]1)S(C)(=O)=O,IC50,'=',13646.0,nM,4.87,,,UO_0000065,,,,,0,CHEMBL5604073,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 3,,,,,Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK,,,CHEMBL5705863,NS3 protease,dengue virus type 3,SINGLE PROTEIN,CHEMBL5604065,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 2.763 None | IC50 CI (lower) = 12.45 uM | IC50 CI (upper) = 14.96 uM | Maximum measured = 95.84 None | Maximum response = 100.0 % | Minimum measured = -8.152 None | R squared = 0.985 None,,,13.646,3
CHEMBL5605103,,,386.43,0.0,4.53,ASAP-0031310,Cc1ccccc1-c1nc2c(C(=O)Nc3ccc4c(c3)CNC4)cc(F)cc2[nH]1,IC50,'=',2196.0,nM,5.66,,,UO_0000065,,,,,0,CHEMBL5604073,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 3,,,,,Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK,,,CHEMBL5705863,NS3 protease,dengue virus type 3,SINGLE PROTEIN,CHEMBL5604065,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 1.93 None | IC50 CI (lower) = 1.975 uM | IC50 CI (upper) = 2.442 uM | Maximum measured = 96.89 None | Maximum response = 100.0 % | Minimum measured = 1.778 None | R squared = 0.987 None,,,2.196,3
CHEMBL5605310,,,399.52,0.0,4.88,ASAP-0031492,NCc1ccc(-c2csc3cc(C(=O)Nc4ccc5c(c4)CNC5)ccc23)cc1,IC50,'=',31579.0,nM,4.5,,,UO_0000065,,,,,0,CHEMBL5604073,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 3,,,,,Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK,,,CHEMBL5705863,NS3 protease,dengue virus type 3,SINGLE PROTEIN,CHEMBL5604065,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 1.389 None | IC50 CI (lower) = 30.01 uM | IC50 CI (upper) = 33.23 uM | Maximum measured = 81.14 None | Maximum response = 100.0 % | Minimum measured = -0.973 None | R squared = 0.995 None,,,31.579,3
CHEMBL5604470,,,397.41,0.0,4.1,ASAP-0031299,N#Cc1ccc(-c2nc3c(C(=O)Nc4ccc5c(c4)CNC5)cc(F)cc3[nH]2)cc1,IC50,'=',1704.0,nM,5.77,,,UO_0000065,,,,,0,CHEMBL5604073,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 3,,,,,Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK,,,CHEMBL5705863,NS3 protease,dengue virus type 3,SINGLE PROTEIN,CHEMBL5604065,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 1.776 None | IC50 CI (lower) = 1.595 uM | IC50 CI (upper) = 1.82 uM | Maximum measured = 95.99 None | Maximum response = 100.0 % | Minimum measured = 1.64 None | R squared = 0.995 None,,,1.704,3
CHEMBL5598749,,,421.88,0.0,4.94,ASAP-0020915,O=C(Nc1cc(Cl)cc(C(=O)Nc2ccc3c(c2)CNC3)c1)OCc1ccccc1,IC50,'=',72465.0,nM,4.14,,,UO_0000065,,,,,0,CHEMBL5604073,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 3,,,,,Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK,,,CHEMBL5705863,NS3 protease,dengue virus type 3,SINGLE PROTEIN,CHEMBL5604065,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 1.585 None | IC50 CI (lower) = 66.12 uM | IC50 CI (upper) = 79.41 uM | Maximum measured = 60.5 None | Maximum response = 100.0 % | Minimum measured = -5.998 None | R squared = 0.974 None,,,72.465,3
CHEMBL5605856,,,406.91,1.0,5.82,ASAP-0027760,NCc1ccc([C@H]2C[C@@H]2c2cc(Cl)cc(NC(=O)OCc3ccccc3)c2)cc1,IC50,'=',6849.0,nM,5.16,,,UO_0000065,,,,,0,CHEMBL5604073,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 3,,,,,Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK,,,CHEMBL5705863,NS3 protease,dengue virus type 3,SINGLE PROTEIN,CHEMBL5604065,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 6.53 None | IC50 CI (lower) = 6.15 uM | IC50 CI (upper) = 7.628 uM | Maximum measured = 99.45 None | Maximum response = 100.0 % | Minimum measured = -10.24 None | R squared = 0.991 None,,,6.849,3
CHEMBL5605186,,,461.01,1.0,6.83,ASAP-0027756,O=C(Nc1cc(Cl)cc([C@H]2C[C@@H]2c2cccc(C3CCNCC3)c2)c1)OCc1ccccc1,IC50,'=',4789.0,nM,5.32,,,UO_0000065,,,,,0,CHEMBL5604073,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 3,,,,,Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK,,,CHEMBL5705863,NS3 protease,dengue virus type 3,SINGLE PROTEIN,CHEMBL5604065,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 2.893 None | IC50 CI (lower) = 4.03 uM | IC50 CI (upper) = 5.69 uM | Maximum measured = 99.83 None | Maximum response = 100.0 % | Minimum measured = -12.24 None | R squared = 0.98 None,,,4.789,3
CHEMBL5605468,,,295.32,0.0,3.16,ASAP-0029832,O=C(Nc1ccc2c(c1)CNC2)c1cc(F)c2[nH]ccc2c1,IC50,'>',99500.0,nM,,,Falls Outside The Dose Series,UO_0000065,,,,,0,CHEMBL5604073,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 3,,,,,Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK,,,CHEMBL5705863,NS3 protease,dengue virus type 3,SINGLE PROTEIN,CHEMBL5604065,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 1.715 None | Maximum measured = 27.79 None | Maximum response = 100.0 % | Minimum measured = -1.599 None | R squared = 0.957 None,,,99.5,3
CHEMBL5598746,,,435.96,0.0,4.02,ASAP-0029471,Cn1cc(CNC(=O)[C@H](Nc2ccc3c(c2)CNC3)c2cc(Cl)cc(C3CC3)c2)cn1,IC50,'=',81762.0,nM,4.09,,,UO_0000065,,,,,0,CHEMBL5604073,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 3,,,,,Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK,,,CHEMBL5705863,NS3 protease,dengue virus type 3,SINGLE PROTEIN,CHEMBL5604065,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 1.054 None | IC50 CI (lower) = 76.23 uM | IC50 CI (upper) = 87.7 uM | Maximum measured = 55.58 None | Maximum response = 100.0 % | Minimum measured = -2.197 None | R squared = 0.991 None,,,81.762,3
CHEMBL3740727,,,719.79,2.0,2.06,ASAP-0000570,N=C(N)NCCC[C@H](NC(=O)c1nccs1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(N)=O)c1ccc(OCc2ccc(C(F)(F)F)cc2)cc1,IC50,'=',2225.0,nM,5.65,,,UO_0000065,,,,,0,CHEMBL5604073,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 3,,,,,Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK,,,CHEMBL5705863,NS3 protease,dengue virus type 3,SINGLE PROTEIN,CHEMBL5604065,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 1.152 None | IC50 CI (lower) = 2.135 uM | IC50 CI (upper) = 2.319 uM | Maximum measured = 99.55 None | Maximum response = 100.0 % | Minimum measured = -1.913 None | R squared = 0.999 None,,,2.225,3
CHEMBL5598605,,,305.34,0.0,3.2,ASAP-0029713,O=C(Nc1ccc2c(c1)CNC2)c1cccc(-c2cnco2)c1,IC50,'=',21244.0,nM,4.67,,,UO_0000065,,,,,0,CHEMBL5604073,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 3,,,,,Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK,,,CHEMBL5705863,NS3 protease,dengue virus type 3,SINGLE PROTEIN,CHEMBL5604065,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 2.278 None | IC50 CI (lower) = 20.11 uM | IC50 CI (upper) = 22.44 uM | Maximum measured = 94.34 None | Maximum response = 100.0 % | Minimum measured = -1.923 None | R squared = 0.994 None,,,21.244,3
CHEMBL5598786,,,296.3,0.0,2.56,ASAP-0029497,O=C(Nc1ccc2c(c1)CNC2)c1cc(F)cc2[nH]ncc12,IC50,'=',23396.0,nM,4.63,,,UO_0000065,,,,,0,CHEMBL5604073,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 3,,,,,Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK,,,CHEMBL5705863,NS3 protease,dengue virus type 3,SINGLE PROTEIN,CHEMBL5604065,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 0.939 None | IC50 CI (lower) = 20.97 uM | IC50 CI (upper) = 26.1 uM | Maximum measured = 73.66 None | Maximum response = 100.0 % | Minimum measured = -2.817 None | R squared = 0.986 None,,,23.396,3
CHEMBL5604332,,,312.76,0.0,3.07,ASAP-0027808,O=C(Nc1ccc2c(c1)CNC2)c1cc(Cl)cc2[nH]ncc12,IC50,'=',13371.0,nM,4.87,,,UO_0000065,,,,,0,CHEMBL5604073,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 3,,,,,Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK,,,CHEMBL5705863,NS3 protease,dengue virus type 3,SINGLE PROTEIN,CHEMBL5604065,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 0.962 None | IC50 CI (lower) = 11.71 uM | IC50 CI (upper) = 15.26 uM | Maximum measured = 87.07 None | Maximum response = 100.0 % | Minimum measured = -0.359 None | R squared = 0.983 None,,,13.371,3
CHEMBL5598717,,,565.08,2.0,6.65,ASAP-0027928,O=C(Nc1cc(Cl)cc([C@H]2CN(Cc3ccccc3)C[C@@H]2c2cccc(-c3nn[nH]n3)c2)c1)OCc1ccccc1,IC50,'=',6031.0,nM,5.22,,,UO_0000065,,,,,0,CHEMBL5604073,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 3,,,,,Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK,,,CHEMBL5705863,NS3 protease,dengue virus type 3,SINGLE PROTEIN,CHEMBL5604065,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 2.734 None | IC50 CI (lower) = 5.554 uM | IC50 CI (upper) = 6.55 uM | Maximum measured = 97.19 None | Maximum response = 100.0 % | Minimum measured = -3.722 None | R squared = 0.994 None,,,6.031,3
CHEMBL5598593,,,309.76,0.0,3.59,ASAP-0027972,Clc1ccc2[nH]cc(Cc3ccc(-c4nn[nH]n4)cc3)c2c1,IC50,'=',44119.0,nM,4.36,,,UO_0000065,,,,,0,CHEMBL5604073,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 3,,,,,Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK,,,CHEMBL5705863,NS3 protease,dengue virus type 3,SINGLE PROTEIN,CHEMBL5604065,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 2.92 None | IC50 CI (lower) = 42.21 uM | IC50 CI (upper) = 46.11 uM | Maximum measured = 93.49 None | Maximum response = 100.0 % | Minimum measured = -1.96 None | R squared = 0.993 None,,,44.119,3
CHEMBL5605497,,,463.97,1.0,5.94,ASAP-0023377,N[C@H]1CC[C@H](c2ccc(NC(=O)c3cc(Cl)cc(NC(=O)OCc4ccccc4)c3)cc2)C1,IC50,'=',5841.0,nM,5.23,,,UO_0000065,,,,,0,CHEMBL5604073,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 3,,,,,Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK,,,CHEMBL5705863,NS3 protease,dengue virus type 3,SINGLE PROTEIN,CHEMBL5604065,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 4.389 None | IC50 CI (lower) = 4.629 uM | IC50 CI (upper) = 7.37 uM | Maximum measured = 100.0 None | Maximum response = 100.0 % | Minimum measured = -9.128 None | R squared = 0.979 None,,,5.841,3
CHEMBL5605947,,,435.91,0.0,4.99,ASAP-0027652,O=C(Nc1cc(Cl)cc(C(=O)Nc2ccc3c(c2)CCNC3)c1)OCc1ccccc1,IC50,'=',24351.0,nM,4.61,,,UO_0000065,,,,,0,CHEMBL5604073,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 3,,,,,Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK,,,CHEMBL5705863,NS3 protease,dengue virus type 3,SINGLE PROTEIN,CHEMBL5604065,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 4.318 None | IC50 CI (lower) = 21.98 uM | IC50 CI (upper) = 26.98 uM | Maximum measured = 96.92 None | Maximum response = 100.0 % | Minimum measured = -11.74 None | R squared = 0.961 None,,,24.351,3
CHEMBL5598591,,,373.29,0.0,4.6,ASAP-0029041,CC(C)(C)c1cc(Br)cc(C(=O)Nc2ccc3c(c2)CNC3)c1,IC50,'>',99500.0,nM,,,Falls Outside The Dose Series,UO_0000065,,,,,0,CHEMBL5604073,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 3,,,,,Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK,,,CHEMBL5705863,NS3 protease,dengue virus type 3,SINGLE PROTEIN,CHEMBL5604065,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Maximum measured = -1.082 None | Minimum measured = -12.29 None,,,99.5,3
CHEMBL5598597,,,326.79,0.0,3.41,ASAP-0029027,CN1Cc2ccc(NC(=O)c3cc(Cl)cc4[nH]ncc34)cc2C1,IC50,'=',92766.0,nM,4.03,,,UO_0000065,,,,,0,CHEMBL5604073,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 3,,,,,Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK,,,CHEMBL5705863,NS3 protease,dengue virus type 3,SINGLE PROTEIN,CHEMBL5604065,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 0.806 None | IC50 CI (lower) = 77.52 uM | IC50 CI (upper) = 111.0 uM | Maximum measured = 48.45 None | Maximum response = 100.0 % | Minimum measured = -3.071 None | R squared = 0.97 None,,,92.766,3
CHEMBL5605540,,,452.94,0.0,4.45,ASAP-0027609,CNC(=O)[C@H](Nc1cccc(CN)c1)c1cc(Cl)cc(NC(=O)OCc2ccccc2)c1,IC50,'>',99500.0,nM,,,Falls Outside The Dose Series,UO_0000065,,,,,0,CHEMBL5604073,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 3,,,,,Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK,,,CHEMBL5705863,NS3 protease,dengue virus type 3,SINGLE PROTEIN,CHEMBL5604065,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 2.765 None | Maximum measured = 47.69 None | Maximum response = 100.0 % | Minimum measured = -3.899 None | R squared = 0.972 None,,,99.5,3
CHEMBL3740727,,,719.79,2.0,2.06,ASAP-0000570,N=C(N)NCCC[C@H](NC(=O)c1nccs1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(N)=O)c1ccc(OCc2ccc(C(F)(F)F)cc2)cc1,IC50,'=',2186.0,nM,5.66,,,UO_0000065,,,,,0,CHEMBL5604073,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 3,,,,,Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK,,,CHEMBL5705863,NS3 protease,dengue virus type 3,SINGLE PROTEIN,CHEMBL5604065,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 1.161 None | IC50 CI (lower) = 2.114 uM | IC50 CI (upper) = 2.26 uM | Maximum measured = 99.1 None | Maximum response = 100.0 % | Minimum measured = -0.92 None | R squared = 0.999 None,,,2.186,3
CHEMBL5598577,,,326.79,0.0,3.11,ASAP-0029079,O=C(Nc1ccc2c(c1)CNCC2)c1cc(Cl)cc2[nH]ncc12,IC50,'=',93850.0,nM,4.03,,,UO_0000065,,,,,0,CHEMBL5604073,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 3,,,,,Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK,,,CHEMBL5705863,NS3 protease,dengue virus type 3,SINGLE PROTEIN,CHEMBL5604065,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 1.131 None | IC50 CI (lower) = 85.18 uM | IC50 CI (upper) = 103.41 uM | Maximum measured = 50.73 None | Maximum response = 100.0 % | Minimum measured = -2.971 None | R squared = 0.984 None,,,93.85,3
CHEMBL5604695,,,352.83,0.0,4.19,ASAP-0029944,C=CC[C@H]1NCc2cc(NC(=O)c3cc(Cl)cc4[nH]ncc34)ccc21,IC50,'=',68208.0,nM,4.17,,,UO_0000065,,,,,0,CHEMBL5604073,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 3,,,,,Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK,,,CHEMBL5705863,NS3 protease,dengue virus type 3,SINGLE PROTEIN,CHEMBL5604065,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 1.068 None | IC50 CI (lower) = 62.59 uM | IC50 CI (upper) = 74.33 uM | Maximum measured = 58.59 None | Maximum response = 100.0 % | Minimum measured = -1.847 None | R squared = 0.987 None,,,68.208,3
CHEMBL5605097,,,386.43,0.0,4.53,ASAP-0031293,Cc1cccc(-c2nc3c(C(=O)Nc4ccc5c(c4)CNC5)cc(F)cc3[nH]2)c1,IC50,'=',6161.0,nM,5.21,,,UO_0000065,,,,,0,CHEMBL5604073,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 3,,,,,Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK,,,CHEMBL5705863,NS3 protease,dengue virus type 3,SINGLE PROTEIN,CHEMBL5604065,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 1.828 None | IC50 CI (lower) = 5.523 uM | IC50 CI (upper) = 6.874 uM | Maximum measured = 81.98 None | Maximum response = 100.0 % | Minimum measured = -2.382 None | R squared = 0.984 None,,,6.161,3
CHEMBL5604806,,,420.85,1.0,5.94,ASAP-0027839,O=C(Nc1cc(Cl)cc(-c2ccc3[nH]c(C(=O)O)cc3c2)c1)OCc1ccccc1,IC50,'=',4997.0,nM,5.3,,,UO_0000065,,,,,0,CHEMBL5604073,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 3,,,,,Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK,,,CHEMBL5705863,NS3 protease,dengue virus type 3,SINGLE PROTEIN,CHEMBL5604065,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 2.984 None | IC50 CI (lower) = 4.673 uM | IC50 CI (upper) = 5.343 uM | Maximum measured = 100.14 None | Maximum response = 100.0 % | Minimum measured = -3.109 None | R squared = 0.997 None,,,4.997,3
CHEMBL5606112,,,337.45,0.0,3.26,ASAP-0031277,NCCc1csc2cc(C(=O)Nc3ccc4c(c3)CNC4)ccc12,IC50,'>',99500.0,nM,,,Falls Outside The Dose Series,UO_0000065,,,,,0,CHEMBL5604073,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 3,,,,,Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK,,,CHEMBL5705863,NS3 protease,dengue virus type 3,SINGLE PROTEIN,CHEMBL5604065,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 1.432 None | Maximum measured = 47.5 None | Maximum response = 100.0 % | Minimum measured = -7.186 None | R squared = 0.91 None,,,99.5,3
CHEMBL5604989,,,390.39,0.0,4.36,ASAP-0031443,O=C(Nc1ccc2c(c1)CNC2)c1cc(F)cc2[nH]c(-c3cccc(F)c3)nc12,IC50,'=',2730.0,nM,5.56,,,UO_0000065,,,,,0,CHEMBL5604073,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 3,,,,,Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK,,,CHEMBL5705863,NS3 protease,dengue virus type 3,SINGLE PROTEIN,CHEMBL5604065,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 2.377 None | IC50 CI (lower) = 2.493 uM | IC50 CI (upper) = 2.99 uM | Maximum measured = 96.67 None | Maximum response = 100.0 % | Minimum measured = -0.417 None | R squared = 0.991 None,,,2.73,3
CHEMBL5605526,,,409.87,0.0,4.8,ASAP-0016806,NCc1cccc(NC(=O)c2cc(Cl)cc(NC(=O)OCc3ccccc3)c2)c1,IC50,'=',26759.0,nM,4.57,,,UO_0000065,,,,,0,CHEMBL5604073,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 3,,,,,Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK,,,CHEMBL5705863,NS3 protease,dengue virus type 3,SINGLE PROTEIN,CHEMBL5604065,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 3.378 None | IC50 CI (lower) = 25.0 uM | IC50 CI (upper) = 28.64 uM | Maximum measured = 94.8 None | Maximum response = 100.0 % | Minimum measured = -7.136 None | R squared = 0.987 None,,,26.759,3
CHEMBL5605162,,,387.87,0.0,3.27,ASAP-0028981,CNC(=O)[C@H](Nc1cc(CN)cc(C(=O)O)c1)c1cc(Cl)cc(C2CC2)c1,IC50,'>',99500.0,nM,,,Falls Outside The Dose Series,UO_0000065,,,,,0,CHEMBL5604073,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 3,,,,,Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK,,,CHEMBL5705863,NS3 protease,dengue virus type 3,SINGLE PROTEIN,CHEMBL5604065,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 1.401 None | Maximum measured = 10.37 None | Maximum response = 100.0 % | Minimum measured = -2.48 None | R squared = 0.696 None,,,99.5,3
CHEMBL5604344,,,373.21,0.0,2.47,ASAP-0029916,O=C(Nc1ccc2c(c1)CNC2)c1cc(Br)cc2[nH]c(=O)[nH]c12,IC50,'=',21547.0,nM,4.67,,,UO_0000065,,,,,0,CHEMBL5604073,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 3,,,,,Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK,,,CHEMBL5705863,NS3 protease,dengue virus type 3,SINGLE PROTEIN,CHEMBL5604065,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 0.907 None | IC50 CI (lower) = 19.34 uM | IC50 CI (upper) = 24.0 uM | Maximum measured = 74.88 None | Maximum response = 100.0 % | Minimum measured = -2.38 None | R squared = 0.987 None,,,21.547,3
CHEMBL5604703,,,326.79,0.0,3.38,ASAP-0029875,Cc1nc2c(C(=O)Nc3ccc4c(c3)CNC4)cc(Cl)cc2[nH]1,IC50,'>',99500.0,nM,,,Falls Outside The Dose Series,UO_0000065,,,,,0,CHEMBL5604073,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 3,,,,,Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK,,,CHEMBL5705863,NS3 protease,dengue virus type 3,SINGLE PROTEIN,CHEMBL5604065,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 0.5 None | Maximum measured = 41.16 None | Maximum response = 100.0 % | Minimum measured = -7.653 None | R squared = 0.142 None,,,99.5,3
CHEMBL5604471,,,332.41,0.0,3.92,ASAP-0029790,Cc1c(C(=O)Nc2cc(-c3cccnc3)ccn2)cc(C2CC2)n1C,IC50,'=',6221.0,nM,5.21,,,UO_0000065,,,,,0,CHEMBL5604073,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 3,,,,,Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK,,,CHEMBL5705863,NS3 protease,dengue virus type 3,SINGLE PROTEIN,CHEMBL5604065,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 4.205 None | IC50 CI (lower) = 5.652 uM | IC50 CI (upper) = 6.848 uM | Maximum measured = 98.68 None | Maximum response = 100.0 % | Minimum measured = -2.546 None | R squared = 0.994 None,,,6.221,3
CHEMBL5598718,,,298.78,0.0,3.43,ASAP-0029525,Clc1cc(CNc2ccc3c(c2)CNC3)c2cn[nH]c2c1,IC50,'=',42234.0,nM,4.37,,,UO_0000065,,,,,0,CHEMBL5604073,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 3,,,,,Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK,,,CHEMBL5705863,NS3 protease,dengue virus type 3,SINGLE PROTEIN,CHEMBL5604065,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 2.691 None | IC50 CI (lower) = 37.38 uM | IC50 CI (upper) = 47.71 uM | Maximum measured = 79.3 None | Maximum response = 100.0 % | Minimum measured = -9.561 None | R squared = 0.95 None,,,42.234,3
CHEMBL5598576,,,405.88,0.0,4.36,ASAP-0029491,O=C(NCC(F)F)[C@H](Nc1ccc2c(c1)CNC2)c1cc(Cl)cc(C2CC2)c1,IC50,'=',28457.0,nM,4.55,,,UO_0000065,,,,,0,CHEMBL5604073,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 3,,,,,Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK,,,CHEMBL5705863,NS3 protease,dengue virus type 3,SINGLE PROTEIN,CHEMBL5604065,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 0.986 None | IC50 CI (lower) = 26.14 uM | IC50 CI (upper) = 30.98 uM | Maximum measured = 77.08 None | Maximum response = 100.0 % | Minimum measured = -4.221 None | R squared = 0.991 None,,,28.457,3
CHEMBL5604249,,,406.91,1.0,5.82,ASAP-0022797,NCc1cccc([C@H]2C[C@@H]2c2cc(Cl)cc(NC(=O)OCc3ccccc3)c2)c1,IC50,'=',7852.0,nM,5.11,,,UO_0000065,,,,,0,CHEMBL5604073,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 3,,,,,Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK,,,CHEMBL5705863,NS3 protease,dengue virus type 3,SINGLE PROTEIN,CHEMBL5604065,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 3.451 None | IC50 CI (lower) = 7.172 uM | IC50 CI (upper) = 8.596 uM | Maximum measured = 94.34 None | Maximum response = 100.0 % | Minimum measured = -8.578 None | R squared = 0.984 None,,,7.852,3
CHEMBL3919119,,,454.34,,,ASAP-0015081,N=C(N)NCCC[C@H](NC(=O)[C@H](Cc1ccc(CN)cc1)NC(=O)c1ccccc1)B(O)O,IC50,'=',980.0,nM,6.01,,,UO_0000065,,,,,0,CHEMBL5604073,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 3,,,,,Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK,,,CHEMBL5705863,NS3 protease,dengue virus type 3,SINGLE PROTEIN,CHEMBL5604065,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 1.138 None | IC50 CI (lower) = 0.931 uM | IC50 CI (upper) = 1.031 uM | Maximum measured = 99.34 None | Maximum response = 100.0 % | Minimum measured = 3.134 None | R squared = 0.998 None,,,0.98,3
CHEMBL5605142,,,474.95,1.0,6.0,ASAP-0028884,C=CC[C@H](Nc1cc(Cl)cc(NC(=O)OCc2ccccc2)c1)c1cccc(-c2nn[nH]n2)c1,IC50,'=',6430.0,nM,5.19,,,UO_0000065,,,,,0,CHEMBL5604073,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 3,,,,,Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK,,,CHEMBL5705863,NS3 protease,dengue virus type 3,SINGLE PROTEIN,CHEMBL5604065,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 3.013 None | IC50 CI (lower) = 6.018 uM | IC50 CI (upper) = 6.87 uM | Maximum measured = 100.81 None | Maximum response = 100.0 % | Minimum measured = -3.131 None | R squared = 0.996 None,,,6.43,3
CHEMBL5605069,,,311.77,0.0,3.68,ASAP-0030001,O=C(Nc1ccc2c(c1)CNC2)c1cc(Cl)cc2cc[nH]c12,IC50,'=',87872.0,nM,4.06,,,UO_0000065,,,,,0,CHEMBL5604073,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 3,,,,,Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK,,,CHEMBL5705863,NS3 protease,dengue virus type 3,SINGLE PROTEIN,CHEMBL5604065,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 1.217 None | IC50 CI (lower) = 79.88 uM | IC50 CI (upper) = 96.67 uM | Maximum measured = 53.8 None | Maximum response = 100.0 % | Minimum measured = -1.642 None | R squared = 0.98 None,,,87.872,3
CHEMBL5604539,,,388.39,0.0,3.44,ASAP-0030867,O=C(NCC(F)F)[C@H](Nc1ccc2c(c1)CNC2)c1cc(F)cc2[nH]ccc12,IC50,'>',99500.0,nM,,,Falls Outside The Dose Series,UO_0000065,,,,,0,CHEMBL5604073,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 3,,,,,Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK,,,CHEMBL5705863,NS3 protease,dengue virus type 3,SINGLE PROTEIN,CHEMBL5604065,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 10.13 None | Maximum measured = 10.25 None | Maximum response = 100.0 % | Minimum measured = -6.706 None | R squared = 0.033 None,,,99.5,3
CHEMBL5605366,,,425.92,0.0,3.27,ASAP-0029888,O=C(NC1CCOCC1)[C@H](Nc1ccc2c(c1)CNC2)c1cc(Cl)cc2[nH]ncc12,IC50,'=',39513.0,nM,4.4,,,UO_0000065,,,,,0,CHEMBL5604073,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 3,,,,,Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK,,,CHEMBL5705863,NS3 protease,dengue virus type 3,SINGLE PROTEIN,CHEMBL5604065,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 1.0 None | IC50 CI (lower) = 36.57 uM | IC50 CI (upper) = 42.7 uM | Maximum measured = 69.88 None | Maximum response = 100.0 % | Minimum measured = -2.144 None | R squared = 0.991 None,,,39.513,3
CHEMBL5605549,,,294.31,0.0,1.71,ASAP-0029783,O=C(Nc1ccc2c(c1)CNC2)c1cccc2[nH]c(=O)[nH]c12,IC50,'=',40810.0,nM,4.39,,,UO_0000065,,,,,0,CHEMBL5604073,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 3,,,,,Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK,,,CHEMBL5705863,NS3 protease,dengue virus type 3,SINGLE PROTEIN,CHEMBL5604065,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 0.998 None | IC50 CI (lower) = 38.59 uM | IC50 CI (upper) = 43.16 uM | Maximum measured = 71.33 None | Maximum response = 100.0 % | Minimum measured = -0.067 None | R squared = 0.995 None,,,40.81,3
CHEMBL5605238,,,375.5,0.0,4.13,ASAP-0031464,O=C(Nc1ccc2c(c1)CNC2)c1ccc2c(C3=CCNCC3)csc2c1,IC50,'=',54442.0,nM,4.26,,,UO_0000065,,,,,0,CHEMBL5604073,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 3,,,,,Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK,,,CHEMBL5705863,NS3 protease,dengue virus type 3,SINGLE PROTEIN,CHEMBL5604065,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 2.049 None | IC50 CI (lower) = 51.41 uM | IC50 CI (upper) = 57.66 uM | Maximum measured = 79.45 None | Maximum response = 100.0 % | Minimum measured = -1.904 None | R squared = 0.988 None,,,54.442,3
CHEMBL5599838,,,459.98,1.0,5.16,ASAP-0031456,CC(C)NC(=O)[C@H](Nc1ccc2c(c1)CNC2)c1cc(Cl)cc2[nH]c(-c3ccccc3)nc12,IC50,'=',2207.0,nM,5.66,,,UO_0000065,,,,,0,CHEMBL5604073,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 3,,,,,Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK,,,CHEMBL5705863,NS3 protease,dengue virus type 3,SINGLE PROTEIN,CHEMBL5604065,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 0.943 None | IC50 CI (lower) = 2.088 uM | IC50 CI (upper) = 2.332 uM | Maximum measured = 96.45 None | Maximum response = 100.0 % | Minimum measured = 4.502 None | R squared = 0.998 None,,,2.207,3
CHEMBL5604531,,,402.43,0.0,4.23,ASAP-0031290,COc1cccc(-c2nc3c(C(=O)Nc4ccc5c(c4)CNC5)cc(F)cc3[nH]2)c1,IC50,'=',3719.0,nM,5.43,,,UO_0000065,,,,,0,CHEMBL5604073,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 3,,,,,Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK,,,CHEMBL5705863,NS3 protease,dengue virus type 3,SINGLE PROTEIN,CHEMBL5604065,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 1.365 None | IC50 CI (lower) = 3.11 uM | IC50 CI (upper) = 4.448 uM | Maximum measured = 92.0 None | Maximum response = 100.0 % | Minimum measured = 0.699 None | R squared = 0.971 None,,,3.719,3
CHEMBL5606266,,,277.33,0.0,3.02,ASAP-0029756,O=C(Nc1ccc2c(c1)CNC2)c1ccc2[nH]ccc2c1,IC50,'>',99500.0,nM,,,Falls Outside The Dose Series,UO_0000065,,,,,0,CHEMBL5604073,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 3,,,,,Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK,,,CHEMBL5705863,NS3 protease,dengue virus type 3,SINGLE PROTEIN,CHEMBL5604065,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 1.911 None | Maximum measured = 23.95 None | Maximum response = 100.0 % | Minimum measured = -4.722 None | R squared = 0.727 None,,,99.5,3
CHEMBL5604118,,,367.47,0.0,3.55,ASAP-0031158,NCCc1csc2cc(C(=O)Nc3cc([C@H]4CCOC4)ccn3)ccc12,IC50,'>',99500.0,nM,,,Falls Outside The Dose Series,UO_0000065,,,,,0,CHEMBL5604073,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 3,,,,,Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK,,,CHEMBL5705863,NS3 protease,dengue virus type 3,SINGLE PROTEIN,CHEMBL5604065,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Maximum measured = 0.149 None | Minimum measured = -8.911 None,,,99.5,3
CHEMBL5605520,,,352.82,0.0,2.97,ASAP-0028990,OCC#C[C@H](Nc1ccc2c(c1)CNC2)c1cc(Cl)cc2[nH]ncc12,IC50,'=',26215.0,nM,4.58,,,UO_0000065,,,,,0,CHEMBL5604073,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 3,,,,,Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK,,,CHEMBL5705863,NS3 protease,dengue virus type 3,SINGLE PROTEIN,CHEMBL5604065,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 4.483 None | IC50 CI (lower) = 24.61 uM | IC50 CI (upper) = 27.93 uM | Maximum measured = 95.32 None | Maximum response = 100.0 % | Minimum measured = -10.25 None | R squared = 0.984 None,,,26.215,3
CHEMBL5605533,,,418.88,0.0,4.75,ASAP-0029841,Cc1cccc(-c2nc3c(C(=O)Nc4ccc5c(c4)CNC5)cc(Cl)cc3[nH]2)c1O,IC50,'=',4441.0,nM,5.35,,,UO_0000065,,,,,0,CHEMBL5604073,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 3,,,,,Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK,,,CHEMBL5705863,NS3 protease,dengue virus type 3,SINGLE PROTEIN,CHEMBL5604065,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 3.715 None | IC50 CI (lower) = 3.683 uM | IC50 CI (upper) = 5.354 uM | Maximum measured = 96.26 None | Maximum response = 100.0 % | Minimum measured = -10.12 None | R squared = 0.979 None,,,4.441,3
CHEMBL5598575,,,399.92,0.0,3.74,ASAP-0029415,COCCNC(=O)[C@H](Nc1ccc2c(c1)CNC2)c1cc(Cl)cc(C2CC2)c1,IC50,'=',63358.0,nM,4.2,,,UO_0000065,,,,,0,CHEMBL5604073,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 3,,,,,Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK,,,CHEMBL5705863,NS3 protease,dengue virus type 3,SINGLE PROTEIN,CHEMBL5604065,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 1.053 None | IC50 CI (lower) = 57.21 uM | IC50 CI (upper) = 70.17 uM | Maximum measured = 63.66 None | Maximum response = 100.0 % | Minimum measured = -0.752 None | R squared = 0.982 None,,,63.358,3
CHEMBL5605910,,,413.91,0.0,3.13,ASAP-0029914,CCOCCNC(=O)[C@H](Nc1ccc2c(c1)CNC2)c1cc(Cl)cc2[nH]ncc12,IC50,'>',99500.0,nM,,,Falls Outside The Dose Series,UO_0000065,,,,,0,CHEMBL5604073,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 3,,,,,Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK,,,CHEMBL5705863,NS3 protease,dengue virus type 3,SINGLE PROTEIN,CHEMBL5604065,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 1.166 None | Maximum measured = 37.99 None | Maximum response = 100.0 % | Minimum measured = -0.481 None | R squared = 0.98 None,,,99.5,3
CHEMBL5604180,,,312.76,0.0,3.07,ASAP-0029911,O=C(Nc1ccc2c(c1)CNC2)c1cc(Cl)cc2cn[nH]c12,IC50,'=',41870.0,nM,4.38,,,UO_0000065,,,,,0,CHEMBL5604073,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 3,,,,,Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK,,,CHEMBL5705863,NS3 protease,dengue virus type 3,SINGLE PROTEIN,CHEMBL5604065,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 1.045 None | IC50 CI (lower) = 39.62 uM | IC50 CI (upper) = 44.25 uM | Maximum measured = 71.26 None | Maximum response = 100.0 % | Minimum measured = -1.292 None | R squared = 0.995 None,,,41.87,3
CHEMBL5598927,,,372.22,0.0,2.8,ASAP-0029728,O=C1Cc2c(cc(Br)cc2C(=O)Nc2ccc3c(c2)CNC3)N1,IC50,'=',17849.0,nM,4.75,,,UO_0000065,,,,,0,CHEMBL5604073,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 3,,,,,Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK,,,CHEMBL5705863,NS3 protease,dengue virus type 3,SINGLE PROTEIN,CHEMBL5604065,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 1.045 None | IC50 CI (lower) = 17.0 uM | IC50 CI (upper) = 18.74 uM | Maximum measured = 86.97 None | Maximum response = 100.0 % | Minimum measured = 0.357 None | R squared = 0.997 None,,,17.849,3
CHEMBL5598576,,,405.88,0.0,4.36,ASAP-0030776,O=C(NCC(F)F)[C@H](Nc1ccc2c(c1)CNC2)c1cc(Cl)cc(C2CC2)c1,IC50,'=',23817.0,nM,4.62,,,UO_0000065,,,,,0,CHEMBL5604073,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 3,,,,,Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK,,,CHEMBL5705863,NS3 protease,dengue virus type 3,SINGLE PROTEIN,CHEMBL5604065,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 1.094 None | IC50 CI (lower) = 21.71 uM | IC50 CI (upper) = 26.13 uM | Maximum measured = 81.1 None | Maximum response = 100.0 % | Minimum measured = -3.933 None | R squared = 0.989 None,,,23.817,3
CHEMBL5606160,,,372.4,0.0,4.22,ASAP-0030089,O=C(Nc1ccc2c(c1)CNC2)c1cc(F)cc2[nH]c(-c3ccccc3)nc12,IC50,'=',3568.0,nM,5.45,,,UO_0000065,,,,,0,CHEMBL5604073,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 3,,,,,Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK,,,CHEMBL5705863,NS3 protease,dengue virus type 3,SINGLE PROTEIN,CHEMBL5604065,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 2.439 None | IC50 CI (lower) = 2.905 uM | IC50 CI (upper) = 4.382 uM | Maximum measured = 92.07 None | Maximum response = 100.0 % | Minimum measured = -2.255 None | R squared = 0.959 None,,,3.568,3
CHEMBL5598610,,,383.88,0.0,3.5,ASAP-0029974,CC(C)NC(=O)[C@H](Nc1ccc2c(c1)CNC2)c1cc(Cl)cc2[nH]ncc12,IC50,'=',26162.0,nM,4.58,,,UO_0000065,,,,,0,CHEMBL5604073,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 3,,,,,Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK,,,CHEMBL5705863,NS3 protease,dengue virus type 3,SINGLE PROTEIN,CHEMBL5604065,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 1.199 None | IC50 CI (lower) = 24.02 uM | IC50 CI (upper) = 28.49 uM | Maximum measured = 87.81 None | Maximum response = 100.0 % | Minimum measured = -3.276 None | R squared = 0.99 None,,,26.162,3
CHEMBL5604216,,,397.41,0.0,4.1,ASAP-0031247,N#Cc1cccc(-c2nc3c(C(=O)Nc4ccc5c(c4)CNC5)cc(F)cc3[nH]2)c1,IC50,'=',2307.0,nM,5.64,,,UO_0000065,,,,,0,CHEMBL5604073,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 3,,,,,Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK,,,CHEMBL5705863,NS3 protease,dengue virus type 3,SINGLE PROTEIN,CHEMBL5604065,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 2.192 None | IC50 CI (lower) = 1.966 uM | IC50 CI (upper) = 2.707 uM | Maximum measured = 94.36 None | Maximum response = 100.0 % | Minimum measured = -5.715 None | R squared = 0.968 None,,,2.307,3
CHEMBL5604988,,,399.52,0.0,4.88,ASAP-0031461,NCc1cccc(-c2csc3cc(C(=O)Nc4ccc5c(c4)CNC5)ccc23)c1,IC50,'=',29787.0,nM,4.53,,,UO_0000065,,,,,0,CHEMBL5604073,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 3,,,,,Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK,,,CHEMBL5705863,NS3 protease,dengue virus type 3,SINGLE PROTEIN,CHEMBL5604065,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 1.832 None | IC50 CI (lower) = 28.13 uM | IC50 CI (upper) = 31.54 uM | Maximum measured = 94.14 None | Maximum response = 100.0 % | Minimum measured = -1.579 None | R squared = 0.993 None,,,29.787,3
CHEMBL5604667,,,422.49,0.0,4.2,ASAP-0031355,CC(C)c1nnc(-c2nc3c(C(=O)Nc4ccc5c(c4)CNC5)cc(F)cc3[nH]2)s1,IC50,'=',10818.0,nM,4.97,,,UO_0000065,,,,,0,CHEMBL5604073,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 3,,,,,Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK,,,CHEMBL5705863,NS3 protease,dengue virus type 3,SINGLE PROTEIN,CHEMBL5604065,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 1.449 None | IC50 CI (lower) = 9.076 uM | IC50 CI (upper) = 12.89 uM | Maximum measured = 81.16 None | Maximum response = 100.0 % | Minimum measured = -0.345 None | R squared = 0.962 None,,,10.818,3
CHEMBL5605561,,,333.4,0.0,2.11,ASAP-0031692,O=C(Nc1ccc2c(c1)CNC2)c1cccc2c(C3CNC3)n[nH]c12,IC50,'=',9270.0,nM,5.03,,,UO_0000065,,,,,0,CHEMBL5604073,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 3,,,,,Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK,,,CHEMBL5705863,NS3 protease,dengue virus type 3,SINGLE PROTEIN,CHEMBL5604065,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 0.955 None | IC50 CI (lower) = 8.971 uM | IC50 CI (upper) = 9.579 uM | Maximum measured = 90.35 None | Maximum response = 100.0 % | Minimum measured = 0.978 None | R squared = 0.999 None,,,9.27,3
CHEMBL3740727,,,719.79,2.0,2.06,ASAP-0000570,N=C(N)NCCC[C@H](NC(=O)c1nccs1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(N)=O)c1ccc(OCc2ccc(C(F)(F)F)cc2)cc1,IC50,'=',1495.0,nM,5.83,,,UO_0000065,,,,,0,CHEMBL5604073,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 3,,,,,Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK,,,CHEMBL5705863,NS3 protease,dengue virus type 3,SINGLE PROTEIN,CHEMBL5604065,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 1.091 None | IC50 CI (lower) = 1.442 uM | IC50 CI (upper) = 1.551 uM | Maximum measured = 99.53 None | Maximum response = 100.0 % | Minimum measured = 0.208 None | R squared = 0.999 None,,,1.495,3
CHEMBL5605251,,,493.41,1.0,5.97,ASAP-0015849,CC(C)CNC(=O)c1cc(Cl)ccc1NS(=O)(=O)c1ccc(Oc2ccccc2Cl)cc1,IC50,'=',12111.0,nM,4.92,,,UO_0000065,,,,,0,CHEMBL5604073,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 3,,,,,Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK,,,CHEMBL5705863,NS3 protease,dengue virus type 3,SINGLE PROTEIN,CHEMBL5604065,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 1.284 None | IC50 CI (lower) = 9.895 uM | IC50 CI (upper) = 14.82 uM | Maximum measured = 79.48 None | Maximum response = 100.0 % | Minimum measured = -1.644 None | R squared = 0.953 None,,,12.111,3
CHEMBL5606202,,,344.46,0.0,4.73,ASAP-0021052,Cc1[nH]c2ccccc2c1CN1CCC(c2c[nH]c3ncccc23)CC1,IC50,'>',99500.0,nM,,,Falls Outside The Dose Series,UO_0000065,,,,,0,CHEMBL5604073,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 3,,,,,Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK,,,CHEMBL5705863,NS3 protease,dengue virus type 3,SINGLE PROTEIN,CHEMBL5604065,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 2.927 None | Maximum measured = 11.12 None | Maximum response = 100.0 % | Minimum measured = -2.78 None | R squared = 0.773 None,,,99.5,3
CHEMBL5598898,,,323.78,0.0,3.74,ASAP-0029711,O=C(Nc1ccc2c(c1)CNC2)c1cc(Cl)cc2ccncc12,IC50,'=',69764.0,nM,4.16,,,UO_0000065,,,,,0,CHEMBL5604073,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 3,,,,,Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK,,,CHEMBL5705863,NS3 protease,dengue virus type 3,SINGLE PROTEIN,CHEMBL5604065,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 1.189 None | IC50 CI (lower) = 63.25 uM | IC50 CI (upper) = 76.95 uM | Maximum measured = 60.5 None | Maximum response = 100.0 % | Minimum measured = -3.488 None | R squared = 0.981 None,,,69.764,3
CHEMBL5598685,,,323.83,0.0,4.5,ASAP-0029597,N#C[C@H](Nc1ccc2c(c1)CNC2)c1cc(Cl)cc(C2CC2)c1,IC50,'>',99500.0,nM,,,Falls Outside The Dose Series,UO_0000065,,,,,0,CHEMBL5604073,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 3,,,,,Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK,,,CHEMBL5705863,NS3 protease,dengue virus type 3,SINGLE PROTEIN,CHEMBL5604065,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Maximum measured = 1.006 None | Minimum measured = -33.06 None,,,99.5,3
CHEMBL3740727,,,719.79,2.0,2.06,ASAP-0000570,N=C(N)NCCC[C@H](NC(=O)c1nccs1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(N)=O)c1ccc(OCc2ccc(C(F)(F)F)cc2)cc1,IC50,'=',2219.0,nM,5.65,,,UO_0000065,,,,,0,CHEMBL5604073,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 3,,,,,Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK,,,CHEMBL5705863,NS3 protease,dengue virus type 3,SINGLE PROTEIN,CHEMBL5604065,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 1.149 None | IC50 CI (lower) = 2.146 uM | IC50 CI (upper) = 2.296 uM | Maximum measured = 98.93 None | Maximum response = 100.0 % | Minimum measured = -1.075 None | R squared = 0.999 None,,,2.219,3
CHEMBL5598658,,,355.87,0.0,3.72,ASAP-0029621,CNC(=O)[C@H](Nc1ccc2c(c1)CNC2)c1cc(Cl)cc(C2CC2)c1,IC50,'>',99500.0,nM,,,Falls Outside The Dose Series,UO_0000065,,,,,0,CHEMBL5604073,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 3,,,,,Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK,,,CHEMBL5705863,NS3 protease,dengue virus type 3,SINGLE PROTEIN,CHEMBL5604065,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 3.765 None | Maximum measured = 13.78 None | Maximum response = 100.0 % | Minimum measured = -2.347 None | R squared = 0.857 None,,,99.5,3
CHEMBL5605274,,,390.39,0.0,4.36,ASAP-0031221,O=C(Nc1ccc2c(c1)CNC2)c1cc(F)cc2[nH]c(-c3ccccc3F)nc12,IC50,'=',3444.0,nM,5.46,,,UO_0000065,,,,,0,CHEMBL5604073,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 3,,,,,Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK,,,CHEMBL5705863,NS3 protease,dengue virus type 3,SINGLE PROTEIN,CHEMBL5604065,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 2.184 None | IC50 CI (lower) = 2.864 uM | IC50 CI (upper) = 4.141 uM | Maximum measured = 95.66 None | Maximum response = 100.0 % | Minimum measured = -5.563 None | R squared = 0.969 None,,,3.444,3
CHEMBL5604418,,,351.88,0.0,4.95,ASAP-0029785,Clc1cc([C@@H]2C[C@H]2c2cccc(C3CCNCC3)c2)c2cn[nH]c2c1,IC50,'=',6448.0,nM,5.19,,,UO_0000065,,,,,0,CHEMBL5604073,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 3,,,,,Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK,,,CHEMBL5705863,NS3 protease,dengue virus type 3,SINGLE PROTEIN,CHEMBL5604065,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 17.92 None | IC50 CI (lower) = 0.0 uM | IC50 CI (upper) = -7982982183235092000 uM | Maximum measured = 100.69 None | Maximum response = 100.0 % | Minimum measured = -10.02 None | R squared = 0.992 None,,,6.448,3
CHEMBL5605521,,,296.35,0.0,3.17,ASAP-0030106,O=C(Nc1ccc2c(c1)CNC2)c1cc(F)cc2c1CCC2,IC50,'>',99500.0,nM,,,Falls Outside The Dose Series,UO_0000065,,,,,0,CHEMBL5604073,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 3,,,,,Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK,,,CHEMBL5705863,NS3 protease,dengue virus type 3,SINGLE PROTEIN,CHEMBL5604065,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 1.485 None | Maximum measured = 22.5 None | Maximum response = 100.0 % | Minimum measured = -1.162 None | R squared = 0.927 None,,,99.5,3
CHEMBL5604164,,,345.32,0.0,4.04,ASAP-0030028,O=C(Nc1ccc2c(c1)CNC2)c1cccc2[nH]c(C(F)(F)F)cc12,IC50,'=',31764.0,nM,4.5,,,UO_0000065,,,,,0,CHEMBL5604073,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 3,,,,,Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK,,,CHEMBL5705863,NS3 protease,dengue virus type 3,SINGLE PROTEIN,CHEMBL5604065,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 0.993 None | IC50 CI (lower) = 29.72 uM | IC50 CI (upper) = 33.95 uM | Maximum measured = 74.3 None | Maximum response = 100.0 % | Minimum measured = -1.539 None | R squared = 0.994 None,,,31.764,3
CHEMBL5606201,,,389.85,0.0,3.93,ASAP-0030082,O=C(Nc1ccc2c(c1)CNC2)c1cc(Cl)cc2nn(-c3ccccc3)nc12,IC50,'=',4726.0,nM,5.33,,,UO_0000065,,,,,0,CHEMBL5604073,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 3,,,,,Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK,,,CHEMBL5705863,NS3 protease,dengue virus type 3,SINGLE PROTEIN,CHEMBL5604065,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 3.628 None | IC50 CI (lower) = 4.021 uM | IC50 CI (upper) = 5.554 uM | Maximum measured = 96.52 None | Maximum response = 100.0 % | Minimum measured = -9.582 None | R squared = 0.985 None,,,4.726,3
CHEMBL5606236,,,375.2,0.0,3.32,ASAP-0030085,O=C(Nc1cc2c(cc1Br)CNC2)c1cc(F)cc2[nH]ncc12,IC50,'=',21759.0,nM,4.66,,,UO_0000065,,,,,0,CHEMBL5604073,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 3,,,,,Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK,,,CHEMBL5705863,NS3 protease,dengue virus type 3,SINGLE PROTEIN,CHEMBL5604065,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 1.001 None | IC50 CI (lower) = 20.15 uM | IC50 CI (upper) = 23.49 uM | Maximum measured = 81.81 None | Maximum response = 100.0 % | Minimum measured = -4.603 None | R squared = 0.993 None,,,21.759,3
CHEMBL5604338,,,360.46,0.0,3.49,ASAP-0031404,O=C(Nc1ccc2c(c1)CNC2)c1ccc2[nH]cc(C3CCNCC3)c2c1,IC50,'=',29240.0,nM,4.53,,,UO_0000065,,,,,0,CHEMBL5604073,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 3,,,,,Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK,,,CHEMBL5705863,NS3 protease,dengue virus type 3,SINGLE PROTEIN,CHEMBL5604065,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 3.88 None | IC50 CI (lower) = 27.94 uM | IC50 CI (upper) = 30.6 uM | Maximum measured = 97.59 None | Maximum response = 100.0 % | Minimum measured = -1.371 None | R squared = 0.993 None,,,29.24,3
CHEMBL5599838,,,459.98,1.0,5.16,ASAP-0030826,CC(C)NC(=O)[C@H](Nc1ccc2c(c1)CNC2)c1cc(Cl)cc2[nH]c(-c3ccccc3)nc12,IC50,'=',7062.0,nM,5.15,,,UO_0000065,,,,,0,CHEMBL5604073,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 3,,,,,Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK,,,CHEMBL5705863,NS3 protease,dengue virus type 3,SINGLE PROTEIN,CHEMBL5604065,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 1.029 None | IC50 CI (lower) = 6.595 uM | IC50 CI (upper) = 7.563 uM | Maximum measured = 93.63 None | Maximum response = 100.0 % | Minimum measured = -3.544 None | R squared = 0.996 None,,,7.062,3
CHEMBL5606033,,,293.33,0.0,2.04,ASAP-0029950,O=C1Cc2cc(C(=O)Nc3ccc4c(c3)CNC4)ccc2N1,IC50,'=',7129.0,nM,5.15,,,UO_0000065,,,,,0,CHEMBL5604073,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 3,,,,,Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK,,,CHEMBL5705863,NS3 protease,dengue virus type 3,SINGLE PROTEIN,CHEMBL5604065,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 3.411 None | IC50 CI (lower) = 6.665 uM | IC50 CI (upper) = 7.624 uM | Maximum measured = 99.22 None | Maximum response = 100.0 % | Minimum measured = -4.225 None | R squared = 0.993 None,,,7.129,3
CHEMBL5598845,,,356.22,0.0,3.79,ASAP-0029002,O=C(Nc1ccc2c(c1)CNC2)c1cc(Br)cc2[nH]ccc12,IC50,'=',44599.0,nM,4.35,,,UO_0000065,,,,,0,CHEMBL5604073,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 3,,,,,Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK,,,CHEMBL5705863,NS3 protease,dengue virus type 3,SINGLE PROTEIN,CHEMBL5604065,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 3.104 None | IC50 CI (lower) = 42.59 uM | IC50 CI (upper) = 46.71 uM | Maximum measured = 86.45 None | Maximum response = 100.0 % | Minimum measured = -2.531 None | R squared = 0.991 None,,,44.599,3
CHEMBL3740727,,,719.79,2.0,2.06,ASAP-0000570,N=C(N)NCCC[C@H](NC(=O)c1nccs1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(N)=O)c1ccc(OCc2ccc(C(F)(F)F)cc2)cc1,IC50,'=',2447.0,nM,5.61,,,UO_0000065,,,,,0,CHEMBL5604073,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 3,,,,,Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK,,,CHEMBL5705863,NS3 protease,dengue virus type 3,SINGLE PROTEIN,CHEMBL5604065,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 1.189 None | IC50 CI (lower) = 2.282 uM | IC50 CI (upper) = 2.623 uM | Maximum measured = 99.69 None | Maximum response = 100.0 % | Minimum measured = -3.752 None | R squared = 0.996 None,,,2.447,3
CHEMBL5605184,,,311.32,0.0,2.18,ASAP-0030065,O=C1Cc2c(cc(F)cc2C(=O)Nc2ccc3c(c2)CNC3)N1,IC50,'=',8591.0,nM,5.07,,,UO_0000065,,,,,0,CHEMBL5604073,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 3,,,,,Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK,,,CHEMBL5705863,NS3 protease,dengue virus type 3,SINGLE PROTEIN,CHEMBL5604065,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 1.08 None | IC50 CI (lower) = 8.022 uM | IC50 CI (upper) = 9.199 uM | Maximum measured = 95.55 None | Maximum response = 100.0 % | Minimum measured = -2.791 None | R squared = 0.996 None,,,8.591,3
CHEMBL5604326,,,333.39,0.0,3.15,ASAP-0030062,C=CC[C@H]1NCc2cc(NC(=O)c3cccc4c3CC(=O)N4)ccc21,IC50,'>',99500.0,nM,,,Falls Outside The Dose Series,UO_0000065,,,,,0,CHEMBL5604073,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 3,,,,,Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK,,,CHEMBL5705863,NS3 protease,dengue virus type 3,SINGLE PROTEIN,CHEMBL5604065,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 1.061 None | Maximum measured = 32.96 None | Maximum response = 100.0 % | Minimum measured = -1.718 None | R squared = 0.953 None,,,99.5,3
CHEMBL5598679,,,293.33,0.0,2.04,ASAP-0029208,O=C1Cc2c(cccc2C(=O)Nc2ccc3c(c2)CNC3)N1,IC50,'=',14233.0,nM,4.85,,,UO_0000065,,,,,0,CHEMBL5604073,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 3,,,,,Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK,,,CHEMBL5705863,NS3 protease,dengue virus type 3,SINGLE PROTEIN,CHEMBL5604065,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 2.893 None | IC50 CI (lower) = 13.53 uM | IC50 CI (upper) = 14.97 uM | Maximum measured = 98.88 None | Maximum response = 100.0 % | Minimum measured = -3.437 None | R squared = 0.995 None,,,14.233,3
CHEMBL5598615,,,367.25,0.0,4.46,ASAP-0029045,O=C(Nc1ccc2c(c1)CNC2)c1cc(Br)cc2ccccc12,IC50,'>',99500.0,nM,,,Falls Outside The Dose Series,UO_0000065,,,,,0,CHEMBL5604073,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 3,,,,,Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK,,,CHEMBL5705863,NS3 protease,dengue virus type 3,SINGLE PROTEIN,CHEMBL5604065,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 1.83 None | Maximum measured = 48.76 None | Maximum response = 100.0 % | Minimum measured = -3.569 None | R squared = 0.964 None,,,99.5,3
CHEMBL5605691,,,312.42,0.0,2.75,ASAP-0027597,Cc1c(C(=O)Nc2cc(CCCN)ccn2)cc(C2CC2)n1C,IC50,'=',34474.0,nM,4.46,,,UO_0000065,,,,,0,CHEMBL5604073,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 3,,,,,Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK,,,CHEMBL5705863,NS3 protease,dengue virus type 3,SINGLE PROTEIN,CHEMBL5604065,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 2.512 None | IC50 CI (lower) = 31.32 uM | IC50 CI (upper) = 37.94 uM | Maximum measured = 92.99 None | Maximum response = 100.0 % | Minimum measured = -6.02 None | R squared = 0.977 None,,,34.474,3
CHEMBL3740727,,,719.79,2.0,2.06,ASAP-0000570,N=C(N)NCCC[C@H](NC(=O)c1nccs1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(N)=O)c1ccc(OCc2ccc(C(F)(F)F)cc2)cc1,IC50,'=',2339.0,nM,5.63,,,UO_0000065,,,,,0,CHEMBL5604073,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 3,,,,,Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK,,,CHEMBL5705863,NS3 protease,dengue virus type 3,SINGLE PROTEIN,CHEMBL5604065,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 1.166 None | IC50 CI (lower) = 2.255 uM | IC50 CI (upper) = 2.427 uM | Maximum measured = 98.72 None | Maximum response = 100.0 % | Minimum measured = -0.22 None | R squared = 0.999 None,,,2.339,3
CHEMBL5604114,,,488.94,0.0,4.42,ASAP-0027813,O=C(Nc1cc(Cl)cc([C@H](C#CCO)Nc2cccc(-c3nn[nH]n3)c2)c1)OCc1ccccc1,IC50,'=',11890.0,nM,4.92,,,UO_0000065,,,,,0,CHEMBL5604073,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 3,,,,,Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK,,,CHEMBL5705863,NS3 protease,dengue virus type 3,SINGLE PROTEIN,CHEMBL5604065,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 2.952 None | IC50 CI (lower) = 11.49 uM | IC50 CI (upper) = 12.3 uM | Maximum measured = 98.39 None | Maximum response = 100.0 % | Minimum measured = -1.62 None | R squared = 0.998 None,,,11.89,3
CHEMBL5605532,,,341.46,1.0,5.1,ASAP-0016252,c1cc(C2CCN(Cc3c[nH]c4ccccc34)CC2)c2ccncc2c1,IC50,'>',99500.0,nM,,,Falls Outside The Dose Series,UO_0000065,,,,,0,CHEMBL5604073,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 3,,,,,Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK,,,CHEMBL5705863,NS3 protease,dengue virus type 3,SINGLE PROTEIN,CHEMBL5604065,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 1.878 None | Maximum measured = 6.464 None | Maximum response = 100.0 % | Minimum measured = -3.076 None | R squared = 0.415 None,,,99.5,3
CHEMBL5604414,,,464.91,1.0,5.53,ASAP-0023480,O=C(Nc1cc(Cl)cc(C(=O)Nc2cccc([C@H]3C[C@H]3C(=O)O)c2)c1)OCc1ccccc1,IC50,'=',22619.0,nM,4.65,,,UO_0000065,,,,,0,CHEMBL5604073,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 3,,,,,Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK,,,CHEMBL5705863,NS3 protease,dengue virus type 3,SINGLE PROTEIN,CHEMBL5604065,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 2.877 None | IC50 CI (lower) = 21.74 uM | IC50 CI (upper) = 23.53 uM | Maximum measured = 96.99 None | Maximum response = 100.0 % | Minimum measured = -3.205 None | R squared = 0.996 None,,,22.619,3
CHEMBL5606457,,,464.87,0.0,3.61,ASAP-0023274,O=C(Nc1cc(Cl)cc(C(=O)Nc2cccc(-n3nn[nH]c3=O)c2)c1)OCc1ccccc1,IC50,'=',10524.0,nM,4.98,,,UO_0000065,,,,,0,CHEMBL5604073,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 3,,,,,Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK,,,CHEMBL5705863,NS3 protease,dengue virus type 3,SINGLE PROTEIN,CHEMBL5604065,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 2.983 None | IC50 CI (lower) = 10.17 uM | IC50 CI (upper) = 10.89 uM | Maximum measured = 97.51 None | Maximum response = 100.0 % | Minimum measured = -2.441 None | R squared = 0.998 None,,,10.524,3
CHEMBL5598576,,,405.88,0.0,4.36,ASAP-0030775,O=C(NCC(F)F)[C@H](Nc1ccc2c(c1)CNC2)c1cc(Cl)cc(C2CC2)c1,IC50,'>',99500.0,nM,,,Falls Outside The Dose Series,UO_0000065,,,,,0,CHEMBL5604073,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 3,,,,,Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK,,,CHEMBL5705863,NS3 protease,dengue virus type 3,SINGLE PROTEIN,CHEMBL5604065,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 1.982 None | Maximum measured = 40.47 None | Maximum response = 100.0 % | Minimum measured = -5.57 None | R squared = 0.951 None,,,99.5,3
CHEMBL5605090,,,336.37,0.0,3.67,ASAP-0030071,C=CC[C@H]1NCc2cc(NC(=O)c3cc(F)cc4[nH]ncc34)ccc21,IC50,'=',32342.0,nM,4.49,,,UO_0000065,,,,,0,CHEMBL5604073,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 3,,,,,Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK,,,CHEMBL5705863,NS3 protease,dengue virus type 3,SINGLE PROTEIN,CHEMBL5604065,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 1.001 None | IC50 CI (lower) = 30.04 uM | IC50 CI (upper) = 34.82 uM | Maximum measured = 74.3 None | Maximum response = 100.0 % | Minimum measured = -3.843 None | R squared = 0.993 None,,,32.342,3
CHEMBL5605639,,,341.72,0.0,3.61,ASAP-0029970,O=C(Nc1ccc2c(c1)CNC2)c1cc(Cl)cc(C(F)(F)F)n1,IC50,'=',10399.0,nM,4.98,,,UO_0000065,,,,,0,CHEMBL5604073,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 3,,,,,Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK,,,CHEMBL5705863,NS3 protease,dengue virus type 3,SINGLE PROTEIN,CHEMBL5604065,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 2.252 None | IC50 CI (lower) = 9.674 uM | IC50 CI (upper) = 11.18 uM | Maximum measured = 100.03 None | Maximum response = 100.0 % | Minimum measured = -1.646 None | R squared = 0.992 None,,,10.399,3
CHEMBL5605499,,,387.24,0.0,2.48,ASAP-0029933,Cn1c(=O)[nH]c2c(C(=O)Nc3ccc4c(c3)CNC4)cc(Br)cc21,IC50,'>',99500.0,nM,,,Falls Outside The Dose Series,UO_0000065,,,,,0,CHEMBL5604073,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 3,,,,,Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK,,,CHEMBL5705863,NS3 protease,dengue virus type 3,SINGLE PROTEIN,CHEMBL5604065,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Maximum measured = 2.244 None | Minimum measured = -27.27 None,,,99.5,3
CHEMBL5598732,,,359.27,0.0,4.43,ASAP-0029050,CC(C)c1cc(Br)cc(C(=O)Nc2ccc3c(c2)CNC3)c1,IC50,'>',99500.0,nM,,,Falls Outside The Dose Series,UO_0000065,,,,,0,CHEMBL5604073,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 3,,,,,Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK,,,CHEMBL5705863,NS3 protease,dengue virus type 3,SINGLE PROTEIN,CHEMBL5604065,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Maximum measured = -0.856 None | Minimum measured = -9.918 None,,,99.5,3
CHEMBL5606384,,,411.9,0.0,2.76,ASAP-0028903,CNC(=O)[C@H](Nc1cc(CN)cc(-c2nn[nH]n2)c1)c1cc(Cl)cc(C2CC2)c1,IC50,'>',99500.0,nM,,,Falls Outside The Dose Series,UO_0000065,,,,,0,CHEMBL5604073,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 3,,,,,Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK,,,CHEMBL5705863,NS3 protease,dengue virus type 3,SINGLE PROTEIN,CHEMBL5604065,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 1.367 None | Maximum measured = 19.96 None | Maximum response = 100.0 % | Minimum measured = -2.567 None | R squared = 0.881 None,,,99.5,3
CHEMBL5598631,,,312.8,0.0,3.68,ASAP-0029051,O=C(Nc1ccc2c(c1)CNC2)c1cc(Cl)cc2c1CCC2,IC50,'>',99500.0,nM,,,Falls Outside The Dose Series,UO_0000065,,,,,0,CHEMBL5604073,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 3,,,,,Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK,,,CHEMBL5705863,NS3 protease,dengue virus type 3,SINGLE PROTEIN,CHEMBL5604065,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 1.311 None | Maximum measured = 17.86 None | Maximum response = 100.0 % | Minimum measured = -3.159 None | R squared = 0.879 None,,,99.5,3
CHEMBL5604375,,,323.79,0.0,3.5,ASAP-0028904,N#C[C@H](Nc1ccc2c(c1)CNC2)c1cc(Cl)cc2[nH]ncc12,IC50,'>',99500.0,nM,,,Falls Outside The Dose Series,UO_0000065,,,,,0,CHEMBL5604073,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 3,,,,,Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK,,,CHEMBL5705863,NS3 protease,dengue virus type 3,SINGLE PROTEIN,CHEMBL5604065,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 2.655 None | Maximum measured = 12.55 None | Maximum response = 100.0 % | Minimum measured = -2.133 None | R squared = 0.73 None,,,99.5,3
CHEMBL3740727,,,719.79,2.0,2.06,ASAP-0000570,N=C(N)NCCC[C@H](NC(=O)c1nccs1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(N)=O)c1ccc(OCc2ccc(C(F)(F)F)cc2)cc1,IC50,'=',1634.0,nM,5.79,,,UO_0000065,,,,,0,CHEMBL5604073,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 3,,,,,Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK,,,CHEMBL5705863,NS3 protease,dengue virus type 3,SINGLE PROTEIN,CHEMBL5604065,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 1.181 None | IC50 CI (lower) = 1.547 uM | IC50 CI (upper) = 1.725 uM | Maximum measured = 99.44 None | Maximum response = 100.0 % | Minimum measured = -0.98 None | R squared = 0.998 None,,,1.634,3
CHEMBL3919119,,,454.34,,,ASAP-0015081,N=C(N)NCCC[C@H](NC(=O)[C@H](Cc1ccc(CN)cc1)NC(=O)c1ccccc1)B(O)O,IC50,'=',819.0,nM,6.09,,,UO_0000065,,,,,0,CHEMBL5604073,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 3,,,,,Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK,,,CHEMBL5705863,NS3 protease,dengue virus type 3,SINGLE PROTEIN,CHEMBL5604065,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 1.175 None | IC50 CI (lower) = 0.787 uM | IC50 CI (upper) = 0.852 uM | Maximum measured = 99.45 None | Maximum response = 100.0 % | Minimum measured = 1.676 None | R squared = 0.998 None,,,0.819,3
CHEMBL5604328,,,459.9,0.0,4.95,ASAP-0027741,N#C[C@H](Nc1cccc(-c2nn[nH]n2)c1)c1cc(Cl)cc(NC(=O)OCc2ccccc2)c1,IC50,'=',9588.0,nM,5.02,,,UO_0000065,,,,,0,CHEMBL5604073,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 3,,,,,Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK,,,CHEMBL5705863,NS3 protease,dengue virus type 3,SINGLE PROTEIN,CHEMBL5604065,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 3.216 None | IC50 CI (lower) = 9.348 uM | IC50 CI (upper) = 9.835 uM | Maximum measured = 100.88 None | Maximum response = 100.0 % | Minimum measured = -1.376 None | R squared = 0.999 None,,,9.588,3
CHEMBL5605462,,,491.94,0.0,4.17,ASAP-0027759,CNC(=O)[C@H](Nc1cc(Cl)cc(NC(=O)OCc2ccccc2)c1)c1cccc(-c2nn[nH]n2)c1,IC50,'=',40376.0,nM,4.39,,,UO_0000065,,,,,0,CHEMBL5604073,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 3,,,,,Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK,,,CHEMBL5705863,NS3 protease,dengue virus type 3,SINGLE PROTEIN,CHEMBL5604065,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 3.164 None | IC50 CI (lower) = 38.75 uM | IC50 CI (upper) = 42.08 uM | Maximum measured = 95.46 None | Maximum response = 100.0 % | Minimum measured = -2.966 None | R squared = 0.994 None,,,40.376,3
CHEMBL5605673,,,425.9,0.0,4.15,ASAP-0027729,CCc1cc(C(=O)Nc2cccc(-n3nn[nH]c3=O)c2)sc1-c1ccc(Cl)cc1,IC50,'=',11902.0,nM,4.92,,,UO_0000065,,,,,0,CHEMBL5604073,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 3,,,,,Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK,,,CHEMBL5705863,NS3 protease,dengue virus type 3,SINGLE PROTEIN,CHEMBL5604065,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 2.214 None | IC50 CI (lower) = 11.07 uM | IC50 CI (upper) = 12.79 uM | Maximum measured = 91.3 None | Maximum response = 100.0 % | Minimum measured = -1.304 None | R squared = 0.991 None,,,11.902,3
CHEMBL5605183,,,389.38,0.0,2.84,ASAP-0030767,O=C(NCC(F)F)[C@H](Nc1ccc2c(c1)CNC2)c1cc(F)cc2[nH]ncc12,IC50,'=',93692.0,nM,4.03,,,UO_0000065,,,,,0,CHEMBL5604073,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 3,,,,,Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK,,,CHEMBL5705863,NS3 protease,dengue virus type 3,SINGLE PROTEIN,CHEMBL5604065,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 0.938 None | IC50 CI (lower) = 84.52 uM | IC50 CI (upper) = 103.86 uM | Maximum measured = 50.37 None | Maximum response = 100.0 % | Minimum measured = -3.202 None | R squared = 0.987 None,,,93.692,3
CHEMBL5605255,,,423.95,0.0,4.61,ASAP-0030850,C=CC[C@H]1NCc2cc(N[C@H](C(=O)NC(C)C)c3cc(Cl)cc4[nH]ncc34)ccc21,IC50,'=',55092.0,nM,4.26,,,UO_0000065,,,,,0,CHEMBL5604073,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 3,,,,,Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK,,,CHEMBL5705863,NS3 protease,dengue virus type 3,SINGLE PROTEIN,CHEMBL5604065,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 0.984 None | IC50 CI (lower) = 50.24 uM | IC50 CI (upper) = 60.41 uM | Maximum measured = 62.19 None | Maximum response = 100.0 % | Minimum measured = -3.679 None | R squared = 0.987 None,,,55.092,3
CHEMBL5598684,,,433.31,0.0,4.85,ASAP-0029352,O=C(Nc1ccc2c(c1)CNC2)c1cc(Br)cc2[nH]c(-c3ccccc3)nc12,IC50,'=',1475.0,nM,5.83,,,UO_0000065,,,,,0,CHEMBL5604073,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 3,,,,,Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK,,,CHEMBL5705863,NS3 protease,dengue virus type 3,SINGLE PROTEIN,CHEMBL5604065,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 3.012 None | IC50 CI (lower) = 1.39 uM | IC50 CI (upper) = 1.565 uM | Maximum measured = 98.43 None | Maximum response = 100.0 % | Minimum measured = -0.564 None | R squared = 0.993 None,,,1.475,3
CHEMBL5598860,,,325.41,0.0,3.36,ASAP-0029521,Cc1c(C(=O)Nc2cc([C@H]3CCOC3)ccn2)cc(C2CC2)n1C,IC50,'>',99500.0,nM,,,Falls Outside The Dose Series,UO_0000065,,,,,0,CHEMBL5604073,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 3,,,,,Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK,,,CHEMBL5705863,NS3 protease,dengue virus type 3,SINGLE PROTEIN,CHEMBL5604065,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 1.102 None | Maximum measured = 36.69 None | Maximum response = 100.0 % | Minimum measured = -4.398 None | R squared = 0.953 None,,,99.5,3
CHEMBL5598765,,,420.9,0.0,3.59,ASAP-0029650,Cn1cc(CCc2nc3c(C(=O)Nc4ccc5c(c4)CNC5)cc(Cl)cc3[nH]2)cn1,IC50,'=',23708.0,nM,4.62,,,UO_0000065,,,,,0,CHEMBL5604073,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 3,,,,,Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK,,,CHEMBL5705863,NS3 protease,dengue virus type 3,SINGLE PROTEIN,CHEMBL5604065,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 1.185 None | IC50 CI (lower) = 19.22 uM | IC50 CI (upper) = 29.24 uM | Maximum measured = 76.31 None | Maximum response = 100.0 % | Minimum measured = -5.449 None | R squared = 0.941 None,,,23.708,3
CHEMBL5598611,,,326.79,0.0,3.08,ASAP-0029588,Cn1cc2cc(Cl)cc(C(=O)Nc3ccc4c(c3)CNC4)c2n1,IC50,'>',99500.0,nM,,,Falls Outside The Dose Series,UO_0000065,,,,,0,CHEMBL5604073,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 3,,,,,Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK,,,CHEMBL5705863,NS3 protease,dengue virus type 3,SINGLE PROTEIN,CHEMBL5604065,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Maximum measured = 6.988 None | Minimum measured = -51.45 None,,,99.5,3
CHEMBL5606033,,,293.33,0.0,2.04,ASAP-0029950,O=C1Cc2cc(C(=O)Nc3ccc4c(c3)CNC4)ccc2N1,IC50,'=',5441.0,nM,5.26,,,UO_0000065,,,,,0,CHEMBL5604073,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 3,,,,,Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK,,,CHEMBL5705863,NS3 protease,dengue virus type 3,SINGLE PROTEIN,CHEMBL5604065,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 2.388 None | IC50 CI (lower) = 4.979 uM | IC50 CI (upper) = 5.945 uM | Maximum measured = 99.31 None | Maximum response = 100.0 % | Minimum measured = -5.492 None | R squared = 0.994 None,,,5.441,3
CHEMBL5606232,,,278.31,0.0,2.42,ASAP-0030093,O=C(Nc1ccc2c(c1)CNC2)c1cccc2cn[nH]c12,IC50,'=',37269.0,nM,4.43,,,UO_0000065,,,,,0,CHEMBL5604073,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 3,,,,,Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK,,,CHEMBL5705863,NS3 protease,dengue virus type 3,SINGLE PROTEIN,CHEMBL5604065,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 2.0 None | IC50 CI (lower) = 34.01 uM | IC50 CI (upper) = 40.84 uM | Maximum measured = 85.77 None | Maximum response = 100.0 % | Minimum measured = -4.233 None | R squared = 0.98 None,,,37.269,3
CHEMBL5605022,,,321.32,0.0,2.43,ASAP-0031265,N#Cc1cc2c(cc1NC(=O)c1cc(F)cc3[nH]ncc13)CNC2,IC50,'=',5390.0,nM,5.27,,,UO_0000065,,,,,0,CHEMBL5604073,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 3,,,,,Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK,,,CHEMBL5705863,NS3 protease,dengue virus type 3,SINGLE PROTEIN,CHEMBL5604065,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 1.115 None | IC50 CI (lower) = 4.869 uM | IC50 CI (upper) = 5.967 uM | Maximum measured = 94.98 None | Maximum response = 100.0 % | Minimum measured = -6.366 None | R squared = 0.992 None,,,5.39,3
CHEMBL5606319,,,426.47,0.0,2.76,ASAP-0031155,O=C(Nc1cc2c(c(C3=CCS(=O)(=O)CC3)c1)CNC2)c1cc(F)cc2[nH]ncc12,IC50,'=',12762.0,nM,4.89,,,UO_0000065,,,,,0,CHEMBL5604073,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 3,,,,,Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK,,,CHEMBL5705863,NS3 protease,dengue virus type 3,SINGLE PROTEIN,CHEMBL5604065,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 1.126 None | IC50 CI (lower) = 11.47 uM | IC50 CI (upper) = 14.2 uM | Maximum measured = 89.3 None | Maximum response = 100.0 % | Minimum measured = -5.994 None | R squared = 0.989 None,,,12.762,3
CHEMBL5605372,,,323.42,0.0,3.22,ASAP-0031633,NCc1csc2cc(C(=O)Nc3ccc4c(c3)CNC4)ccc12,IC50,'=',9070.0,nM,5.04,,,UO_0000065,,,,,0,CHEMBL5604073,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 3,,,,,Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK,,,CHEMBL5705863,NS3 protease,dengue virus type 3,SINGLE PROTEIN,CHEMBL5604065,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 2.601 None | IC50 CI (lower) = 8.634 uM | IC50 CI (upper) = 9.527 uM | Maximum measured = 99.27 None | Maximum response = 100.0 % | Minimum measured = -1.703 None | R squared = 0.996 None,,,9.07,3
CHEMBL5605366,,,425.92,0.0,3.27,ASAP-0029888,O=C(NC1CCOCC1)[C@H](Nc1ccc2c(c1)CNC2)c1cc(Cl)cc2[nH]ncc12,IC50,'=',43867.0,nM,4.36,,,UO_0000065,,,,,0,CHEMBL5604074,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 4,,,,,Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK,,,CHEMBL5705864,NS3 protease,dengue virus type 4,SINGLE PROTEIN,CHEMBL5604066,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 1.03 None | IC50 CI (lower) = 40.77 uM | IC50 CI (upper) = 47.2 uM | Maximum measured = 67.84 None | Maximum response = 100.0 % | Minimum measured = -1.636 None | R squared = 0.992 None,,,43.867,4
CHEMBL5598605,,,305.34,0.0,3.2,ASAP-0029713,O=C(Nc1ccc2c(c1)CNC2)c1cccc(-c2cnco2)c1,IC50,'=',23301.0,nM,4.63,,,UO_0000065,,,,,0,CHEMBL5604074,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 4,,,,,Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK,,,CHEMBL5705864,NS3 protease,dengue virus type 4,SINGLE PROTEIN,CHEMBL5604066,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 3.529 None | IC50 CI (lower) = 22.63 uM | IC50 CI (upper) = 23.99 uM | Maximum measured = 97.13 None | Maximum response = 100.0 % | Minimum measured = -3.123 None | R squared = 0.998 None,,,23.301,4
CHEMBL5605468,,,295.32,0.0,3.16,ASAP-0029832,O=C(Nc1ccc2c(c1)CNC2)c1cc(F)c2[nH]ccc2c1,IC50,'>',99500.0,nM,,,Falls Outside The Dose Series,UO_0000065,,,,,0,CHEMBL5604074,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 4,,,,,Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK,,,CHEMBL5705864,NS3 protease,dengue virus type 4,SINGLE PROTEIN,CHEMBL5604066,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Maximum measured = 2.434 None | Minimum measured = -3.672 None,,,99.5,4
CHEMBL5598898,,,323.78,0.0,3.74,ASAP-0029711,O=C(Nc1ccc2c(c1)CNC2)c1cc(Cl)cc2ccncc12,IC50,'>',99500.0,nM,,,Falls Outside The Dose Series,UO_0000065,,,,,0,CHEMBL5604074,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 4,,,,,Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK,,,CHEMBL5705864,NS3 protease,dengue virus type 4,SINGLE PROTEIN,CHEMBL5604066,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 3.163 None | Maximum measured = 25.74 None | Maximum response = 100.0 % | Minimum measured = -4.215 None | R squared = 0.8 None,,,99.5,4
CHEMBL5598765,,,420.9,0.0,3.59,ASAP-0029650,Cn1cc(CCc2nc3c(C(=O)Nc4ccc5c(c4)CNC5)cc(Cl)cc3[nH]2)cn1,IC50,'=',26411.0,nM,4.58,,,UO_0000065,,,,,0,CHEMBL5604074,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 4,,,,,Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK,,,CHEMBL5705864,NS3 protease,dengue virus type 4,SINGLE PROTEIN,CHEMBL5604066,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 2.142 None | IC50 CI (lower) = 23.77 uM | IC50 CI (upper) = 29.34 uM | Maximum measured = 86.93 None | Maximum response = 100.0 % | Minimum measured = -4.37 None | R squared = 0.978 None,,,26.411,4
CHEMBL5598658,,,355.87,0.0,3.72,ASAP-0029621,CNC(=O)[C@H](Nc1ccc2c(c1)CNC2)c1cc(Cl)cc(C2CC2)c1,IC50,'>',99500.0,nM,,,Falls Outside The Dose Series,UO_0000065,,,,,0,CHEMBL5604074,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 4,,,,,Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK,,,CHEMBL5705864,NS3 protease,dengue virus type 4,SINGLE PROTEIN,CHEMBL5604066,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Maximum measured = 0.711 None | Minimum measured = -2.777 None,,,99.5,4
CHEMBL5598786,,,296.3,0.0,2.56,ASAP-0029497,O=C(Nc1ccc2c(c1)CNC2)c1cc(F)cc2[nH]ncc12,IC50,'>',99500.0,nM,,,Falls Outside The Dose Series,UO_0000065,,,,,0,CHEMBL5604074,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 4,,,,,Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK,,,CHEMBL5705864,NS3 protease,dengue virus type 4,SINGLE PROTEIN,CHEMBL5604066,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 1.208 None | Maximum measured = 44.89 None | Maximum response = 100.0 % | Minimum measured = -4.073 None | R squared = 0.978 None,,,99.5,4
CHEMBL5605372,,,323.42,0.0,3.22,ASAP-0031633,NCc1csc2cc(C(=O)Nc3ccc4c(c3)CNC4)ccc12,IC50,'=',11790.0,nM,4.93,,,UO_0000065,,,,,0,CHEMBL5604074,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 4,,,,,Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK,,,CHEMBL5705864,NS3 protease,dengue virus type 4,SINGLE PROTEIN,CHEMBL5604066,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 3.904 None | IC50 CI (lower) = 11.19 uM | IC50 CI (upper) = 12.42 uM | Maximum measured = 98.86 None | Maximum response = 100.0 % | Minimum measured = -1.843 None | R squared = 0.992 None,,,11.79,4
CHEMBL5605103,,,386.43,0.0,4.53,ASAP-0031310,Cc1ccccc1-c1nc2c(C(=O)Nc3ccc4c(c3)CNC4)cc(F)cc2[nH]1,IC50,'=',3243.0,nM,5.49,,,UO_0000065,,,,,0,CHEMBL5604074,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 4,,,,,Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK,,,CHEMBL5705864,NS3 protease,dengue virus type 4,SINGLE PROTEIN,CHEMBL5604066,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 3.421 None | IC50 CI (lower) = 3.081 uM | IC50 CI (upper) = 3.414 uM | Maximum measured = 98.68 None | Maximum response = 100.0 % | Minimum measured = 0.07 None | R squared = 0.998 None,,,3.243,4
CHEMBL5606112,,,337.45,0.0,3.26,ASAP-0031277,NCCc1csc2cc(C(=O)Nc3ccc4c(c3)CNC4)ccc12,IC50,'>',99500.0,nM,,,Falls Outside The Dose Series,UO_0000065,,,,,0,CHEMBL5604074,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 4,,,,,Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK,,,CHEMBL5705864,NS3 protease,dengue virus type 4,SINGLE PROTEIN,CHEMBL5604066,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 1.551 None | Maximum measured = 38.59 None | Maximum response = 100.0 % | Minimum measured = -2.566 None | R squared = 0.981 None,,,99.5,4
CHEMBL5604470,,,397.41,0.0,4.1,ASAP-0031299,N#Cc1ccc(-c2nc3c(C(=O)Nc4ccc5c(c4)CNC5)cc(F)cc3[nH]2)cc1,IC50,'=',1917.0,nM,5.72,,,UO_0000065,,,,,0,CHEMBL5604074,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 4,,,,,Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK,,,CHEMBL5705864,NS3 protease,dengue virus type 4,SINGLE PROTEIN,CHEMBL5604066,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 3.141 None | IC50 CI (lower) = 1.855 uM | IC50 CI (upper) = 1.981 uM | Maximum measured = 97.86 None | Maximum response = 100.0 % | Minimum measured = -0.772 None | R squared = 0.998 None,,,1.917,4
CHEMBL3919119,,,454.34,,,ASAP-0015081,N=C(N)NCCC[C@H](NC(=O)[C@H](Cc1ccc(CN)cc1)NC(=O)c1ccccc1)B(O)O,IC50,'=',793.0,nM,6.1,,,UO_0000065,,,,,0,CHEMBL5604074,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 4,,,,,Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK,,,CHEMBL5705864,NS3 protease,dengue virus type 4,SINGLE PROTEIN,CHEMBL5604066,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 1.486 None | IC50 CI (lower) = 0.723 uM | IC50 CI (upper) = 0.869 uM | Maximum measured = 99.66 None | Maximum response = 100.0 % | Minimum measured = -0.879 None | R squared = 0.988 None,,,0.793,4
CHEMBL5605540,,,452.94,0.0,4.45,ASAP-0027609,CNC(=O)[C@H](Nc1cccc(CN)c1)c1cc(Cl)cc(NC(=O)OCc2ccccc2)c1,IC50,'>',99500.0,nM,,,Falls Outside The Dose Series,UO_0000065,,,,,0,CHEMBL5604074,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 4,,,,,Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK,,,CHEMBL5705864,NS3 protease,dengue virus type 4,SINGLE PROTEIN,CHEMBL5604066,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 4.243 None | Maximum measured = 43.81 None | Maximum response = 100.0 % | Minimum measured = -0.958 None | R squared = 0.996 None,,,99.5,4
CHEMBL5606153,,,423.9,1.0,5.11,ASAP-0021119,Cc1ccc(NC(=O)c2cc(Cl)cc(NC(=O)OCc3ccccc3)c2)cc1CN,IC50,'=',70702.0,nM,4.15,,,UO_0000065,,,,,0,CHEMBL5604074,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 4,,,,,Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK,,,CHEMBL5705864,NS3 protease,dengue virus type 4,SINGLE PROTEIN,CHEMBL5604066,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 2.125 None | IC50 CI (lower) = 65.51 uM | IC50 CI (upper) = 76.3 uM | Maximum measured = 64.94 None | Maximum response = 100.0 % | Minimum measured = -2.177 None | R squared = 0.972 None,,,70.702,4
CHEMBL5606202,,,344.46,0.0,4.73,ASAP-0021052,Cc1[nH]c2ccccc2c1CN1CCC(c2c[nH]c3ncccc23)CC1,IC50,'>',99500.0,nM,,,Falls Outside The Dose Series,UO_0000065,,,,,0,CHEMBL5604074,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 4,,,,,Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK,,,CHEMBL5705864,NS3 protease,dengue virus type 4,SINGLE PROTEIN,CHEMBL5604066,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Maximum measured = -0.255 None | Minimum measured = -1.844 None,,,99.5,4
CHEMBL5606457,,,464.87,0.0,3.61,ASAP-0023274,O=C(Nc1cc(Cl)cc(C(=O)Nc2cccc(-n3nn[nH]c3=O)c2)c1)OCc1ccccc1,IC50,'=',13947.0,nM,4.86,,,UO_0000065,,,,,0,CHEMBL5604074,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 4,,,,,Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK,,,CHEMBL5705864,NS3 protease,dengue virus type 4,SINGLE PROTEIN,CHEMBL5604066,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 3.319 None | IC50 CI (lower) = 13.56 uM | IC50 CI (upper) = 14.34 uM | Maximum measured = 99.06 None | Maximum response = 100.0 % | Minimum measured = -0.738 None | R squared = 0.998 None,,,13.947,4
CHEMBL5605532,,,341.46,1.0,5.1,ASAP-0016252,c1cc(C2CCN(Cc3c[nH]c4ccccc34)CC2)c2ccncc2c1,IC50,'>',99500.0,nM,,,Falls Outside The Dose Series,UO_0000065,,,,,0,CHEMBL5604074,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 4,,,,,Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK,,,CHEMBL5705864,NS3 protease,dengue virus type 4,SINGLE PROTEIN,CHEMBL5604066,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 1.297 None | Maximum measured = 0.847 None | Maximum response = 100.0 % | Minimum measured = -1.029 None | R squared = 0.099 None,,,99.5,4
CHEMBL5605186,,,461.01,1.0,6.83,ASAP-0027756,O=C(Nc1cc(Cl)cc([C@H]2C[C@@H]2c2cccc(C3CCNCC3)c2)c1)OCc1ccccc1,IC50,'=',5509.0,nM,5.26,,,UO_0000065,,,,,0,CHEMBL5604074,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 4,,,,,Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK,,,CHEMBL5705864,NS3 protease,dengue virus type 4,SINGLE PROTEIN,CHEMBL5604066,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 6.383 None | IC50 CI (lower) = 4.57 uM | IC50 CI (upper) = 6.641 uM | Maximum measured = 99.89 None | Maximum response = 100.0 % | Minimum measured = -3.106 None | R squared = 0.999 None,,,5.509,4
CHEMBL5606429,,,378.41,0.0,3.36,ASAP-0031147,O=C(Nc1cc2c(c(C3=CCOCC3)c1)CNC2)c1cc(F)cc2[nH]ncc12,IC50,'=',29924.0,nM,4.52,,,UO_0000065,,,,,0,CHEMBL5604074,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 4,,,,,Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK,,,CHEMBL5705864,NS3 protease,dengue virus type 4,SINGLE PROTEIN,CHEMBL5604066,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 1.768 None | IC50 CI (lower) = 28.21 uM | IC50 CI (upper) = 31.74 uM | Maximum measured = 95.73 None | Maximum response = 100.0 % | Minimum measured = -0.554 None | R squared = 0.993 None,,,29.924,4
CHEMBL5604988,,,399.52,0.0,4.88,ASAP-0031461,NCc1cccc(-c2csc3cc(C(=O)Nc4ccc5c(c4)CNC5)ccc23)c1,IC50,'=',43725.0,nM,4.36,,,UO_0000065,,,,,0,CHEMBL5604074,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 4,,,,,Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK,,,CHEMBL5705864,NS3 protease,dengue virus type 4,SINGLE PROTEIN,CHEMBL5604066,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 2.756 None | IC50 CI (lower) = 42.12 uM | IC50 CI (upper) = 45.39 uM | Maximum measured = 94.9 None | Maximum response = 100.0 % | Minimum measured = -1.837 None | R squared = 0.995 None,,,43.725,4
CHEMBL5599838,,,459.98,1.0,5.16,ASAP-0031456,CC(C)NC(=O)[C@H](Nc1ccc2c(c1)CNC2)c1cc(Cl)cc2[nH]c(-c3ccccc3)nc12,IC50,'=',4384.0,nM,5.36,,,UO_0000065,,,,,0,CHEMBL5604074,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 4,,,,,Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK,,,CHEMBL5705864,NS3 protease,dengue virus type 4,SINGLE PROTEIN,CHEMBL5604066,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 1.182 None | IC50 CI (lower) = 4.084 uM | IC50 CI (upper) = 4.707 uM | Maximum measured = 98.47 None | Maximum response = 100.0 % | Minimum measured = 1.495 None | R squared = 0.996 None,,,4.384,4
CHEMBL5605310,,,399.52,0.0,4.88,ASAP-0031492,NCc1ccc(-c2csc3cc(C(=O)Nc4ccc5c(c4)CNC5)ccc23)cc1,IC50,'=',53235.0,nM,4.27,,,UO_0000065,,,,,0,CHEMBL5604074,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 4,,,,,Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK,,,CHEMBL5705864,NS3 protease,dengue virus type 4,SINGLE PROTEIN,CHEMBL5604066,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 2.037 None | IC50 CI (lower) = 51.25 uM | IC50 CI (upper) = 55.3 uM | Maximum measured = 77.58 None | Maximum response = 100.0 % | Minimum measured = -2.253 None | R squared = 0.995 None,,,53.235,4
CHEMBL5605069,,,311.77,0.0,3.68,ASAP-0030001,O=C(Nc1ccc2c(c1)CNC2)c1cc(Cl)cc2cc[nH]c12,IC50,'>',99500.0,nM,,,Falls Outside The Dose Series,UO_0000065,,,,,0,CHEMBL5604074,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 4,,,,,Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK,,,CHEMBL5705864,NS3 protease,dengue virus type 4,SINGLE PROTEIN,CHEMBL5604066,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Maximum measured = 3.184 None | Minimum measured = -3.052 None,,,99.5,4
CHEMBL5598611,,,326.79,0.0,3.08,ASAP-0029588,Cn1cc2cc(Cl)cc(C(=O)Nc3ccc4c(c3)CNC4)c2n1,IC50,'>',99500.0,nM,,,Falls Outside The Dose Series,UO_0000065,,,,,0,CHEMBL5604074,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 4,,,,,Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK,,,CHEMBL5705864,NS3 protease,dengue virus type 4,SINGLE PROTEIN,CHEMBL5604066,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 1.587 None | Maximum measured = 44.04 None | Maximum response = 100.0 % | Minimum measured = -3.423 None | R squared = 0.91 None,,,99.5,4
CHEMBL5605521,,,296.35,0.0,3.17,ASAP-0030106,O=C(Nc1ccc2c(c1)CNC2)c1cc(F)cc2c1CCC2,IC50,'>',99500.0,nM,,,Falls Outside The Dose Series,UO_0000065,,,,,0,CHEMBL5604074,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 4,,,,,Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK,,,CHEMBL5705864,NS3 protease,dengue virus type 4,SINGLE PROTEIN,CHEMBL5604066,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Maximum measured = 0.135 None | Minimum measured = -2.142 None,,,99.5,4
CHEMBL5598576,,,405.88,0.0,4.36,ASAP-0029491,O=C(NCC(F)F)[C@H](Nc1ccc2c(c1)CNC2)c1cc(Cl)cc(C2CC2)c1,IC50,'>',99500.0,nM,,,Falls Outside The Dose Series,UO_0000065,,,,,0,CHEMBL5604074,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 4,,,,,Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK,,,CHEMBL5705864,NS3 protease,dengue virus type 4,SINGLE PROTEIN,CHEMBL5604066,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 1.517 None | Maximum measured = 15.44 None | Maximum response = 100.0 % | Minimum measured = -6.437 None | R squared = 0.618 None,,,99.5,4
CHEMBL5598685,,,323.83,0.0,4.5,ASAP-0029597,N#C[C@H](Nc1ccc2c(c1)CNC2)c1cc(Cl)cc(C2CC2)c1,IC50,'>',99500.0,nM,,,Falls Outside The Dose Series,UO_0000065,,,,,0,CHEMBL5604074,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 4,,,,,Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK,,,CHEMBL5705864,NS3 protease,dengue virus type 4,SINGLE PROTEIN,CHEMBL5604066,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Maximum measured = 1.195 None | Minimum measured = -7.842 None,,,99.5,4
CHEMBL5605090,,,336.37,0.0,3.67,ASAP-0030071,C=CC[C@H]1NCc2cc(NC(=O)c3cc(F)cc4[nH]ncc34)ccc21,IC50,'>',99500.0,nM,,,Falls Outside The Dose Series,UO_0000065,,,,,0,CHEMBL5604074,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 4,,,,,Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK,,,CHEMBL5705864,NS3 protease,dengue virus type 4,SINGLE PROTEIN,CHEMBL5604066,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 1.264 None | Maximum measured = 36.78 None | Maximum response = 100.0 % | Minimum measured = -0.398 None | R squared = 0.995 None,,,99.5,4
CHEMBL3740727,,,719.79,2.0,2.06,ASAP-0000570,N=C(N)NCCC[C@H](NC(=O)c1nccs1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(N)=O)c1ccc(OCc2ccc(C(F)(F)F)cc2)cc1,IC50,'=',1471.0,nM,5.83,,,UO_0000065,,,,,0,CHEMBL5604074,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 4,,,,,Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK,,,CHEMBL5705864,NS3 protease,dengue virus type 4,SINGLE PROTEIN,CHEMBL5604066,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 1.277 None | IC50 CI (lower) = 1.425 uM | IC50 CI (upper) = 1.518 uM | Maximum measured = 99.76 None | Maximum response = 100.0 % | Minimum measured = 0.852 None | R squared = 0.999 None,,,1.471,4
CHEMBL5604375,,,323.79,0.0,3.5,ASAP-0028904,N#C[C@H](Nc1ccc2c(c1)CNC2)c1cc(Cl)cc2[nH]ncc12,IC50,'>',99500.0,nM,,,Falls Outside The Dose Series,UO_0000065,,,,,0,CHEMBL5604074,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 4,,,,,Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK,,,CHEMBL5705864,NS3 protease,dengue virus type 4,SINGLE PROTEIN,CHEMBL5604066,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 5.984 None | Maximum measured = 6.391 None | Maximum response = 100.0 % | Minimum measured = -1.003 None | R squared = 0.688 None,,,99.5,4
CHEMBL5605947,,,435.91,0.0,4.99,ASAP-0027652,O=C(Nc1cc(Cl)cc(C(=O)Nc2ccc3c(c2)CCNC3)c1)OCc1ccccc1,IC50,'=',32118.0,nM,4.49,,,UO_0000065,,,,,0,CHEMBL5604074,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 4,,,,,Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK,,,CHEMBL5705864,NS3 protease,dengue virus type 4,SINGLE PROTEIN,CHEMBL5604066,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 3.855 None | IC50 CI (lower) = 30.67 uM | IC50 CI (upper) = 33.64 uM | Maximum measured = 94.53 None | Maximum response = 100.0 % | Minimum measured = -3.727 None | R squared = 0.993 None,,,32.118,4
CHEMBL3919119,,,454.34,,,ASAP-0015081,N=C(N)NCCC[C@H](NC(=O)[C@H](Cc1ccc(CN)cc1)NC(=O)c1ccccc1)B(O)O,IC50,'=',503.0,nM,6.3,,,UO_0000065,,,,,0,CHEMBL5604074,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 4,,,,,Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK,,,CHEMBL5705864,NS3 protease,dengue virus type 4,SINGLE PROTEIN,CHEMBL5604066,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 1.315 None | IC50 CI (lower) = 0.478 uM | IC50 CI (upper) = 0.529 uM | Maximum measured = 99.75 None | Maximum response = 100.0 % | Minimum measured = 4.212 None | R squared = 0.997 None,,,0.503,4
CHEMBL5605251,,,493.41,1.0,5.97,ASAP-0015849,CC(C)CNC(=O)c1cc(Cl)ccc1NS(=O)(=O)c1ccc(Oc2ccccc2Cl)cc1,IC50,'=',15022.0,nM,4.82,,,UO_0000065,,,,,0,CHEMBL5604074,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 4,,,,,Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK,,,CHEMBL5705864,NS3 protease,dengue virus type 4,SINGLE PROTEIN,CHEMBL5604066,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 1.462 None | IC50 CI (lower) = 13.56 uM | IC50 CI (upper) = 16.65 uM | Maximum measured = 86.8 None | Maximum response = 100.0 % | Minimum measured = -0.546 None | R squared = 0.986 None,,,15.022,4
CHEMBL5604414,,,464.91,1.0,5.53,ASAP-0027767,O=C(Nc1cc(Cl)cc(C(=O)Nc2cccc([C@H]3C[C@H]3C(=O)O)c2)c1)OCc1ccccc1,IC50,'=',32847.0,nM,4.48,,,UO_0000065,,,,,0,CHEMBL5604074,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 4,,,,,Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK,,,CHEMBL5705864,NS3 protease,dengue virus type 4,SINGLE PROTEIN,CHEMBL5604066,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 3.304 None | IC50 CI (lower) = 31.58 uM | IC50 CI (upper) = 34.16 uM | Maximum measured = 97.3 None | Maximum response = 100.0 % | Minimum measured = -0.987 None | R squared = 0.995 None,,,32.847,4
CHEMBL5605497,,,463.97,1.0,5.94,ASAP-0023377,N[C@H]1CC[C@H](c2ccc(NC(=O)c3cc(Cl)cc(NC(=O)OCc4ccccc4)c3)cc2)C1,IC50,'=',7637.0,nM,5.12,,,UO_0000065,,,,,0,CHEMBL5604074,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 4,,,,,Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK,,,CHEMBL5705864,NS3 protease,dengue virus type 4,SINGLE PROTEIN,CHEMBL5604066,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 3.539 None | IC50 CI (lower) = 7.396 uM | IC50 CI (upper) = 7.886 uM | Maximum measured = 100.0 None | Maximum response = 100.0 % | Minimum measured = -2.982 None | R squared = 0.998 None,,,7.637,4
CHEMBL5605691,,,312.42,0.0,2.75,ASAP-0027597,Cc1c(C(=O)Nc2cc(CCCN)ccn2)cc(C2CC2)n1C,IC50,'=',39227.0,nM,4.41,,,UO_0000065,,,,,0,CHEMBL5604074,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 4,,,,,Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK,,,CHEMBL5705864,NS3 protease,dengue virus type 4,SINGLE PROTEIN,CHEMBL5604066,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 5.604 None | IC50 CI (lower) = 36.96 uM | IC50 CI (upper) = 41.63 uM | Maximum measured = 97.75 None | Maximum response = 100.0 % | Minimum measured = -3.15 None | R squared = 0.99 None,,,39.227,4
CHEMBL5598593,,,309.76,0.0,3.59,ASAP-0027972,Clc1ccc2[nH]cc(Cc3ccc(-c4nn[nH]n4)cc3)c2c1,IC50,'=',99140.0,nM,4.0,,,UO_0000065,,,,,0,CHEMBL5604074,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 4,,,,,Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK,,,CHEMBL5705864,NS3 protease,dengue virus type 4,SINGLE PROTEIN,CHEMBL5604066,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 2.154 None | IC50 CI (lower) = 94.69 uM | IC50 CI (upper) = 103.8 uM | Maximum measured = 51.01 None | Maximum response = 100.0 % | Minimum measured = -1.525 None | R squared = 0.987 None,,,99.14,4
CHEMBL5598749,,,421.88,0.0,4.94,ASAP-0020915,O=C(Nc1cc(Cl)cc(C(=O)Nc2ccc3c(c2)CNC3)c1)OCc1ccccc1,IC50,'=',91263.0,nM,4.04,,,UO_0000065,,,,,0,CHEMBL5604074,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 4,,,,,Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK,,,CHEMBL5705864,NS3 protease,dengue virus type 4,SINGLE PROTEIN,CHEMBL5604066,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 2.459 None | IC50 CI (lower) = 86.58 uM | IC50 CI (upper) = 96.2 uM | Maximum measured = 54.44 None | Maximum response = 100.0 % | Minimum measured = -4.008 None | R squared = 0.979 None,,,91.263,4
CHEMBL5598591,,,373.29,0.0,4.6,ASAP-0029041,CC(C)(C)c1cc(Br)cc(C(=O)Nc2ccc3c(c2)CNC3)c1,IC50,'>',99500.0,nM,,,Falls Outside The Dose Series,UO_0000065,,,,,0,CHEMBL5604074,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 4,,,,,Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK,,,CHEMBL5705864,NS3 protease,dengue virus type 4,SINGLE PROTEIN,CHEMBL5604066,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Maximum measured = 2.195 None | Minimum measured = -7.988 None,,,99.5,4
CHEMBL5598732,,,359.27,0.0,4.43,ASAP-0029050,CC(C)c1cc(Br)cc(C(=O)Nc2ccc3c(c2)CNC3)c1,IC50,'>',99500.0,nM,,,Falls Outside The Dose Series,UO_0000065,,,,,0,CHEMBL5604074,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 4,,,,,Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK,,,CHEMBL5705864,NS3 protease,dengue virus type 4,SINGLE PROTEIN,CHEMBL5604066,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Maximum measured = 0.036 None | Minimum measured = -9.741 None,,,99.5,4
CHEMBL5606384,,,411.9,0.0,2.76,ASAP-0028903,CNC(=O)[C@H](Nc1cc(CN)cc(-c2nn[nH]n2)c1)c1cc(Cl)cc(C2CC2)c1,IC50,'>',99500.0,nM,,,Falls Outside The Dose Series,UO_0000065,,,,,0,CHEMBL5604074,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 4,,,,,Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK,,,CHEMBL5705864,NS3 protease,dengue virus type 4,SINGLE PROTEIN,CHEMBL5604066,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 1.466 None | Maximum measured = 8.093 None | Maximum response = 100.0 % | Minimum measured = -1.862 None | R squared = 0.735 None,,,99.5,4
CHEMBL5604326,,,333.39,0.0,3.15,ASAP-0030062,C=CC[C@H]1NCc2cc(NC(=O)c3cccc4c3CC(=O)N4)ccc21,IC50,'>',99500.0,nM,,,Falls Outside The Dose Series,UO_0000065,,,,,0,CHEMBL5604074,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 4,,,,,Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK,,,CHEMBL5705864,NS3 protease,dengue virus type 4,SINGLE PROTEIN,CHEMBL5604066,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 1.127 None | Maximum measured = 6.082 None | Maximum response = 100.0 % | Minimum measured = -1.395 None | R squared = 0.736 None,,,99.5,4
CHEMBL5606236,,,375.2,0.0,3.32,ASAP-0030085,O=C(Nc1cc2c(cc1Br)CNC2)c1cc(F)cc2[nH]ncc12,IC50,'>',99500.0,nM,,,Falls Outside The Dose Series,UO_0000065,,,,,0,CHEMBL5604074,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 4,,,,,Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK,,,CHEMBL5705864,NS3 protease,dengue virus type 4,SINGLE PROTEIN,CHEMBL5604066,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 1.198 None | Maximum measured = 34.8 None | Maximum response = 100.0 % | Minimum measured = -2.419 None | R squared = 0.988 None,,,99.5,4
CHEMBL5606266,,,277.33,0.0,3.02,ASAP-0029756,O=C(Nc1ccc2c(c1)CNC2)c1ccc2[nH]ccc2c1,IC50,'>',99500.0,nM,,,Falls Outside The Dose Series,UO_0000065,,,,,0,CHEMBL5604074,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 4,,,,,Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK,,,CHEMBL5705864,NS3 protease,dengue virus type 4,SINGLE PROTEIN,CHEMBL5604066,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 1.772 None | Maximum measured = 16.19 None | Maximum response = 100.0 % | Minimum measured = -1.586 None | R squared = 0.897 None,,,99.5,4
CHEMBL5605985,,,416.48,0.0,2.84,ASAP-0031120,CC(C)(c1nc2c(C(=O)Nc3ccc4c(c3)CNC4)cc(F)cc2[nH]1)S(C)(=O)=O,IC50,'=',18004.0,nM,4.75,,,UO_0000065,,,,,0,CHEMBL5604074,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 4,,,,,Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK,,,CHEMBL5705864,NS3 protease,dengue virus type 4,SINGLE PROTEIN,CHEMBL5604066,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 4.382 None | IC50 CI (lower) = 17.56 uM | IC50 CI (upper) = 18.46 uM | Maximum measured = 98.04 None | Maximum response = 100.0 % | Minimum measured = -1.968 None | R squared = 0.999 None,,,18.004,4
CHEMBL5604989,,,390.39,0.0,4.36,ASAP-0031443,O=C(Nc1ccc2c(c1)CNC2)c1cc(F)cc2[nH]c(-c3cccc(F)c3)nc12,IC50,'=',3733.0,nM,5.43,,,UO_0000065,,,,,0,CHEMBL5604074,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 4,,,,,Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK,,,CHEMBL5705864,NS3 protease,dengue virus type 4,SINGLE PROTEIN,CHEMBL5604066,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 3.774 None | IC50 CI (lower) = 3.575 uM | IC50 CI (upper) = 3.898 uM | Maximum measured = 98.57 None | Maximum response = 100.0 % | Minimum measured = -0.703 None | R squared = 0.999 None,,,3.733,4
CHEMBL3740727,,,719.79,2.0,2.06,ASAP-0000570,N=C(N)NCCC[C@H](NC(=O)c1nccs1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(N)=O)c1ccc(OCc2ccc(C(F)(F)F)cc2)cc1,IC50,'=',1057.0,nM,5.98,,,UO_0000065,,,,,0,CHEMBL5604074,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 4,,,,,Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK,,,CHEMBL5705864,NS3 protease,dengue virus type 4,SINGLE PROTEIN,CHEMBL5604066,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 1.223 None | IC50 CI (lower) = 1.015 uM | IC50 CI (upper) = 1.101 uM | Maximum measured = 99.78 None | Maximum response = 100.0 % | Minimum measured = 1.329 None | R squared = 0.999 None,,,1.057,4
CHEMBL5598679,,,293.33,0.0,2.04,ASAP-0029208,O=C1Cc2c(cccc2C(=O)Nc2ccc3c(c2)CNC3)N1,IC50,'=',15134.0,nM,4.82,,,UO_0000065,,,,,0,CHEMBL5604074,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 4,,,,,Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK,,,CHEMBL5705864,NS3 protease,dengue virus type 4,SINGLE PROTEIN,CHEMBL5604066,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 5.653 None | IC50 CI (lower) = 14.59 uM | IC50 CI (upper) = 15.7 uM | Maximum measured = 98.8 None | Maximum response = 100.0 % | Minimum measured = -2.095 None | R squared = 0.998 None,,,15.134,4
CHEMBL5598615,,,367.25,0.0,4.46,ASAP-0029045,O=C(Nc1ccc2c(c1)CNC2)c1cc(Br)cc2ccccc12,IC50,'>',99500.0,nM,,,Falls Outside The Dose Series,UO_0000065,,,,,0,CHEMBL5604074,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 4,,,,,Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK,,,CHEMBL5705864,NS3 protease,dengue virus type 4,SINGLE PROTEIN,CHEMBL5604066,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 3.935 None | Maximum measured = 43.15 None | Maximum response = 100.0 % | Minimum measured = -3.355 None | R squared = 0.955 None,,,99.5,4
CHEMBL5605162,,,387.87,0.0,3.27,ASAP-0028981,CNC(=O)[C@H](Nc1cc(CN)cc(C(=O)O)c1)c1cc(Cl)cc(C2CC2)c1,IC50,'>',99500.0,nM,,,Falls Outside The Dose Series,UO_0000065,,,,,0,CHEMBL5604074,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 4,,,,,Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK,,,CHEMBL5705864,NS3 protease,dengue virus type 4,SINGLE PROTEIN,CHEMBL5604066,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Maximum measured = 1.322 None | Minimum measured = -2.969 None,,,99.5,4
CHEMBL5598631,,,312.8,0.0,3.68,ASAP-0029051,O=C(Nc1ccc2c(c1)CNC2)c1cc(Cl)cc2c1CCC2,IC50,'>',99500.0,nM,,,Falls Outside The Dose Series,UO_0000065,,,,,0,CHEMBL5604074,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 4,,,,,Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK,,,CHEMBL5705864,NS3 protease,dengue virus type 4,SINGLE PROTEIN,CHEMBL5604066,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Maximum measured = 1.178 None | Minimum measured = -2.748 None,,,99.5,4
CHEMBL5604667,,,422.49,0.0,4.2,ASAP-0031355,CC(C)c1nnc(-c2nc3c(C(=O)Nc4ccc5c(c4)CNC5)cc(F)cc3[nH]2)s1,IC50,'=',9861.0,nM,5.01,,,UO_0000065,,,,,0,CHEMBL5604074,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 4,,,,,Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK,,,CHEMBL5705864,NS3 protease,dengue virus type 4,SINGLE PROTEIN,CHEMBL5604066,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 4.406 None | IC50 CI (lower) = 9.48 uM | IC50 CI (upper) = 10.26 uM | Maximum measured = 94.83 None | Maximum response = 100.0 % | Minimum measured = 0.705 None | R squared = 0.995 None,,,9.861,4
CHEMBL5604344,,,373.21,0.0,2.47,ASAP-0029916,O=C(Nc1ccc2c(c1)CNC2)c1cc(Br)cc2[nH]c(=O)[nH]c12,IC50,'=',38670.0,nM,4.41,,,UO_0000065,,,,,0,CHEMBL5604074,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 4,,,,,Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK,,,CHEMBL5705864,NS3 protease,dengue virus type 4,SINGLE PROTEIN,CHEMBL5604066,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 2.011 None | IC50 CI (lower) = 36.04 uM | IC50 CI (upper) = 41.49 uM | Maximum measured = 84.35 None | Maximum response = 100.0 % | Minimum measured = -2.628 None | R squared = 0.987 None,,,38.67,4
CHEMBL5598575,,,399.92,0.0,3.74,ASAP-0029415,COCCNC(=O)[C@H](Nc1ccc2c(c1)CNC2)c1cc(Cl)cc(C2CC2)c1,IC50,'>',99500.0,nM,,,Falls Outside The Dose Series,UO_0000065,,,,,0,CHEMBL5604074,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 4,,,,,Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK,,,CHEMBL5705864,NS3 protease,dengue virus type 4,SINGLE PROTEIN,CHEMBL5604066,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Maximum measured = 5.693 None | Minimum measured = -5.089 None,,,99.5,4
CHEMBL5605142,,,474.95,1.0,6.0,ASAP-0028883,C=CC[C@H](Nc1cc(Cl)cc(NC(=O)OCc2ccccc2)c1)c1cccc(-c2nn[nH]n2)c1,IC50,'=',7778.0,nM,5.11,,,UO_0000065,,,,,0,CHEMBL5604074,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 4,,,,,Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK,,,CHEMBL5705864,NS3 protease,dengue virus type 4,SINGLE PROTEIN,CHEMBL5604066,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 2.722 None | IC50 CI (lower) = 7.295 uM | IC50 CI (upper) = 8.293 uM | Maximum measured = 100.25 None | Maximum response = 100.0 % | Minimum measured = 0.082 None | R squared = 0.994 None,,,7.778,4
CHEMBL5604328,,,459.9,0.0,4.95,ASAP-0027741,N#C[C@H](Nc1cccc(-c2nn[nH]n2)c1)c1cc(Cl)cc(NC(=O)OCc2ccccc2)c1,IC50,'=',12446.0,nM,4.91,,,UO_0000065,,,,,0,CHEMBL5604074,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 4,,,,,Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK,,,CHEMBL5705864,NS3 protease,dengue virus type 4,SINGLE PROTEIN,CHEMBL5604066,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 3.14 None | IC50 CI (lower) = 11.96 uM | IC50 CI (upper) = 12.95 uM | Maximum measured = 100.17 None | Maximum response = 100.0 % | Minimum measured = -0.253 None | R squared = 0.997 None,,,12.446,4
CHEMBL5604332,,,312.76,0.0,3.07,ASAP-0027808,O=C(Nc1ccc2c(c1)CNC2)c1cc(Cl)cc2[nH]ncc12,IC50,'>',99500.0,nM,,,Falls Outside The Dose Series,UO_0000065,,,,,0,CHEMBL5604074,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 4,,,,,Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK,,,CHEMBL5705864,NS3 protease,dengue virus type 4,SINGLE PROTEIN,CHEMBL5604066,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 2.798 None | Maximum measured = 28.23 None | Maximum response = 100.0 % | Minimum measured = -1.054 None | R squared = 0.973 None,,,99.5,4
CHEMBL5605526,,,409.87,0.0,4.8,ASAP-0016806,NCc1cccc(NC(=O)c2cc(Cl)cc(NC(=O)OCc3ccccc3)c2)c1,IC50,'=',34571.0,nM,4.46,,,UO_0000065,,,,,0,CHEMBL5604074,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 4,,,,,Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK,,,CHEMBL5705864,NS3 protease,dengue virus type 4,SINGLE PROTEIN,CHEMBL5604066,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 5.611 None | IC50 CI (lower) = 33.24 uM | IC50 CI (upper) = 35.96 uM | Maximum measured = 96.02 None | Maximum response = 100.0 % | Minimum measured = -3.641 None | R squared = 0.996 None,,,34.571,4
CHEMBL5598597,,,326.79,0.0,3.41,ASAP-0029027,CN1Cc2ccc(NC(=O)c3cc(Cl)cc4[nH]ncc34)cc2C1,IC50,'>',99500.0,nM,,,Falls Outside The Dose Series,UO_0000065,,,,,0,CHEMBL5604074,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 4,,,,,Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK,,,CHEMBL5705864,NS3 protease,dengue virus type 4,SINGLE PROTEIN,CHEMBL5604066,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 1.552 None | Maximum measured = 24.71 None | Maximum response = 100.0 % | Minimum measured = -2.071 None | R squared = 0.96 None,,,99.5,4
CHEMBL5598717,,,565.08,2.0,6.65,ASAP-0027928,O=C(Nc1cc(Cl)cc([C@H]2CN(Cc3ccccc3)C[C@@H]2c2cccc(-c3nn[nH]n3)c2)c1)OCc1ccccc1,IC50,'=',6834.0,nM,5.17,,,UO_0000065,,,,,0,CHEMBL5604074,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 4,,,,,Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK,,,CHEMBL5705864,NS3 protease,dengue virus type 4,SINGLE PROTEIN,CHEMBL5604066,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 2.429 None | IC50 CI (lower) = 6.402 uM | IC50 CI (upper) = 7.296 uM | Maximum measured = 98.68 None | Maximum response = 100.0 % | Minimum measured = -1.823 None | R squared = 0.995 None,,,6.834,4
CHEMBL5604114,,,488.94,0.0,4.42,ASAP-0027813,O=C(Nc1cc(Cl)cc([C@H](C#CCO)Nc2cccc(-c3nn[nH]n3)c2)c1)OCc1ccccc1,IC50,'=',15913.0,nM,4.8,,,UO_0000065,,,,,0,CHEMBL5604074,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 4,,,,,Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK,,,CHEMBL5705864,NS3 protease,dengue virus type 4,SINGLE PROTEIN,CHEMBL5604066,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 2.657 None | IC50 CI (lower) = 15.18 uM | IC50 CI (upper) = 16.69 uM | Maximum measured = 98.28 None | Maximum response = 100.0 % | Minimum measured = -1.771 None | R squared = 0.996 None,,,15.913,4
CHEMBL5604249,,,406.91,1.0,5.82,ASAP-0022797,NCc1cccc([C@H]2C[C@@H]2c2cc(Cl)cc(NC(=O)OCc3ccccc3)c2)c1,IC50,'=',7937.0,nM,5.1,,,UO_0000065,,,,,0,CHEMBL5604074,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 4,,,,,Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK,,,CHEMBL5705864,NS3 protease,dengue virus type 4,SINGLE PROTEIN,CHEMBL5604066,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 3.512 None | IC50 CI (lower) = 7.638 uM | IC50 CI (upper) = 8.247 uM | Maximum measured = 96.92 None | Maximum response = 100.0 % | Minimum measured = -1.82 None | R squared = 0.997 None,,,7.937,4
CHEMBL5605184,,,311.32,0.0,2.18,ASAP-0030065,O=C1Cc2c(cc(F)cc2C(=O)Nc2ccc3c(c2)CNC3)N1,IC50,'=',53673.0,nM,4.27,,,UO_0000065,,,,,0,CHEMBL5604074,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 4,,,,,Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK,,,CHEMBL5705864,NS3 protease,dengue virus type 4,SINGLE PROTEIN,CHEMBL5604066,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 1.521 None | IC50 CI (lower) = 51.04 uM | IC50 CI (upper) = 56.45 uM | Maximum measured = 74.53 None | Maximum response = 100.0 % | Minimum measured = -1.249 None | R squared = 0.993 None,,,53.673,4
CHEMBL5606160,,,372.4,0.0,4.22,ASAP-0030089,O=C(Nc1ccc2c(c1)CNC2)c1cc(F)cc2[nH]c(-c3ccccc3)nc12,IC50,'=',5405.0,nM,5.27,,,UO_0000065,,,,,0,CHEMBL5604074,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 4,,,,,Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK,,,CHEMBL5705864,NS3 protease,dengue virus type 4,SINGLE PROTEIN,CHEMBL5604066,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 3.509 None | IC50 CI (lower) = 4.845 uM | IC50 CI (upper) = 6.029 uM | Maximum measured = 94.88 None | Maximum response = 100.0 % | Minimum measured = -2.046 None | R squared = 0.992 None,,,5.405,4
CHEMBL5605639,,,341.72,0.0,3.61,ASAP-0029970,O=C(Nc1ccc2c(c1)CNC2)c1cc(Cl)cc(C(F)(F)F)n1,IC50,'=',22968.0,nM,4.64,,,UO_0000065,,,,,0,CHEMBL5604074,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 4,,,,,Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK,,,CHEMBL5705864,NS3 protease,dengue virus type 4,SINGLE PROTEIN,CHEMBL5604066,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 3.727 None | IC50 CI (lower) = 22.32 uM | IC50 CI (upper) = 23.63 uM | Maximum measured = 98.65 None | Maximum response = 100.0 % | Minimum measured = -1.927 None | R squared = 0.998 None,,,22.968,4
CHEMBL5605255,,,423.95,0.0,4.61,ASAP-0030850,C=CC[C@H]1NCc2cc(N[C@H](C(=O)NC(C)C)c3cc(Cl)cc4[nH]ncc34)ccc21,IC50,'>',99500.0,nM,,,Falls Outside The Dose Series,UO_0000065,,,,,0,CHEMBL5604074,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 4,,,,,Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK,,,CHEMBL5705864,NS3 protease,dengue virus type 4,SINGLE PROTEIN,CHEMBL5604066,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 1.188 None | Maximum measured = 49.1 None | Maximum response = 100.0 % | Minimum measured = -1.606 None | R squared = 0.992 None,,,99.5,4
CHEMBL5606319,,,426.47,0.0,2.76,ASAP-0031155,O=C(Nc1cc2c(c(C3=CCS(=O)(=O)CC3)c1)CNC2)c1cc(F)cc2[nH]ncc12,IC50,'=',49988.0,nM,4.3,,,UO_0000065,,,,,0,CHEMBL5604074,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 4,,,,,Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK,,,CHEMBL5705864,NS3 protease,dengue virus type 4,SINGLE PROTEIN,CHEMBL5604066,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 1.161 None | IC50 CI (lower) = 48.18 uM | IC50 CI (upper) = 51.86 uM | Maximum measured = 68.67 None | Maximum response = 100.0 % | Minimum measured = -1.121 None | R squared = 0.997 None,,,49.988,4
CHEMBL5604531,,,402.43,0.0,4.23,ASAP-0031290,COc1cccc(-c2nc3c(C(=O)Nc4ccc5c(c4)CNC5)cc(F)cc3[nH]2)c1,IC50,'=',5321.0,nM,5.27,,,UO_0000065,,,,,0,CHEMBL5604074,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 4,,,,,Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK,,,CHEMBL5705864,NS3 protease,dengue virus type 4,SINGLE PROTEIN,CHEMBL5604066,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 2.431 None | IC50 CI (lower) = 4.756 uM | IC50 CI (upper) = 5.953 uM | Maximum measured = 93.58 None | Maximum response = 100.0 % | Minimum measured = -0.347 None | R squared = 0.988 None,,,5.321,4
CHEMBL5605561,,,333.4,0.0,2.11,ASAP-0031692,O=C(Nc1ccc2c(c1)CNC2)c1cccc2c(C3CNC3)n[nH]c12,IC50,'=',32175.0,nM,4.49,,,UO_0000065,,,,,0,CHEMBL5604074,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 4,,,,,Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK,,,CHEMBL5705864,NS3 protease,dengue virus type 4,SINGLE PROTEIN,CHEMBL5604066,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 1.158 None | IC50 CI (lower) = 31.31 uM | IC50 CI (upper) = 33.06 uM | Maximum measured = 78.31 None | Maximum response = 100.0 % | Minimum measured = 0.462 None | R squared = 0.999 None,,,32.175,4
CHEMBL5605274,,,390.39,0.0,4.36,ASAP-0031221,O=C(Nc1ccc2c(c1)CNC2)c1cc(F)cc2[nH]c(-c3ccccc3F)nc12,IC50,'=',5232.0,nM,5.28,,,UO_0000065,,,,,0,CHEMBL5604074,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 4,,,,,Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK,,,CHEMBL5705864,NS3 protease,dengue virus type 4,SINGLE PROTEIN,CHEMBL5604066,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 3.88 None | IC50 CI (lower) = 4.897 uM | IC50 CI (upper) = 5.589 uM | Maximum measured = 97.77 None | Maximum response = 100.0 % | Minimum measured = -2.216 None | R squared = 0.998 None,,,5.232,4
CHEMBL5605908,,,403.42,0.0,3.63,ASAP-0031141,COc1cc(-c2cc(NC(=O)c3cc(F)cc4[nH]ncc34)cc3c2CNC3)ccn1,IC50,'=',42482.0,nM,4.37,,,UO_0000065,,,,,0,CHEMBL5604074,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 4,,,,,Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK,,,CHEMBL5705864,NS3 protease,dengue virus type 4,SINGLE PROTEIN,CHEMBL5604066,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 1.463 None | IC50 CI (lower) = 40.47 uM | IC50 CI (upper) = 44.6 uM | Maximum measured = 80.59 None | Maximum response = 100.0 % | Minimum measured = -1.416 None | R squared = 0.995 None,,,42.482,4
CHEMBL5605238,,,375.5,0.0,4.13,ASAP-0031464,O=C(Nc1ccc2c(c1)CNC2)c1ccc2c(C3=CCNCC3)csc2c1,IC50,'=',70031.0,nM,4.16,,,UO_0000065,,,,,0,CHEMBL5604074,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 4,,,,,Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK,,,CHEMBL5705864,NS3 protease,dengue virus type 4,SINGLE PROTEIN,CHEMBL5604066,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 2.752 None | IC50 CI (lower) = 68.55 uM | IC50 CI (upper) = 71.54 uM | Maximum measured = 72.84 None | Maximum response = 100.0 % | Minimum measured = -0.878 None | R squared = 0.997 None,,,70.031,4
CHEMBL5598577,,,326.79,0.0,3.11,ASAP-0029079,O=C(Nc1ccc2c(c1)CNCC2)c1cc(Cl)cc2[nH]ncc12,IC50,'>',99500.0,nM,,,Falls Outside The Dose Series,UO_0000065,,,,,0,CHEMBL5604074,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 4,,,,,Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK,,,CHEMBL5705864,NS3 protease,dengue virus type 4,SINGLE PROTEIN,CHEMBL5604066,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 1.944 None | Maximum measured = 11.15 None | Maximum response = 100.0 % | Minimum measured = -1.547 None | R squared = 0.874 None,,,99.5,4
CHEMBL3740727,,,719.79,2.0,2.06,ASAP-0000570,N=C(N)NCCC[C@H](NC(=O)c1nccs1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(N)=O)c1ccc(OCc2ccc(C(F)(F)F)cc2)cc1,IC50,'=',2575.0,nM,5.59,,,UO_0000065,,,,,0,CHEMBL5604074,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 4,,,,,Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK,,,CHEMBL5705864,NS3 protease,dengue virus type 4,SINGLE PROTEIN,CHEMBL5604066,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 1.39 None | IC50 CI (lower) = 2.466 uM | IC50 CI (upper) = 2.69 uM | Maximum measured = 99.16 None | Maximum response = 100.0 % | Minimum measured = 0.426 None | R squared = 0.998 None,,,2.575,4
CHEMBL5605549,,,294.31,0.0,1.71,ASAP-0029783,O=C(Nc1ccc2c(c1)CNC2)c1cccc2[nH]c(=O)[nH]c12,IC50,'=',74491.0,nM,4.13,,,UO_0000065,,,,,0,CHEMBL5604074,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 4,,,,,Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK,,,CHEMBL5705864,NS3 protease,dengue virus type 4,SINGLE PROTEIN,CHEMBL5604066,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 3.327 None | IC50 CI (lower) = 72.71 uM | IC50 CI (upper) = 76.32 uM | Maximum measured = 72.75 None | Maximum response = 100.0 % | Minimum measured = -1.931 None | R squared = 0.995 None,,,74.491,4
CHEMBL5598927,,,372.22,0.0,2.8,ASAP-0029728,O=C1Cc2c(cc(Br)cc2C(=O)Nc2ccc3c(c2)CNC3)N1,IC50,'=',87949.0,nM,4.06,,,UO_0000065,,,,,0,CHEMBL5604074,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 4,,,,,Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK,,,CHEMBL5705864,NS3 protease,dengue virus type 4,SINGLE PROTEIN,CHEMBL5604066,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 1.597 None | IC50 CI (lower) = 82.36 uM | IC50 CI (upper) = 93.91 uM | Maximum measured = 56.53 None | Maximum response = 100.0 % | Minimum measured = -1.347 None | R squared = 0.985 None,,,87.949,4
CHEMBL5598743,,,425.96,0.0,4.27,ASAP-0029555,O=C(NC1CCOCC1)[C@H](Nc1ccc2c(c1)CNC2)c1cc(Cl)cc(C2CC2)c1,IC50,'>',99500.0,nM,,,Falls Outside The Dose Series,UO_0000065,,,,,0,CHEMBL5604074,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 4,,,,,Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK,,,CHEMBL5705864,NS3 protease,dengue virus type 4,SINGLE PROTEIN,CHEMBL5604066,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 0.865 None | Maximum measured = 21.81 None | Maximum response = 100.0 % | Minimum measured = -1.078 None | R squared = 0.962 None,,,99.5,4
CHEMBL5598746,,,435.96,0.0,4.02,ASAP-0029471,Cn1cc(CNC(=O)[C@H](Nc2ccc3c(c2)CNC3)c2cc(Cl)cc(C3CC3)c2)cn1,IC50,'>',99500.0,nM,,,Falls Outside The Dose Series,UO_0000065,,,,,0,CHEMBL5604074,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 4,,,,,Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK,,,CHEMBL5705864,NS3 protease,dengue virus type 4,SINGLE PROTEIN,CHEMBL5604066,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 3.082 None | Maximum measured = 8.206 None | Maximum response = 100.0 % | Minimum measured = -4.379 None | R squared = 0.566 None,,,99.5,4
CHEMBL5598860,,,325.41,0.0,3.36,ASAP-0029521,Cc1c(C(=O)Nc2cc([C@H]3CCOC3)ccn2)cc(C2CC2)n1C,IC50,'>',99500.0,nM,,,Falls Outside The Dose Series,UO_0000065,,,,,0,CHEMBL5604074,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 4,,,,,Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK,,,CHEMBL5705864,NS3 protease,dengue virus type 4,SINGLE PROTEIN,CHEMBL5604066,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Maximum measured = 2.197 None | Minimum measured = -6.438 None,,,99.5,4
CHEMBL5605183,,,389.38,0.0,2.84,ASAP-0030767,O=C(NCC(F)F)[C@H](Nc1ccc2c(c1)CNC2)c1cc(F)cc2[nH]ncc12,IC50,'>',99500.0,nM,,,Falls Outside The Dose Series,UO_0000065,,,,,0,CHEMBL5604074,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 4,,,,,Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK,,,CHEMBL5705864,NS3 protease,dengue virus type 4,SINGLE PROTEIN,CHEMBL5604066,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 1.071 None | Maximum measured = 44.69 None | Maximum response = 100.0 % | Minimum measured = -1.498 None | R squared = 0.993 None,,,99.5,4
CHEMBL5598576,,,405.88,0.0,4.36,ASAP-0030776,O=C(NCC(F)F)[C@H](Nc1ccc2c(c1)CNC2)c1cc(Cl)cc(C2CC2)c1,IC50,'>',99500.0,nM,,,Falls Outside The Dose Series,UO_0000065,,,,,0,CHEMBL5604074,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 4,,,,,Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK,,,CHEMBL5705864,NS3 protease,dengue virus type 4,SINGLE PROTEIN,CHEMBL5604066,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 1.447 None | Maximum measured = 22.23 None | Maximum response = 100.0 % | Minimum measured = -1.083 None | R squared = 0.979 None,,,99.5,4
CHEMBL5605716,,,305.34,0.0,2.8,ASAP-0029967,O=C(Nc1ccc2c(c1)CNC2)c1cccc2nc(O)ccc12,IC50,'>',99500.0,nM,,,Falls Outside The Dose Series,UO_0000065,,,,,0,CHEMBL5604074,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 4,,,,,Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK,,,CHEMBL5705864,NS3 protease,dengue virus type 4,SINGLE PROTEIN,CHEMBL5604066,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 1.855 None | Maximum measured = 1.914 None | Maximum response = 100.0 % | Minimum measured = -0.946 None | R squared = 0.263 None,,,99.5,4
CHEMBL5604164,,,345.32,0.0,4.04,ASAP-0030028,O=C(Nc1ccc2c(c1)CNC2)c1cccc2[nH]c(C(F)(F)F)cc12,IC50,'>',99500.0,nM,,,Falls Outside The Dose Series,UO_0000065,,,,,0,CHEMBL5604074,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 4,,,,,Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK,,,CHEMBL5705864,NS3 protease,dengue virus type 4,SINGLE PROTEIN,CHEMBL5604066,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 1.515 None | Maximum measured = 13.65 None | Maximum response = 100.0 % | Minimum measured = -2.717 None | R squared = 0.883 None,,,99.5,4
CHEMBL5598684,,,433.31,0.0,4.85,ASAP-0029352,O=C(Nc1ccc2c(c1)CNC2)c1cc(Br)cc2[nH]c(-c3ccccc3)nc12,IC50,'=',2956.0,nM,5.53,,,UO_0000065,,,,,0,CHEMBL5604074,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 4,,,,,Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK,,,CHEMBL5705864,NS3 protease,dengue virus type 4,SINGLE PROTEIN,CHEMBL5604066,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 3.959 None | IC50 CI (lower) = 2.833 uM | IC50 CI (upper) = 3.084 uM | Maximum measured = 98.46 None | Maximum response = 100.0 % | Minimum measured = -1.591 None | R squared = 0.999 None,,,2.956,4
CHEMBL5606033,,,293.33,0.0,2.04,ASAP-0029950,O=C1Cc2cc(C(=O)Nc3ccc4c(c3)CNC4)ccc2N1,IC50,'=',8206.0,nM,5.09,,,UO_0000065,,,,,0,CHEMBL5604074,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 4,,,,,Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK,,,CHEMBL5705864,NS3 protease,dengue virus type 4,SINGLE PROTEIN,CHEMBL5604066,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 5.502 None | IC50 CI (lower) = 8.016 uM | IC50 CI (upper) = 8.4 uM | Maximum measured = 98.76 None | Maximum response = 100.0 % | Minimum measured = -1.337 None | R squared = 0.998 None,,,8.206,4
CHEMBL5606232,,,278.31,0.0,2.42,ASAP-0030093,O=C(Nc1ccc2c(c1)CNC2)c1cccc2cn[nH]c12,IC50,'=',44972.0,nM,4.35,,,UO_0000065,,,,,0,CHEMBL5604074,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 4,,,,,Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK,,,CHEMBL5705864,NS3 protease,dengue virus type 4,SINGLE PROTEIN,CHEMBL5604066,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 3.377 None | IC50 CI (lower) = 43.95 uM | IC50 CI (upper) = 46.02 uM | Maximum measured = 91.67 None | Maximum response = 100.0 % | Minimum measured = -0.392 None | R squared = 0.998 None,,,44.972,4
CHEMBL5605022,,,321.32,0.0,2.43,ASAP-0031265,N#Cc1cc2c(cc1NC(=O)c1cc(F)cc3[nH]ncc13)CNC2,IC50,'=',36934.0,nM,4.43,,,UO_0000065,,,,,0,CHEMBL5604074,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 4,,,,,Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK,,,CHEMBL5705864,NS3 protease,dengue virus type 4,SINGLE PROTEIN,CHEMBL5604066,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 1.114 None | IC50 CI (lower) = 35.42 uM | IC50 CI (upper) = 38.51 uM | Maximum measured = 74.76 None | Maximum response = 100.0 % | Minimum measured = -1.7 None | R squared = 0.997 None,,,36.934,4
CHEMBL5604118,,,367.47,0.0,3.55,ASAP-0031158,NCCc1csc2cc(C(=O)Nc3cc([C@H]4CCOC4)ccn3)ccc12,IC50,'>',99500.0,nM,,,Falls Outside The Dose Series,UO_0000065,,,,,0,CHEMBL5604074,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 4,,,,,Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK,,,CHEMBL5705864,NS3 protease,dengue virus type 4,SINGLE PROTEIN,CHEMBL5604066,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 1.637 None | Maximum measured = 3.362 None | Maximum response = 100.0 % | Minimum measured = -2.365 None | R squared = 0.238 None,,,99.5,4
CHEMBL5604338,,,360.46,0.0,3.49,ASAP-0031404,O=C(Nc1ccc2c(c1)CNC2)c1ccc2[nH]cc(C3CCNCC3)c2c1,IC50,'=',36746.0,nM,4.43,,,UO_0000065,,,,,0,CHEMBL5604074,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 4,,,,,Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK,,,CHEMBL5705864,NS3 protease,dengue virus type 4,SINGLE PROTEIN,CHEMBL5604066,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 5.751 None | IC50 CI (lower) = 36.11 uM | IC50 CI (upper) = 37.39 uM | Maximum measured = 98.84 None | Maximum response = 100.0 % | Minimum measured = -0.757 None | R squared = 0.999 None,,,36.746,4
CHEMBL3740727,,,719.79,2.0,2.06,ASAP-0000570,N=C(N)NCCC[C@H](NC(=O)c1nccs1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(N)=O)c1ccc(OCc2ccc(C(F)(F)F)cc2)cc1,IC50,'=',1738.0,nM,5.76,,,UO_0000065,,,,,0,CHEMBL5604074,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 4,,,,,Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK,,,CHEMBL5705864,NS3 protease,dengue virus type 4,SINGLE PROTEIN,CHEMBL5604066,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 1.3 None | IC50 CI (lower) = 1.688 uM | IC50 CI (upper) = 1.79 uM | Maximum measured = 99.46 None | Maximum response = 100.0 % | Minimum measured = 1.199 None | R squared = 0.999 None,,,1.738,4
CHEMBL5605856,,,406.91,1.0,5.82,ASAP-0027760,NCc1ccc([C@H]2C[C@@H]2c2cc(Cl)cc(NC(=O)OCc3ccccc3)c2)cc1,IC50,'=',6873.0,nM,5.16,,,UO_0000065,,,,,0,CHEMBL5604074,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 4,,,,,Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK,,,CHEMBL5705864,NS3 protease,dengue virus type 4,SINGLE PROTEIN,CHEMBL5604066,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 5.223 None | IC50 CI (lower) = 6.644 uM | IC50 CI (upper) = 7.109 uM | Maximum measured = 99.43 None | Maximum response = 100.0 % | Minimum measured = -2.579 None | R squared = 0.998 None,,,6.873,4
CHEMBL5604806,,,420.85,1.0,5.94,ASAP-0027839,O=C(Nc1cc(Cl)cc(-c2ccc3[nH]c(C(=O)O)cc3c2)c1)OCc1ccccc1,IC50,'=',6916.0,nM,5.16,,,UO_0000065,,,,,0,CHEMBL5604074,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 4,,,,,Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK,,,CHEMBL5705864,NS3 protease,dengue virus type 4,SINGLE PROTEIN,CHEMBL5604066,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 2.809 None | IC50 CI (lower) = 6.44 uM | IC50 CI (upper) = 7.426 uM | Maximum measured = 100.11 None | Maximum response = 100.0 % | Minimum measured = 0.071 None | R squared = 0.994 None,,,6.916,4
CHEMBL5604180,,,312.76,0.0,3.07,ASAP-0029911,O=C(Nc1ccc2c(c1)CNC2)c1cc(Cl)cc2cn[nH]c12,IC50,'>',99500.0,nM,,,Falls Outside The Dose Series,UO_0000065,,,,,0,CHEMBL5604074,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 4,,,,,Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK,,,CHEMBL5705864,NS3 protease,dengue virus type 4,SINGLE PROTEIN,CHEMBL5604066,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 3.118 None | Maximum measured = 27.94 None | Maximum response = 100.0 % | Minimum measured = -2.102 None | R squared = 0.95 None,,,99.5,4
CHEMBL5604703,,,326.79,0.0,3.38,ASAP-0029875,Cc1nc2c(C(=O)Nc3ccc4c(c3)CNC4)cc(Cl)cc2[nH]1,IC50,'=',26724.0,nM,4.57,,,UO_0000065,,,,,0,CHEMBL5604074,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 4,,,,,Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK,,,CHEMBL5705864,NS3 protease,dengue virus type 4,SINGLE PROTEIN,CHEMBL5604066,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 2.084 None | IC50 CI (lower) = 22.6 uM | IC50 CI (upper) = 31.6 uM | Maximum measured = 77.56 None | Maximum response = 100.0 % | Minimum measured = -1.647 None | R squared = 0.938 None,,,26.724,4
CHEMBL5605533,,,418.88,0.0,4.75,ASAP-0029841,Cc1cccc(-c2nc3c(C(=O)Nc4ccc5c(c4)CNC5)cc(Cl)cc3[nH]2)c1O,IC50,'=',3539.0,nM,5.45,,,UO_0000065,,,,,0,CHEMBL5604074,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 4,,,,,Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK,,,CHEMBL5705864,NS3 protease,dengue virus type 4,SINGLE PROTEIN,CHEMBL5604066,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 5.346 None | IC50 CI (lower) = 3.025 uM | IC50 CI (upper) = 4.142 uM | Maximum measured = 98.38 None | Maximum response = 100.0 % | Minimum measured = -4.631 None | R squared = 0.996 None,,,3.539,4
CHEMBL5604418,,,351.88,0.0,4.95,ASAP-0029785,Clc1cc([C@@H]2C[C@H]2c2cccc(C3CCNCC3)c2)c2cn[nH]c2c1,IC50,'=',5838.0,nM,5.23,,,UO_0000065,,,,,0,CHEMBL5604074,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 4,,,,,Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK,,,CHEMBL5705864,NS3 protease,dengue virus type 4,SINGLE PROTEIN,CHEMBL5604066,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 14.44 None | IC50 CI (lower) = 0.0 uM | IC50 CI (upper) = 6405173075445682000 uM | Maximum measured = 100.1 None | Maximum response = 100.0 % | Minimum measured = -3.88 None | R squared = 0.998 None,,,5.838,4
CHEMBL5605499,,,387.24,0.0,2.48,ASAP-0029933,Cn1c(=O)[nH]c2c(C(=O)Nc3ccc4c(c3)CNC4)cc(Br)cc21,IC50,'>',99500.0,nM,,,Falls Outside The Dose Series,UO_0000065,,,,,0,CHEMBL5604074,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 4,,,,,Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK,,,CHEMBL5705864,NS3 protease,dengue virus type 4,SINGLE PROTEIN,CHEMBL5604066,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Maximum measured = 0.871 None | Minimum measured = -4.358 None,,,99.5,4
CHEMBL5605115,,,375.2,0.0,3.32,ASAP-0030792,O=C(Nc1cc(Br)c2c(c1)CNC2)c1cc(F)cc2[nH]ncc12,IC50,'>',99500.0,nM,,,Falls Outside The Dose Series,UO_0000065,,,,,0,CHEMBL5604074,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 4,,,,,Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK,,,CHEMBL5705864,NS3 protease,dengue virus type 4,SINGLE PROTEIN,CHEMBL5604066,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 0.899 None | Maximum measured = 39.87 None | Maximum response = 100.0 % | Minimum measured = -1.067 None | R squared = 0.946 None,,,99.5,4
CHEMBL5598718,,,298.78,0.0,3.43,ASAP-0029525,Clc1cc(CNc2ccc3c(c2)CNC3)c2cn[nH]c2c1,IC50,'=',38774.0,nM,4.41,,,UO_0000065,,,,,0,CHEMBL5604074,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 4,,,,,Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK,,,CHEMBL5705864,NS3 protease,dengue virus type 4,SINGLE PROTEIN,CHEMBL5604066,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 3.282 None | IC50 CI (lower) = 36.44 uM | IC50 CI (upper) = 41.26 uM | Maximum measured = 91.74 None | Maximum response = 100.0 % | Minimum measured = -3.794 None | R squared = 0.994 None,,,38.774,4
CHEMBL5605664,,,390.39,0.0,4.36,ASAP-0031237,O=C(Nc1ccc2c(c1)CNC2)c1cc(F)cc2[nH]c(-c3ccc(F)cc3)nc12,IC50,'=',3650.0,nM,5.44,,,UO_0000065,,,,,0,CHEMBL5604074,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 4,,,,,Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK,,,CHEMBL5705864,NS3 protease,dengue virus type 4,SINGLE PROTEIN,CHEMBL5604066,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 4.03 None | IC50 CI (lower) = 3.44 uM | IC50 CI (upper) = 3.871 uM | Maximum measured = 98.09 None | Maximum response = 100.0 % | Minimum measured = -0.544 None | R squared = 0.998 None,,,3.65,4
CHEMBL5605097,,,386.43,0.0,4.53,ASAP-0031293,Cc1cccc(-c2nc3c(C(=O)Nc4ccc5c(c4)CNC5)cc(F)cc3[nH]2)c1,IC50,'=',5904.0,nM,5.23,,,UO_0000065,,,,,0,CHEMBL5604074,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 4,,,,,Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK,,,CHEMBL5705864,NS3 protease,dengue virus type 4,SINGLE PROTEIN,CHEMBL5604066,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 3.752 None | IC50 CI (lower) = 5.172 uM | IC50 CI (upper) = 6.74 uM | Maximum measured = 94.51 None | Maximum response = 100.0 % | Minimum measured = -1.156 None | R squared = 0.987 None,,,5.904,4
CHEMBL5599838,,,459.98,1.0,5.16,ASAP-0030826,CC(C)NC(=O)[C@H](Nc1ccc2c(c1)CNC2)c1cc(Cl)cc2[nH]c(-c3ccccc3)nc12,IC50,'=',14644.0,nM,4.83,,,UO_0000065,,,,,0,CHEMBL5604074,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 4,,,,,Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK,,,CHEMBL5705864,NS3 protease,dengue virus type 4,SINGLE PROTEIN,CHEMBL5604066,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 1.146 None | IC50 CI (lower) = 14.19 uM | IC50 CI (upper) = 15.12 uM | Maximum measured = 92.08 None | Maximum response = 100.0 % | Minimum measured = 0.128 None | R squared = 0.999 None,,,14.644,4
CHEMBL5598845,,,356.22,0.0,3.79,ASAP-0029002,O=C(Nc1ccc2c(c1)CNC2)c1cc(Br)cc2[nH]ccc12,IC50,'=',33752.0,nM,4.47,,,UO_0000065,,,,,0,CHEMBL5604074,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 4,,,,,Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK,,,CHEMBL5705864,NS3 protease,dengue virus type 4,SINGLE PROTEIN,CHEMBL5604066,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 4.993 None | IC50 CI (lower) = 32.84 uM | IC50 CI (upper) = 34.69 uM | Maximum measured = 95.3 None | Maximum response = 100.0 % | Minimum measured = -0.593 None | R squared = 0.998 None,,,33.752,4
CHEMBL5605520,,,352.82,0.0,2.97,ASAP-0028990,OCC#C[C@H](Nc1ccc2c(c1)CNC2)c1cc(Cl)cc2[nH]ncc12,IC50,'=',22280.0,nM,4.65,,,UO_0000065,,,,,0,CHEMBL5604074,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 4,,,,,Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK,,,CHEMBL5705864,NS3 protease,dengue virus type 4,SINGLE PROTEIN,CHEMBL5604066,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 6.313 None | IC50 CI (lower) = 21.34 uM | IC50 CI (upper) = 23.26 uM | Maximum measured = 98.07 None | Maximum response = 100.0 % | Minimum measured = -5.294 None | R squared = 0.996 None,,,22.28,4
CHEMBL5604539,,,388.39,0.0,3.44,ASAP-0030867,O=C(NCC(F)F)[C@H](Nc1ccc2c(c1)CNC2)c1cc(F)cc2[nH]ccc12,IC50,'>',99500.0,nM,,,Falls Outside The Dose Series,UO_0000065,,,,,0,CHEMBL5604074,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 4,,,,,Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK,,,CHEMBL5705864,NS3 protease,dengue virus type 4,SINGLE PROTEIN,CHEMBL5604066,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 1.579 None | Maximum measured = 11.76 None | Maximum response = 100.0 % | Minimum measured = -1.333 None | R squared = 0.888 None,,,99.5,4
CHEMBL5604695,,,352.83,0.0,4.19,ASAP-0029944,C=CC[C@H]1NCc2cc(NC(=O)c3cc(Cl)cc4[nH]ncc34)ccc21,IC50,'>',99500.0,nM,,,Falls Outside The Dose Series,UO_0000065,,,,,0,CHEMBL5604074,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 4,,,,,Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK,,,CHEMBL5705864,NS3 protease,dengue virus type 4,SINGLE PROTEIN,CHEMBL5604066,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 1.423 None | Maximum measured = 15.73 None | Maximum response = 100.0 % | Minimum measured = -1.947 None | R squared = 0.903 None,,,99.5,4
CHEMBL5605462,,,491.94,0.0,4.17,ASAP-0027759,CNC(=O)[C@H](Nc1cc(Cl)cc(NC(=O)OCc2ccccc2)c1)c1cccc(-c2nn[nH]n2)c1,IC50,'=',61597.0,nM,4.21,,,UO_0000065,,,,,0,CHEMBL5604074,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 4,,,,,Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK,,,CHEMBL5705864,NS3 protease,dengue virus type 4,SINGLE PROTEIN,CHEMBL5604066,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 3.254 None | IC50 CI (lower) = 58.66 uM | IC50 CI (upper) = 64.68 uM | Maximum measured = 85.02 None | Maximum response = 100.0 % | Minimum measured = -0.933 None | R squared = 0.987 None,,,61.597,4
CHEMBL3740727,,,719.79,2.0,2.06,ASAP-0000570,N=C(N)NCCC[C@H](NC(=O)c1nccs1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(N)=O)c1ccc(OCc2ccc(C(F)(F)F)cc2)cc1,IC50,'=',1859.0,nM,5.73,,,UO_0000065,,,,,0,CHEMBL5604074,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 4,,,,,Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK,,,CHEMBL5705864,NS3 protease,dengue virus type 4,SINGLE PROTEIN,CHEMBL5604066,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 1.31 None | IC50 CI (lower) = 1.787 uM | IC50 CI (upper) = 1.933 uM | Maximum measured = 99.61 None | Maximum response = 100.0 % | Minimum measured = -0.459 None | R squared = 0.999 None,,,1.859,4
CHEMBL5598576,,,405.88,0.0,4.36,ASAP-0030775,O=C(NCC(F)F)[C@H](Nc1ccc2c(c1)CNC2)c1cc(Cl)cc(C2CC2)c1,IC50,'>',99500.0,nM,,,Falls Outside The Dose Series,UO_0000065,,,,,0,CHEMBL5604074,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 4,,,,,Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK,,,CHEMBL5705864,NS3 protease,dengue virus type 4,SINGLE PROTEIN,CHEMBL5604066,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 3.646 None | Maximum measured = 7.352 None | Maximum response = 100.0 % | Minimum measured = -2.055 None | R squared = 0.732 None,,,99.5,4
CHEMBL5606201,,,389.85,0.0,3.93,ASAP-0030082,O=C(Nc1ccc2c(c1)CNC2)c1cc(Cl)cc2nn(-c3ccccc3)nc12,IC50,'=',5254.0,nM,5.28,,,UO_0000065,,,,,0,CHEMBL5604074,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 4,,,,,Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK,,,CHEMBL5705864,NS3 protease,dengue virus type 4,SINGLE PROTEIN,CHEMBL5604066,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 4.557 None | IC50 CI (lower) = 4.987 uM | IC50 CI (upper) = 5.536 uM | Maximum measured = 98.51 None | Maximum response = 100.0 % | Minimum measured = -1.465 None | R squared = 0.999 None,,,5.254,4
CHEMBL5606033,,,293.33,0.0,2.04,ASAP-0029950,O=C1Cc2cc(C(=O)Nc3ccc4c(c3)CNC4)ccc2N1,IC50,'=',14015.0,nM,4.85,,,UO_0000065,,,,,0,CHEMBL5604074,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 4,,,,,Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK,,,CHEMBL5705864,NS3 protease,dengue virus type 4,SINGLE PROTEIN,CHEMBL5604066,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 5.517 None | IC50 CI (lower) = 13.6 uM | IC50 CI (upper) = 14.44 uM | Maximum measured = 98.66 None | Maximum response = 100.0 % | Minimum measured = -2.425 None | R squared = 0.998 None,,,14.015,4
CHEMBL3740727,,,719.79,2.0,2.06,ASAP-0000570,N=C(N)NCCC[C@H](NC(=O)c1nccs1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(N)=O)c1ccc(OCc2ccc(C(F)(F)F)cc2)cc1,IC50,'=',2669.0,nM,5.57,,,UO_0000065,,,,,0,CHEMBL5604074,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 4,,,,,Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK,,,CHEMBL5705864,NS3 protease,dengue virus type 4,SINGLE PROTEIN,CHEMBL5604066,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 1.408 None | IC50 CI (lower) = 2.512 uM | IC50 CI (upper) = 2.835 uM | Maximum measured = 99.4 None | Maximum response = 100.0 % | Minimum measured = -1.413 None | R squared = 0.997 None,,,2.669,4
CHEMBL5605673,,,425.9,0.0,4.15,ASAP-0027729,CCc1cc(C(=O)Nc2cccc(-n3nn[nH]c3=O)c2)sc1-c1ccc(Cl)cc1,IC50,'=',13062.0,nM,4.88,,,UO_0000065,,,,,0,CHEMBL5604074,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 4,,,,,Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK,,,CHEMBL5705864,NS3 protease,dengue virus type 4,SINGLE PROTEIN,CHEMBL5604066,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 2.759 None | IC50 CI (lower) = 12.4 uM | IC50 CI (upper) = 13.76 uM | Maximum measured = 96.77 None | Maximum response = 100.0 % | Minimum measured = -0.095 None | R squared = 0.994 None,,,13.062,4
CHEMBL5604849,,,409.96,0.0,4.89,ASAP-0030790,O=C(NCCC1CC1)[C@H](Nc1ccc2c(c1)CNC2)c1cc(Cl)cc(C2CC2)c1,IC50,'>',99500.0,nM,,,Falls Outside The Dose Series,UO_0000065,,,,,0,CHEMBL5604074,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 4,,,,,Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK,,,CHEMBL5705864,NS3 protease,dengue virus type 4,SINGLE PROTEIN,CHEMBL5604066,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 12.06 None | Maximum measured = 12.85 None | Maximum response = 100.0 % | Minimum measured = -5.272 None | R squared = 0.629 None,,,99.5,4
CHEMBL5598610,,,383.88,0.0,3.5,ASAP-0029000,CC(C)NC(=O)[C@H](Nc1ccc2c(c1)CNC2)c1cc(Cl)cc2[nH]ncc12,IC50,'=',49803.0,nM,4.3,,,UO_0000065,,,,,0,CHEMBL5604074,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 4,,,,,Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK,,,CHEMBL5705864,NS3 protease,dengue virus type 4,SINGLE PROTEIN,CHEMBL5604066,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 1.666 None | IC50 CI (lower) = 47.49 uM | IC50 CI (upper) = 52.23 uM | Maximum measured = 78.66 None | Maximum response = 100.0 % | Minimum measured = -2.721 None | R squared = 0.994 None,,,49.803,4
CHEMBL3740727,,,719.79,2.0,2.06,ASAP-0000570,N=C(N)NCCC[C@H](NC(=O)c1nccs1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(N)=O)c1ccc(OCc2ccc(C(F)(F)F)cc2)cc1,IC50,'=',1143.0,nM,5.94,,,UO_0000065,,,,,0,CHEMBL5604074,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 4,,,,,Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK,,,CHEMBL5705864,NS3 protease,dengue virus type 4,SINGLE PROTEIN,CHEMBL5604066,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 1.176 None | IC50 CI (lower) = 1.107 uM | IC50 CI (upper) = 1.18 uM | Maximum measured = 99.9 None | Maximum response = 100.0 % | Minimum measured = 0.372 None | R squared = 0.999 None,,,1.143,4
CHEMBL5605910,,,413.91,0.0,3.13,ASAP-0029914,CCOCCNC(=O)[C@H](Nc1ccc2c(c1)CNC2)c1cc(Cl)cc2[nH]ncc12,IC50,'>',99500.0,nM,,,Falls Outside The Dose Series,UO_0000065,,,,,0,CHEMBL5604074,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 4,,,,,Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK,,,CHEMBL5705864,NS3 protease,dengue virus type 4,SINGLE PROTEIN,CHEMBL5604066,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 1.065 None | Maximum measured = 20.24 None | Maximum response = 100.0 % | Minimum measured = -0.967 None | R squared = 0.971 None,,,99.5,4
CHEMBL5604471,,,332.41,0.0,3.92,ASAP-0029790,Cc1c(C(=O)Nc2cc(-c3cccnc3)ccn2)cc(C2CC2)n1C,IC50,'=',6829.0,nM,5.17,,,UO_0000065,,,,,0,CHEMBL5604074,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 4,,,,,Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK,,,CHEMBL5705864,NS3 protease,dengue virus type 4,SINGLE PROTEIN,CHEMBL5604066,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 7.757 None | IC50 CI (lower) = 6.406 uM | IC50 CI (upper) = 7.278 uM | Maximum measured = 99.48 None | Maximum response = 100.0 % | Minimum measured = -1.66 None | R squared = 0.999 None,,,6.829,4
CHEMBL5604216,,,397.41,0.0,4.1,ASAP-0031247,N#Cc1cccc(-c2nc3c(C(=O)Nc4ccc5c(c4)CNC5)cc(F)cc3[nH]2)c1,IC50,'=',2861.0,nM,5.54,,,UO_0000065,,,,,0,CHEMBL5604074,"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3",F,BAO_0000019,assay format,dengue virus type 4,,,,,Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK,,,CHEMBL5705864,NS3 protease,dengue virus type 4,SINGLE PROTEIN,CHEMBL5604066,71,AI-driven Structure-enabled Antiviral Platform (ASAP),,2024,,Baseline response = 0.0 % | Hill slope = 3.195 None | IC50 CI (lower) = 2.681 uM | IC50 CI (upper) = 3.052 uM | Maximum measured = 96.34 None | Maximum response = 100.0 % | Minimum measured = -0.79 None | R squared = 0.996 None,,,2.861,4
